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Introduction 
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Introducti on and aims of the study
Hunti ngton’s disease (HD) is an autosomal dominant inherited disease, determined 
by a mutati on in the Htt  gene coding for the protein Hunti ngti n. The occurrence of an 
expansion of the cytosine adenine guanine (CAG) repeat on chromosome 4 leads to 
destructi on of brain neurons1. At an unknown point in life, pathogenic processes give rise 
to gradually progressing disturbance of motor functi on, cogniti ve ability, and behaviour. 
Other symptoms include weight loss and sleep disturbances. Pati ents typically display the 
fi rst symptoms between 35 and 45 years of age and die 15 to 20 years later2.
Geneti c testi ng allows for the identi fi cati on of individuals that carry the HD gene. A 
unique research situati on arises from the ability to identi fy individuals who do not show 
symptoms but will certainly do so in the future. These so called ‘premanifest gene carriers’ 
play a valuable role in understanding underlying processes of HD prior to the appearance 
of symptoms. Commonly, aft er disease onset, ‘manifest’ HD pati ents demonstrate gradual 
cogniti ve decline, motor dysfuncti on and behavioural abnormaliti es3. The occurrence and 
severity of such symptoms vary per individual, even so, four successive disease stages can 
be determined. Stages 1 and 2 are classifi ed as ‘early HD’ and 3 and 4 as ‘late stage HD’.4 
The clinical aspects of the disease have been studied extensively since the fi rst descripti on 
of the disease by George Hunti ngton in 18725. Also, the cellular and ti ssue changes of HD 
have been documented. However, this has not resulted in a cure for the disease. Symptom 
suppression is the only treatment opti on currently available. 
Currently, the complex disease process of HD is not understood. It is not possible to exactly 
predict how and when symptoms will arise, or how the disease will develop. However, in 
order to progress towards therapeuti c interventi ons clinical research requires consensus 
about the measures that could be used to objecti vely reﬂ ect the status and progression of 
the disease. This thesis focuses on the determinati on of early biomarkers in premanifest 
gene carriers and pati ents with early HD. The identi fi cati on of one or more suitable 
biomarkers would allow for future clinical interventi ons to be accurately monitored. 
The ideal biomarker would closely reﬂ ect the disease state of HD gene carriers, be non-
invasive and objecti ve. All clinical functi oning domains have the potenti al to deliver 
biomarkers that can meet these criteria. However, due to focus on motor behaviour, 
cogniti ve decline was overlooked as an important domain in the HD symptom spectrum 
for many years. Recently, cogniti ve deteriorati on has received more att enti on6;7. This 
has resulted in the recogniti on that cogniti ve deteriorati on can be part of the course 
of HD from its earliest disease phase onwards8. Diminished executi ve functi oning and 
psychomotor speed have been shown in premanifest gene carriers9, however, reports on 
memory functi oning remain inconclusive. In manifest HD memory, psychomotor speed 
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and executi ve functi oning have been implicated10. However, it is unclear which cogniti ve 
(sub)domains demonstrate the most consistent deteriorati on and which areas of cogniti ve 
functi oning could deliver a cogniti ve biomarker. Therefore, we aimed to provide an 
overview of the (sub)domains of cogniti ve functi oning in HD per disease stage, and to 
indicate which domains have the highest biomarker potenti al (Chapter 2). Furthermore, 
we aimed to examine one of the cogniti ve subdomains to further understand the cogniti ve 
process (Chapter 3). 
The search for biomarkers extends into the fi eld of brain imaging. The widespread 
applicati on of magneti c resonance imaging (MRI) has allowed for in vivo explorati on of the 
HD brain11. From the fi rst autopsies performed on HD pati ents in the twenti eth century 
there has been evidence that brain changes are apparent in HD12. Especially cell loss in 
the caudate nucleus and putamen has been observed13. The extent of atrophy in the 
other subcorti cal grey matt er structures in the brain is not well established. Therefore, 
we aimed to quanti fy atrophy of the subcorti cal grey matt er structures to determine their 
involvement in HD pathology (Chapter 4). 
 
Atrophy of the caudate nucleus and putamen has been shown to occur prior to clinical 
changes. Therefore, atrophy of these regions is a strong candidate biomarker. However, 
given that cell loss is the fi nal outcome of a sequence of pathological events, it is not 
unlikely that other changes prior to widespread atrophy could be detected. With this 
in mind, magneti c resonance spectroscopy (MRS) has been applied in HD, and has 
demonstrated metabolite disturbances in large brain regions14. Quanti fying metabolic 
changes in individual brain structures, especially prior to disease onset, is desirable due 
to the localised nature of profound brain changes in HD. Applicati on of in vivo MRS has 
the potenti al to measure metabolite concentrati ons present in individual brain structures 
in HD and thereby give insight into pathofysiological changes. Therefore, we aimed to 
quanti fy brain metabolites by applying MRS in subcorti cal brain structures and to assess 
the potenti al of metabolites as biomarkers (Chapter 5). 
 
Inherent structural or functi onal changes of the subcorti cal grey matt er structures may not 
be the only cause of their dysfuncti on in HD. The connecti vity of the subcorti cal structures 
with other areas of the brain may also play a role in their disturbances. Diff usion tensor 
imaging (DTI) provides insight into the structural integrity and structural connecti vity of 
brain ti ssues. DTI has previously been applied to determine the integrity of subcorti cal 
structures in HD and has shown diminished integrity of the caudate nucleus, putamen 
and overall white matt er15;16. Examining specifi c white matt er pathways to and from brain 
structures important to HD, may provide further insight into early brain changes. The 
quanti fi cati on and integrity of major white matt er pathways using DTI in premanifest and 
early HD is described (Chapter 6). 
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Autopsy, has shown iron accumulati on in the basal ganglia HD brains17. The processes and 
ti ming of iron accumulati on in the course of HD are not fully understood. Furthermore, the 
relati onship between atrophy and iron accumulati on has not been examined. Magneti c 
fi eld inhomogeneiti es were assessed for quanti fi cati on of iron levels in premanifest 
and manifest HD (Chapter 7). Understanding whether excessive iron accumulati on is 
related to cellular loss, or whether this occurs prior to such loss will not only determine 
the independence of such disease processes but will give insight into iron as a potenti al 
biomarker. 
 
In an eff ort to bridge the gap between the structural brain changes and the functi onal 
deteriorati on, insight is required into the functi oning of the brain. Studying potenti al 
changes in functi onal connecti vity networks using resti ng state fMRI, may add to the 
knowledge of functi onal changes in HD. We explored the nature and ti ming of functi onal 
disturbances in the HD brain at rest and described the potenti al of resti ng state fMRI as a 
biomarker for HD (Chapter 8).
In the fi nal chapter (Chapter 9) the conclusions are summarised and discussed. 
Recommendati ons for future research are given.  
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Chapter 2
A review of cognition in 
Huntington’s Disease
Eve M Dumas1, Simon JA van den Bogaard1, 
Huub AM Middelkoop1,2, Raymund AC Roos1
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The Netherlands
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Abstract
With the prospect of potenti al treatments for Hunti ngton’s disease (HD), non-invasive 
markers of disease progression are needed. Cogniti ve impairment has long been 
recognised as one of the core symptoms of HD. The fi rst aim of this review is to provide 
insight into the onset and nature of cogniti ve loss in the progressing stages of HD. The 
second aim is to provide an overview of the cogniti ve functi ons that have been examined 
in an att empt to identi fy those areas that have the most potenti al to yield a cogniti ve 
biomarker. Literature, consisti ng of 110 studies, since the implementati on of geneti c 
testi ng unti l the beginning of 2011 has been included in this review. The clinical features 
of premanifest HD include defi cits in psychomotor speed, negati ve emoti on recogniti on 
and to some extent in executi ve functi oning. The clinical profi le of manifest HD includes 
impairment in memory, psychomotor speed, negati ve emoti on recogniti on and executi ve 
functi oning. Furthermore, potenti al candidate biomarkers should be most expected from 
such domains as working memory, psychomotor speed, recogniti on of negati ve emoti ons, 
att enti onal and visuospati al executi ve functi ons. 
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Introducti on 
Disturbance in cogniti ve functi oning eventually ending in dementi a is a core symptom in 
Hunti ngton’s Disease (HD), and was referred to in the fi rst report by George Hunti ngton 
when he discussed ‘insanity’ and ‘impairment of the mind’1. An expanded cytosine 
adenine guanine (CAG) repeat on the short arm of chromosome four eventually causes 
neuronal loss in the brain. As a consequence of these brain changes disturbances in motor 
functi oning, behaviour and cogniti ve functi oning are the most frequently reported clinical 
symptoms. Despite HD classically being regarded as a disease of motor impairment, 
cogniti ve decline as an early symptom has increasingly been recognised. A recent report of 
the symptom type with which HD manifested, found that 8.4% of a group of 615 pati ents 
in Europe were rated by a clinician as having fi rst disease symptoms of a cogniti ve nature. 
An additi onal 13.2% had a mixed onset of motor and/or cogniti ve and/or psychiatric 
symptoms2. In a group of 1238 pati ents, over a period of two to ten years aft er receiving 
the diagnosis, companions reported intellectual decline and memory loss3. Self-reporti ng 
of cogniti ve abiliti es has proven to be problemati c in HD, as pati ents have been shown to 
demonstrate impaired awareness, which was found to relate to problems with executi ve 
functi oning, memory and global cogniti ve functi oning4. For this reason the need for 
objecti ve assessments, e.g. formal neuropsychological testi ng, has become apparent. 
Although it has become clear through numerous reports of formal examinati on that 
cogniti ve decline occurs and worsens in the course of HD5-9, the progression of decline over 
the stages of HD is not well-established. 
With the growing prospect of potenti al treatment for HD, the need for accurate, sensiti ve 
and non-invasive biomarkers of disease progression has become clear. Since the discovery 
of the HD CAG repeat expansion in 1993, geneti c testi ng has become widely available for 
both pati ents and family members10. Since then, at-risk individuals could undergo geneti c 
screening. If found to carry the gene and with no overt symptoms, these individuals 
are referred to as premanifest gene carriers of HD. However, this test result gives litt le 
indicati on of how and when the disease will start, or in which disease stage pati ents are 
in. The ideal biomarker for HD would objecti vely pinpoint the start of the disease and/
or current disease phase of a gene carrier. Any improvement (or stabilisati on) as a result 
of an interventi on would then accurately be reﬂ ected by this measure. Such a measure 
could thereby serve as an outcome measure in future clinical trials. To date, no single 
(cogniti ve) measure is generally accepted as a suﬃ  ciently sensiti ve measure to serve in 
such trials. Currently, the most frequently used outcome measures are such measures as 
the Total Functi onal Capacity Score (range 1-13) or the Mini-Mental state examinati on 
(range 0-30), however, these are oft en insensiti ve to small changes in functi on. The search 
for an adequate biomarker has given rise to many observati onal studies of all domains 
of the disease, including invasive, non-invasive, wet and dry biomarkers11-14. Cogniti ve 
research has att empted to identi fy candidate cogniti ve biomarkers for a long ti me and 
eve_manuscript_0108.indd   17 1-8-2012   13:12:00
18| Chapter 2
much research has been performed to assess feasibility. However, again no single measure 
is currently accepted as a suﬃ  ciently sensiti ve marker of current or changing cogniti ve 
functi oning. 
This review has two aims, fi rstly, to provide insight into the onset and nature of specifi c 
and global cogniti ve loss in the successive stages of HD, secondly, to provide an overview 
of results from the functi onal (sub)domains that have been examined in an att empt to 
identi fy a cogniti ve biomarker. 
Cogniti ve Domains and stages of Hunti ngton’s disease
From the start of research into cogniti ve functi oning in HD in 1974 there have been many 
att empts to categorise the defi cits seen into domains of cogniti ve functi oning15. This has 
been done for two main reasons, fi rst to try to grasp the nature of cogniti ve decline for 
diagnosti c and treatment purposes, and secondly to identi fy cogniti ve biomarkers as a 
means for tracking disease progression. For the purpose of this review, the results of the 
reports that have been reviewed have been categorised in accordance with the above 
menti oned goals. Firstly, in accordance with the clinical diagnosis of cogniti ve decline and 
dementi a, the fi ve domains set out in the Diagnositi c and Stati sti cal manual of Mental 
disorders, fourth editi on (DSM-IV)16 were used as a starti ng point for classifi cati on. These 
are; amnesia, aphasia, apraxia, agnosia and executi ve dysfuncti oning. As there is no 
evidence to suggest disorders in praxis in HD, rather only in motor functi oning aff ecti ng 
psychomotor speed, we chose to collect all results under the classifi cati on psychomotor 
speed. The same is the case for agnosia, which in this review has been relabelled as 
emoti on recogniti on, as this was found to be the most prominently examined functi on 
found to show defi ciencies. 
Although the division of functi ons exists, cogniti ve processes are complicated and 
complex and therefore it is oft en very diﬃ  cult to pinpoint just one specifi c functi on that 
is responsible for the correct performance of a task. As a result the DSM-IV discusses a 
number of functi ons related to, or collected under, one of the main umbrella terms of 
the fi ve domains. This sub-specifi cati on will also be discussed throughout this review. 
Specifi cally under the domain memory, we will address declarati ve, non-declarati ve, 
verbal, visual, working and general memory. Under emoti on recogniti on the emoti ons 
happiness, surprise, sadness, fear, disgust, anger and general negati ve emoti ons will 
specifi cally be addressed. Under executi ve functi ons both general and the specifi c 
functi ons of att enti on, categorisati on, verbal and visual-spati al executi ve functi oning 
will be considered. Additi onally, in terms of the search for a biomarker, an additi onal 
specifi c domain has proven to be of interest and will be used as a means to categorise 
experimental fi ndings, namely global cogniti ve functi oning. 
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Methods
All literature relati ng to cogniti on in HD between the discovery and applicati on of 
direct geneti c testi ng in the mid nineteen nineti es and January 2011, was included. 
Literature searches were performed in four databases. The searches were performed 
with the following terms in Pubmed, (“hunti ngton disease” (Majr) OR hunti ngton 
(ti ) OR hunti ngton’s (ti ) OR hunti ngtons (ti ) OR hunti ngton* (ti ) OR hunti ngti n* (ti )) 
AND (cogniti on OR cogniti ve OR “Cogniti on Disorders” (Mesh:noexp) OR psychology 
OR neuropsych* OR Neuropsychological Tests), Embase, (*Hunti ngton Chorea/ OR 
hunti ngton$.ti  OR *Hunti ngti n/ OR hunti ngti n$.ti ) AND ( exp Cogniti on/ OR exp Cogniti ve 
Defect/ OR exp Psychology/ OR exp Psychological Aspect/ OR exp Neuropsychology/ 
OR Neuropsychological Test/ OR exp Learning disorder/ OR (cogniti on OR cogniti ve OR 
psychology OR neuropsych* OR Neuropsychological Test* OR learning).mp), Web of 
Science, ti = (hunti ngton* OR hunti ngti n*) AND ts= (cogniti on OR cogniti ve OR psychol* 
OR neuropsych*) and PsycINFO, (exp *hunti ngtons disease/ OR hunti ngton*.ti  OR 
hunti ngti n*.ti ) AND (exp Cogniti on/ OR exp cogniti ons/ or exp cogniti ve ability/ or exp 
cogniti ve assessment/ or exp cogniti ve impairment/ or exp cogniti ve processing speed/ 
OR exp memory/ or exp memory decay/ or exp memory disorders/ or exp memory 
trace/ or exp memory training/ OR exp Psychology/ OR exp Neuropsychology/ OR exp 
Neuropsychological Assessment/ OR exp learning/ or exp learning ability/ or exp learning 
disabiliti es/ or exp learning disorders/ OR (cogniti on OR cogniti ve OR memory OR 
psychology OR neuropsych* OR Neuropsychological Test* OR learning).
 
Of the approximately 1000 papers that were found with this search strategy the 
majority (± 75%) purely referred to cogniti on in HD without having objecti vely examined 
cogniti ve abiliti es or having an aim related to cogniti on and were therefore removed. The 
remaining ± 25% was examined and only included if they fulfi lled the following criteria: 
were writt en in the English language, had examined human gene carriers or pati ents 
with directly confi rmed presence of the HD gene and, for cross-secti onal reports, had 
directly compared the cogniti ve performance of the HD parti cipants to control subjects. 
Papers were excluded if: the study was performed prior to the implementati on of the 
geneti c test, data was collected as part of a clinical interventi on trial, if it was not defi ned 
how HD was determined or tested, if pati ent data were compared to data from other 
pati ent groups or to norm data only17. This approach yielded 110 strictly selected papers, 
which is comparable to the report by Stout et al. (2011) of approximately 150 reports of 
“neurocogniti ve functi on” since the identi fi cati on of the HD gene18. 
Each report was examined and the results categorised based on the domains of cogniti ve 
functi oning as described above. For the majority of results it was evident how they should 
be categorised and sub-categorised as the authors had indicated how they had done so. 
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For other results where the described test had not been categorised by the authors, a 
categorisati on was made based on the cogniti ve abiliti es required and/or how this had 
been categorised by other studies. The categorisati on of the Verbal Fluency Test or the 
Controlled Oral Word Associati on Test (lett ers F-A-S) from the Unifi ed Hunti ngton’s Disease 
Rati ng Scale (UHDRS), proved more complicated. In neuropsychological manuals it is oft en 
listed under language abiliti es19, however in the majority of HD research it is regarded as 
a test of executi ve functi oning13,20,21. To correspond to the majority of studies in the HD 
fi eld, results from this specifi c test were categorised under executi ve functi oning. For 
each domain the absence or presence of a signifi cant diff erence to controls for the pati ent 
groups was noted. A study was classifi ed as fi nding a diff erence between HD mutati on 
carriers and controls when the authors had stated that this was the case, based on the 
stati sti cal criteria they had described, and not on the basis of a signifi cance cut-off  point. 
This was done as many diff erent stati sti cal approaches have been taken, rendering direct 
comparability unfeasible. 
Further subdivision in results per disease stage was achieved with the following. For HD 
pati ents a disti ncti on was made between those with early or mild HD versus pati ents 
with moderate/severe or late stage HD, most oft en related to the disease stages defi ned 
by Shoulson and Fahn22. Where it was possible to ascertain the stage of severity of the 
disease from the text the presence or absence of a cogniti ve defect in this domain was 
noted only for that group. This same approach was taken to studies of premanifest HD. 
Numerous studies classifi ed premanifest gene carriers based on the number of years 
to esti mated disease onset23 as either far from – or close to – disease onset. In practi cal 
terms this yielded a split on average around 10 years from esti mated disease onset11,13,24. 
In cases whereby it was not clear in which phase or stage of the disease the parti cipants 
fell, a notati on of diff erence to controls was noted for both parti cipant groups (ie. both 
premanifest groups, or both HD pati ent groups). From these notati ons it was possible to 
indicate the number of ti mes that a diff erence to controls was or was not found, for each 
disease stages, for the cogniti ve domains. These data were used to construct graphical 
displays of the presence and staging of cogniti ve defects (fi gures 2-10).
Anmesia/Memory
In the domain memory, all functi onal tests related to the recall of previously learnt 
informati on or to the learning of new informati on were classifi ed. This included sub-types 
of long-term memory such as declarati ve memory, with subdivision of semanti c memory 
(factual informati on) and episodic memory (situati on specifi c informati on related to a 
persons life). Also non-declarati ve memory was specifi ed and related to all tasks testi ng 
skill related or automated procedural memory. Furthermore, in the subtype of short-term 
memory, working memory was included, referring to storage, retrieval and applicati on of 
informati on that is required only brieﬂ y. In additi on, two other sub-categories of short-
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term memory were 
recognised, namely 
verbal memory and 
visuo-spati al short-
term memory25. In 
HD research a quarter 
of the research into 
cogniti on in HD has 
been related to 
memory (fi gure 1). The 
distributi on of positi ve 
and negati ve fi ndings 
in regards to memory 
research over the 
diff erent stages of HD 
is shown in fi gure 2. 
In manifest HD, cross-
secti onal fi ndings in 
the various domains 
of memory provide 
a fairly homogenous 
profi le of impaired 
memory functi oning in both early and late stage HD8,11,26-44. Longitudinal studies found 
both evidence for the presence of the specifi c types of amnesti c disorders in manifest 
HD5,38,45-47, and against such defi ciencies in the same or other subdomains of memory 
functi oning5,6,45,46,48. The results from the smaller studies (n = 20-40) oft en (just) failed to 
reach signifi cance for the majority of memory measures, and oft en found just a limited 
number of measures show signifi cance. For example, a group of measures of memory 
approached stati sti cal signifi cance (p<0.10) over one- and two-year follow-up periods48. 
In other studies visual memory was found to decline over annual visits45 and over 16 
months46. This was also found by a moderately sized study which had reached signifi cant 
levels (p< 0.05) for visuo-spati al memory. However, in this same group verbal learning, just 
failed to reach signifi cance (p between 0.06 and 0.09) over 3 annual visits5. A larger study 
(117 early HD pati ents vs. 119 controls) did not fi nd diff erences with a computerised visual 
working memory task over a one year period in pati ents with stage 1 HD, but did fi nd this 
in pati ents in stage 26. These fi ndings do suggest that overall memory decline does occur 
in manifest HD and that for specifi c sub-domains there is a relati ve consensus in terms of 
decline in visual memory, and more uncertainty about verbal memory.  
Figure 1. Proporti on of research performed per separate domain of cogniti ve 
functi oning. 
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Memory
 
Figure 2. For the cogniti ve domain: Memory, the number of positi ve and negati ve fi ndings over disease stages. 
Memory functi oning in premanifest gene carriers is not as clear cut as that of manifest 
subjects. Cross-secti onally, many diff erent types of memory have been investi gated and 
results show that in some studies evidence is found for a defect, albeit someti mes not in 
all, but in a limited number of subdomains11,18,30,49-59, whereby for poorer working memory 
the most consistent fi ndings were present (Figure 3). The larger studies (n>100) did 
show diff erence to controls with strong signifi cance levels11,18. This was similar to smaller 
studies (n<30), who found diff erences in other sub-domains, such as prospecti ve and 
visual memory49 and explicit motor sequence learning30.  Examinati on of the ti ming of 
onset of such defi cits reveals that the majority of these fi ndings apply to premanifest gene 
carriers close to onset, as is shown in fi gure 2. In contrast, there is also a substanti al body 
of evidence to suggest that cross-secti onal memory functi oning in some domains, such as 
verbal memory, is equal to that of controls21,32,38,42,60-68.
Longitudinal studies in premanifest gene carriers found that memory related tasks showed 
more decline over longer periods of ti me (120 and 30 months respecti vely) than in 
controls9,47. However, others, including shorter follow-up periods (12 to 24 months), found 
that there was no diff erence in task performance over ti me6,64,69,70. These results suggest 
that memory decline is a slow process in premanifest gene carriers. 
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The interpretati on of studies of memory functi oning is complicated by the many domains 
that have been investi gated. All types of memory functi oning are complex and thought 
to recruit numerous diff erent brain regions. Therefore although one type of short term 
memory, say working memory is found to be poorer in HD, this does not mean that the 
sub-types of long-term memory are equally aff ected. 
Memory
Figure 3. Memory research divided into sub-domains of memory functi oning. The number in each secti on of a 
bar represents the number of positi ve versus negati ve fi ndings. 
For this reason it is preferable to examine the subtype of memory that is impaired, fi gure 
3 shows the distributi on of research fi ndings over some domains of memory functi oning 
(where subtype informati on was provided in the literature). From this graph it becomes 
clear that there is not one single patt ern of memory impairment that is valid for all 
subdomains, rather that the impairment patt ern is unique to each memory subtype. When 
taken together the fi ndings from the cross-secti onal studies strongly suggest that there 
are defi cits present in (sub)domains of memory functi oning that diff erenti ate premanifest 
gene carriers from controls, however the limited evidence for further longitudinal decline 
may suggest that the rate of decline of memory functi oning is not so pronounced. Of the 
subdomains of memory, the clearest fi ndings related to problems with working memory, 
therefore this may be the most appropriate memory based candidate for biomarker 
selecti on. 
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Aphasia / Language
Aphasia relates to all language producing or understanding functi ons. An important 
issue arises when examining language abiliti es in HD as the motor impairment can also 
cause dysarthria, which could be mistakenly be regarded as a language problem. The 
presence of slurred or poorly comprehendible speech does not relate to the cogniti ve 
functi on required for speech producti on or understanding. Therefore when examining 
language abiliti es it has proven vital to disti nguish between the content and the practi cal 
impairment. The language abiliti es that were collected under this domain were: 
spontaneous speech, ability to repeat words or phrases, comprehension, naming, reading 
and writi ng19. 
Of all cogniti ve domains the least amount of research has been performed into language 
functi ons in HD (Figure 1). In manifest HD, decline in language functi ons has been reported 
both cross-secti onally38,71,-74, and over a number of years38,45,47. In premanifest gene carriers, 
except for one study18, no diff erences in language functi on were found either cross-
secti onally or over ti me (Figure 4)38,47,61,66,73. 
Aphasia/language
Figure 4. For the cogniti ve domain: Aphasia/language, the number of positi ve and negati ve fi ndings over disease 
stages
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Psychomotor speed
The speed of thinking and acti ng oft en referred to as psychomotor speed, has proven 
important in HD literature. Pati ents are known to have defi cits in their motor abiliti es, one 
result of which is bradykinesia. However, the slowing of brain processes related to task 
performance is also an important measure of functi oning and should ideally be separated 
from poor motor performance alone. Understandably, in clinical practi ce this can prove 
to be diﬃ  cult. The speed and/or strength with which motor movements are performed, 
although not strictly responsible for the correct performance of a motor procedure, is 
also a domain oft en examined as part of neuropsychological testi ng. The deteriorati on 
of psychomotor speed oft en reﬂ ected by slowed performance of a task is a frequently 
reported phenomenon in HD. 
In manifest HD all fi ndings show the presence of a defi cit in psychomotor 
speed8,33,34,37,43,75-79, also longitudinally5,6. Given that the gene carriers are labelled as 
manifest based on the existence of motor defi cits, the impact of motor impairment on 
cogniti ve functi oning is to be expected. This was further investi gated by Aron et al., (2003) 
and diff erenti ated between reacti on ti me and movement ti me during a cogniti ve test. 
The separate analysis of these two constructs showed that the most purely motor based 
parameter, motor ti me, was not diff erent between pati ents and controls, but that only the 
more cogniti vely related reacti on ti me was diff erent between the groups75. This suggests 
that despite their motor impairment, the HD pati ents are most slowed by their cogniti ve 
processes rather than their actual hand movements. That not all diff erences in cogniti ve 
performance can be explained by the negati ve inﬂ uence of motor impairment was also 
demonstrated by Lawrence et al., (1996) when they studied pati ents in the early stages 
of HD with impaired psychomotor speed. The inﬂ uence of this slowing was examined in 
relati on to the performance on other cogniti ve tasks in which psychomotor speed was 
incorporated. Even when psychomotor speed was accounted for, slowing did not explain 
the diff erences in visuo-spati al functi oning37.   
The majority of cross-secti onal fi ndings in premanifest HD point towards slower 
psychomotor speed especially when the group premanifest gene carriers close to onset 
is examined (Figure 5)18,49,50,52,55,60,65,77,78,80,81. This was also confi rmed longitudinally6,9,69,82,83. 
However, as seen in other cogniti ve domains not all reports found diff erences in 
psychomotor speed between premanifest gene carriers and controls, either cross-
secti onally21,60,61,64,66,84 or longitudinally64,70. Nonetheless, given that the largest body of 
evidence both from smaller and larger studies has repeatedly demonstrated this defi cit, 
with someti mes highly signifi cant results, psychomotor dysfuncti on does seem to be 
present prior to disease onset.
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Psychomotor speed
Figure 5. For the cogniti ve domain: Psychomotor speed, the number of positi ve and negati ve fi ndings over 
disease stages
Emoti on Recogniti on
Research into problems with recogniti on in HD has been largely limited to the recogniti on 
of odor, faces and emoti ons (fi gure 6), with by far the most research performed on the 
latt er. Recogniti on of emoti on has been extensively researched in both premanifest gene 
carriers and pati ents with HD. This functi on could be categorised under memory, however, 
those with defi cits of emoti on recogniti on do remember what each emoti on type means, 
only cannot recognise it upon presentati on, therefore this is discussed as a separate 
domain.
In manifest HD the recogniti on of certain emoti ons was found to be diff erent between 
pati ents and controls in almost all studies11,67,73,85-91. However, this does not apply for 
all emoti ons, with negati ve emoti ons most aff ected and no evidence for defi cits in the 
recogniti on of positi ve emoti ons such as happiness and only one report of diminished 
surprise89. This extensive defi cit of negati ve emoti on recogniti on in manifest HD was also 
supported by evidence from longitudinal reports6,91. Figure 7 shows the distributi on of 
fi ndings in regards to specifi c emoti on types and shows that there is the most evidence for 
problems with disgust, followed by fear. To gain more insight into these defi cits Hayes et 
al. (2007), assessed pati ents with seven tests of emoti on recogniti on and found consistent 
results with impairment in multi ple types of disgust recogniti on88. In a subsequent study 
they examined pati ents in early to late HD and found that their impairment of anger, 
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fear and sadness recogniti on was correlated to a decline in general cogniti ve functi oning, 
however the impaired recogniti on of disgust was not. Furthermore in the majority of 
pati ents disgust was the most poorly recognised emoti on89. This suggests that disgust 
recogniti on is related to HD pathology and the recogniti on of other emoti ons maybe 
related to general cogniti ve ability.
Emoti on recogniti on
Figure 6. For the cogniti ve domain: Emoti on recogniti on, the number of positi ve and negati ve fi ndings over 
disease stages
In manifest HD there has been some evidence found for impaired odor recogniti on11,92-94 
and general recogniti on76. Odor recogniti on was not found to be diff erent in premanifest 
HD to controls93. 
The fi rst detectable emoti on recogniti on defi cits in premanifest HD appears to be poorer 
recogniti on of one or more of the negati ve emoti ons67,85,91,95 also in gene carriers more 
than 12 years from disease onset11,18. Only one report found that premanifest gene carriers 
were worse at recognising a positi ve emoti on, namely happiness90. A minority of studies 
report no diff erences in emoti on recogniti on cross-secti onally73,96. However, even these 
studies demonstrated trends towards signifi cance for emoti ons such as fear73 in a group of 
20 gene carriers, and to a lesser extent, in a small study of 13 gene carriers, disgust96. The 
only longitudinal study in a large sample size did not fi nd decline over a one year follow-
up6.
Overall these fi ndings do suggest that the recogniti on of negati ve emoti ons starts early on, 
and does not decline at a rapid rate initi ally but more so aft er disease onset. Although such 
longitudinal fi ndings should be replicated, there does seem to be conclusive evidence that 
eve_manuscript_0108.indd   27 1-8-2012   13:13:03
28| Chapter 2
recogniti on of negati ve emoti ons is impaired in both premanifest and manifest HD, which 
suggests potenti al as a biomarker. 
Emoti on recogniti on
Figure 7. Emoti on recogniti on – per emoti on research divided into sub-domains of memory functi oning. The 
number in each secti on of a bar represents the number of positi ve versus negati ve fi ndings. 
Executi ve (dys)functi oning
The most commonly assessed area of cogniti ve functi oning in HD research is that of 
executi ve functi oning. All reports of higher order functi ons of att enti on, planning, 
categorising, sequencing and abstracti ng were collected under executi ve functi oning. 
These are regarded as the most complex of behaviours and are needed to be able to adapt 
in ﬂ exible manner to many daily life situati ons, whereby conceptualisati on of the task at 
hand, planning, acti on and evaluati on of the performed task are required. Many diff erent 
types of complex functi oning shelter under the term executi ve functi on, these include, 
att enti on, task-switching, categorisati on abiliti es and cogniti ve ﬂ exibility. As executi ve 
functi oning requires so many integrated cogniti ve functi ons many factors can confound 
correct performance19. 
Early reports found problems in executi ve functi oning, so much so that tests of this 
functi on were implemented in standardised assessment batt eries, of which the Unifi ed 
Hunti ngton’s Disease Rati ng Scale is the most frequently applied97. Motor, behavioural 
and cogniti ve functi ons are assessed with this tool. The three cogniti ve tests including 
in this rati ng scale are the Symbol Digit Modaliti es Test (SDMT), the verbal ﬂ uency or 
Controlled Oral Word Associati on (FAS,) and the Stroop Colour naming, Word reading and 
Interference cards (Stroop). Within HD research, fi ndings regarding these three tests are 
oft en referred to as reﬂ ecti ng executi ve functi oning. 
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Almost all cross-secti onal reports demonstrate diff erences between manifest HD 
and controls8,26,27,29,34,36-38,40-45,72,73,75,77-79,93,98-113, and in the few cases where this was not 
demonstrated this was always in early HD pati ents and not later stage HD (Figure 8)58,114,115. 
Impairment of executi ve functi oning in manifest HD was also found longitudinally on 
numerous occasions5,6,9,38,41,45,47,48,113,116.
Executi ve functi oning
Figure 8. For the cogniti ve domain: Executi ve functi oning, number of positi ve and negati ve fi ndings over disease 
stages.
The reports on executi ve functi oning in premanifest gene carriers fi nd almost equal 
support for and against the presence of a dysfuncti on. A number of studies regard their 
fi ndings as evidence for the presence of subtle cogniti ve changes many years prior to the 
onset of motor symptoms18,49,78 and some suggest that this domain would represent a good 
biomarker50,77. Those papers that fi nd support for executi ve dysfuncti on in premanifest 
HD38,52-54,65,73,81,96,101,117-121 include both studies with smaller and larger sample sizes (up 
to 700+ premanifest gene carriers). However just as many negati ve fi ndings have been 
demonstrated21,42,53,55,58,60-62,64,66,67,84,93,100,102,105,110-112,122 generally by studies with lower sample 
sizes. 
Longitudinal research into executi ve functi oning also provides a mixed view on whether or 
not this domain is eff ected in premanifest HD. Reports confi rming the decline of executi ve 
functi oning are present over 120 months in 43 premanifest gene carriers, over 12 months 
in 12 gene carriers and over 30 months in 38 gene carriers respecti vely9,38,69 as are reports 
against the presence of a dysfuncti on over 24 months in 22 gene carriers and 36 months in 
33 gene carriers64,70.
From all these reports the conclusion can be drawn that executi ve functi oning is impaired 
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in manifest HD. There is mixed evidence for executi ve dysfuncti on in premanifest HD, but 
that the majority of reports points towards a dysfuncti on, albeit with a slowly progressive 
decline. Lemiere et al., (2002) suggested that some tests of executi ve functi oning may be 
suitable for demonstrati ng diff erences between premanifest gene carriers and controls 
at one point, but not for showing evoluti on of disease progression over ti me38. It may 
be that premanifest gene carriers are worse at some ti mes, stable over longer periods 
and that sudden drops in ability are related to staging within the disease. Furthermore, 
some but not all tests of executi ve functi oning showed diff erence to controls, therefore 
it is important to identi fy which subtypes of executi ve functi oning are aff ected. Noted 
however, that not all reports specifi ed the subdomains of executi ve functi oning examined. 
Figure 9 gives an overview of those reports that specifi ed if their results pertained to 
sub-types of executi ve functi oning, namely, att enti on, categorisati on, verbal, visual or 
unspecifi ed or to general executi ve functi oning. The graph shows that there is litt le 
evidence for problems with categorisati on, att enti on or verbal executi ve functi oning in 
premanifest HD, and that there is evidence for early disturbances in visual and more 
general or mixed types of executi ve functi oning. In premanifest HD, the impairment of 
visual-spati al executi ve functi on is seen as in manifest HD. Furthermore, in manifest HD 
the evidence for att enti on impairment is apparent, both in early and later stages. 
Executi ve functi oning
Figure 9. Executi ve functi oning research divided into sub-domains. The number in each secti on of a bar 
represents the number of positi ve versus negati ve fi ndings.
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Global cogniti ve (dys)functi oning
A number of diff erent measures have been used to examine global cogniti ve functi oning 
in both premanifest and manifest HD. The most commonly used have been the MMSE, 
various versions of the Wechsler Adult Intelligence Scale (WAIS), and the Matti  s Dementi a 
Rati ng Scale. More recently the Nati onal Adult Reading Test (NART) has been widely 
applied and, as an esti mate of premorbid IQ, it is a very brief measure to administer as 
opposed to the many hours it can take to administer the WAIS or other IQ tests. These 
and other measures of multi ple cogniti ve domains such as the Cambridge examinati on 
for mental disorders of the elderly (CAMCOG) have proven crucial in clinical setti  ngs for 
dementi a screening purposes. 
In pati ents with manifest HD the fi ndings of impaired global functi oning have been 
mixed (Figure 10). A number of studies clearly fi nd diff erences between pati ents and 
controls29,39,41,42,45,72,78,79,93. However the stage at which this occurs is not yet enti rely clear. 
It appears that there is less evidence for the early HD stage than there is evidence for the 
advanced HD group by both cross-secti onal114,115 as longitudinal design38,41,45,47. A study 
found poorer performance on the MMSE by HD pati ents. However, when the group 
was broken down into early and late HD, the early stage HD pati ents reached borderline 
signifi cance and the result was mainly created by the late stage HD pati ents115. However, 
there is also evidence that these measures are not sensiti ve to change as reports of similar 
global cogniti ve functi oning in manifest HD as controls are also available93,107,110,116,123. It 
must be noted however that of these reports, the majority are in early manifest HD. These 
reports of comparable functi oning were also confi rmed longitudinally by two studies5,116.
As depicted in Figure 10, it does not seem as if measures of global cogniti ve functi oning 
are sensiti ve to the subtle changes reported in premanifest HD but that, as the disease 
progresses in early and certainly later stages of HD, a broad defi cit is measurable. As with 
the other domains diff erent tests have been applied, and a clear sensiti ve measure is not 
apparent. Recently, a comparison study of the MMSE and the more recently developed 
Montreal Cogniti ve Assessment (MoCA) as screening tools for cogniti ve defi cits in HD 
was performed. Both global cogniti ve functi oning and subdomains of the two tests were 
examined in HD pati ents as compared to controls. Pati ents performed worse in every 
domain examined in at least one of the two tests, if not on both. The MoCa has the 
additi onal benefi t to the MMSE in assessing the domains known to be aff ected, such as 
executi ve functi oning. Overall on the basis of Reciever Operator Characteristi c curves 
(ROC) the MoCA achieved higher sensiti vity, and may be a bett er general screening 
measure due to its broader coverage of cogniti ve domains72. 
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Global cogniti ve functi oning
Figure 10. For the cogniti ve domain: Global cogniti ve functi oning, the number of positi ve and negati ve fi ndings 
over disease stages. 
Findings in premanifest gene carriers were more homogeneous than those of the manifest 
groups. Overall the majority of studies did not fi nd diff erences between premanifest HD 
and controls either cross-secti onally42,50,58,60,61,66,93,95,110,123-126 or longitudinally38,47,69,70,125. 
A few reports do suggest changes in global functi oning prior to disease onset, with such 
fi ndings as premanifest gene carriers far from expected onset not being signifi cantly 
worse than controls for global measures, but that premanifest gene carriers near to onset 
were worse78. The WAIS-R, for example, was used to assess the eff ect of proximity to 
disease onset on generalised measures of intelligence. Premanifest gene carriers close 
to onset (n=15) showed signifi cantly lower total, performance and verbal IQ as opposed 
to healthy controls. Premanifest gene carriers far from onset only demonstrated lowered 
performance IQ. The authors regard these fi ndings as support for a linear model of 
cogniti ve decline in premanifest HD, whereby not all functi ons decrease at the same 
ti me49.
Discussion
This review aimed to provide informati on on the profi le of cogniti ve functi oning over the 
course of HD. Secondly we aimed to indicate which domains of functi oning could provide 
the best candidate biomarkers for research purposes. 
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Amnesia/ memory
Memory defi cits in premanifest HD are not clear cut, furthermore there is evidence that 
memory tests are suscepti ble to re-tests or learning eff ects45. More research is needed 
to confi rm the presence of learning eff ects in memory tests, however if this is the case 
then such assessments are not suitable for tracking disease progression over ti me, both 
clinically or from a research point of view. Memory functi ons do seem impaired in manifest 
HD, and for this reason, memory functi oning has been suggested as suitable state marker, 
namely a feature at some point during the course of the disease, rather than a trait 
marker, a feature present regardless of the course of the disease33. In terms of suitability 
of memory tasks for a biomarker of cogniti on in HD, the most promising candidate 
subdomain for delivering such as task seems to be working memory.
Aphasia /language
Language defi cits in HD generally only occur aft er disease onset and are limited in their 
prevalence or severity. The literature on this subject has focused on many specifi c aspects 
of language functi oning. This very specifi c approach indirectly demonstrates that global 
language defi cits are not a main feature of the disease symptoms. For this reason language 
defi cits do not seem to belong to the cogniti ve profi le of HD. Furthermore, this domain 
does not seem to lend itself for applicati on as a sensiti ve biomarker, especially not in 
premanifest gene carriers.
Psychomotor speed
Changes in psychomotor speed are suggested to be among the fi rst changes in premanifest 
gene carriers, and this is regarded as support for the hypothesis that subtle cogniti ve 
changes occur 10 years or more prior to disease manifestati on6,49,50. Furthermore cogniti ve 
slowing may be a good target for a cogniti ve biomarker. Evidence for this can be found in 
results from a large group of premanifest gene carriers that were compared to healthy 
controls on a batt ery of cogniti ve tests, which cross-secti onally revealed diff erences in 
tests of memory, executi ve functi on and psychomotor speed. The surprising element of 
these fi ndings lays in the higher sensiti vity of low demand cogniti ve tests, as opposed to 
more complex tests. These low demand tests all had a psychomotor ti med element to 
them, which indicate suitability of such tests52.
Emoti on recogniti on 
Diminished recogniti on of negati ve emoti ons can appear very early in the disease process, 
and may be pathologically linked to HD. Currently the most likely candidate for a cogniti ve 
biomarker is disgust recogniti on. However, due to the negati ve longitudinal fi ndings 
over periods of three and twelve months, a longer longitudinal follow-up is desirable to 
understand the potenti al rate of change of this defi cit and its suitability as a sensiti ve 
biomarker. The reports on this domain have examined in detail diff erent emoti ons, so 
to further validate and understand this construct, gain could be achieved by combining 
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emoti on recogniti on assessments and functi onal MRI scanning. 
Executi ve (dys)functi oning
Defi ciencies in executi ve functi ons are part of the cogniti ve profi le in HD, with some subtle 
changes detectable prior to motor onset of the disease. Executi ve functi oning has also long 
been regarded as a good candidate biomarker for cogniti ve functi oning in HD, however 
this statement may be too broad as not all reports of executi ve functi oning showed 
diff erence to controls. The sudden rise in evidence for att enti on dysfuncti on in manifest 
HD as opposed to the lack of fi ndings in premanifest HD may suggest that att enti on is an 
appropriately sensiti ve marker of disease state. Disti nguishing between the subtypes of 
executi ve functi oning may be vital in identi fying the most appropriate biomarker. That 
this disti ncti on may be important in premanifest HD was also noted by Lawrence et al., 
(2000), who discussed that in depth analysis of visual and spati al functi ons may be relevant 
to understanding the early cogniti ve changes in HD36. Future research should focus on 
att enti on and visual sub-types of executi ve functi oning as the other potenti al biomarker 
candidates. 
Global cogniti ve (dys)functi oning
The overall evidence for impairment in global functi oning is not persuasive, with litt le to 
no evidence of impairment in premanifest HD, and with almost equal numbers of reports 
for and against the presence of a defi cit in early manifest HD. For this reason it may be 
relevant to establish premorbid IQ levels from a clinical point of view at some point during 
diagnosti c or treatment procedures, but not to measure IQ over several ti me points as 
the longitudinal evidence is insuﬃ  cient. In our opinion such measures are not sensiti ve 
enough to be considered as a biomarker.
Limitati ons and considerati ons
Reviewing the cogniti ve literature was complicated by a number of issues, and some 
limitati ons have consequences for the conclusions drawn. The literature search was 
limited by the choice of search terms used. In compiling the fi gures we did not take into 
account size of the groups studied. However, in drawing our global conclusions, we did 
to some extent take into account the sample sizes and other methodological issues when 
appropriate. The study sizes discussed varied from numerous smaller studies with 10 or 
15 parti cipants and moderately sized studies of 30 to 100 parti cipants to a limited number 
of studies with more than 500 subjects in a group. The increase in sample size positi vely 
aff ects the chance that signifi cant diff erences between groups will be found. This is 
positi ve when trying to investi gate subtle changes that may be overshadowed by inter-
subject variability, however if a diff erence is demonstrated with a small study size this may 
indicate that the sensiti vity of this defi cit is very high. This same concept applies to the 
presence and length of follow-up studies. For successful biomarker evaluati on longitudinal 
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assessment of the results is essenti al. However, how long should this follow-up ideally be? 
The longitudinal studies discussed in this review varied in length from three months to ten 
years. This issue could not enti rely be taken into account when compiling the results or 
when drawing conclusions. This may have aff ected the conclusions drawn. However, there 
is no golden rule that can be followed as to under which circumstances we feel a defi cit 
is proven. These diff erences in length of follow-up restrict the potenti al for att empti ng to 
understand in great detail the nature of cogniti ve changes in HD. However, this issue is not 
enti rely restricti ve as the presence of positi ve fi ndings from studies of all sizes has allowed 
us to draw conclusions on important functi onal domains as well as general assumpti ons on 
when the defi cits become apparent or seem to be most prominent.
A further problem was posed by the manner in which groups were defi ned. Although all 
studies based their disease assessment on the absence or presence of motor symptoms, 
there was large variati on in how ‘motor symptoms’ were defi ned. Some reports did not 
specify how this was determined. Others defi ned premanifest HD in a varied manner 
either using a defi niti on of low Total Motor scores on the UHDRS with predefi ned cut-off  
points to the use of diagnosti c confi dence rati ngs97, also with diff erent cut-off  points. In 
this review we have approached the fi ndings based on the manner in which the authors 
describe the groups. However this can potenti ally seriously impact the conclusions drawn 
in regards to the stage at which a defi cit is present. This variability makes it complicated 
to interpret numerous fi ndings, and therefore it would be advisable for the HD research 
community to construct guidelines for study design, so that future communicati ons are 
directly comparable. 
Reports of dysfuncti on in a parti cular cogniti ve domain may be clouded or over-reported 
due to the majority of papers only investi gati ng sub-domains of a functi on, this was taken 
into account as much as possible but it remains challenging to draw global conclusions. 
Furthermore, in the later disease stages, other disease aspects can have great impact 
on test performance. Such results can be confounded by medicati on, severe movement 
disorder, behavioural issues and other functi onal limitati ons. Depression, apathy and 
anxiety, as some of the most frequently occurring (30-60%) behavioural issues, and these 
can directly eff ect moti vati on and test performance, as well as the treatment given for 
such conditi ons127,128. It was not possible to take all this into account when comparing 
results. 
Highly sensiti ve measurement techniques have proven useful in the detecti on of early 
changes. Devices such as oculomotor eye trackers have been used to register responses in 
a memory task in premanifest HD and found that these outcomes measures were sensiti ve 
to subtle diff erences to controls69 Furthermore, although performance on memory tasks 
was not diff erent between premanifest gene carriers and controls, measurement by EEG 
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recording63 and fMRI scanning68 did show diff erences in brain reacti ons using memory 
tasks. For this reason it is advisable, where possible, to make use of such technological 
enhancements. The use of physiologically based measurement tools such as MRI in 
combinati on with cogniti ve assessments may prove most sensiti ve. This is especially so 
when investi gati ng the subtle changes associated with premanifest HD, because the results 
are then supported by other objecti vely quanti fi ed measures with known correlati ons to 
brain changes in HD.
Despite its limitati ons, this review also has its strengths, which lie in the comprehensive 
nature of the study and the objecti ve assessment of the arti cles. Furthermore this review 
tries to discuss both the division of disease stage according to premanifest and manifest, 
but also their subdivision, in an att empt to provide informati on on the staging of defi cits. 
Prior to this review no single paper had addressed cogniti ve functi oning in all disease 
stages. The strict selecti on criteria imposed on the papers included allow for conclusions to 
be drawn that can have relevance from both a clinical and scienti fi c point of view. 
Conclusions
Drawing conclusions for clinical purposes from research papers should be approached 
cauti ously. The results and conclusions discussed above are based on group diff erences 
and can never be projected onto a personal basis without considering the individual at 
hand. Having said this, the overall profi le of cogniti ve disorder in HD can be summarised as 
follows. In premanifest gene carriers there are typically no to litt le defi ciencies in memory, 
language or global cogniti ve functi ons. Diff erences can be found in tasks assessing the 
functi ons of psychomotor speed, negati ve emoti on recogniti on, and to some degree in 
executi ve functi oning. In manifest HD adequate functi oning appears to remain intact for 
the longest periods for language and global functi onal domains, however as a result of the 
progressing cogniti ve decline resulti ng in dementi a, during end stage HD, these functi ons 
can also show marked deteriorati on. During the progression of the disease, impairments 
can be expected in memory (especially visuo-spati al), psychomotor speed, negati ve 
emoti on recogniti on, and executi ve functi oning. For this reason we suggest that these 
four functi onal (sub)domains should be recognised when clinically diagnosing substanti al 
cogniti ve decline or dementi a due to Hunti ngton’s Disease. 
The most promising domains and sub-domains for providing a cogniti ve biomarker appear 
to be working memory, measures of psychomotor speed, recogniti on of negati ve emoti ons 
(in parti cular disgust), att enti on and executi ve functi ons, because measures of these 
functi ons seem to detect early changes that progress during the disease. Having said this, 
the importance of longitudinal investi gati on of such candidates must be reiterated. A 
biomarker will only prove useful when it is sensiti ve to change over ti me, preferably not 
only in manifest but also in premanifest HD.
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Abstract
Objecti ve
Working memory defi cits have been found in Hunti ngton’s disease (HD) and in a small 
group of premanifest HD gene carriers. However, the nature and extent of these defi cits 
are not known. We aimed to determine, in a large cross-secti onal and 12-month 
longitudinal study, the degree of visuospati al working memory dysfuncti on across multi ple 
disease stages including both premanifest and early HD. We also examined the relati onship 
between visuospati al working memory and motor dysfuncti on. 
Method
We examined 363 parti cipants from the TRACK-HD study, including 62 premanifest gene 
carriers far from esti mated disease onset (preHD-A), 58 premanifest gene carriers close to 
disease onset (preHD-B), 77 stage 1 HD pati ents (HD1), 44 stage 2 HD pati ents (HD2), and 
122 healthy controls. For the visuospati al working memory test, parti cipants performed 64 
simple and moderately diﬃ  cult trials at baseline, and 64 moderate and diﬃ  cult trials aft er 
12 months.
Results
Cross-secti onally, diff erences in visuospati al working memory capacity were seen in 
PreHD-B and in the two HD groups when compared to the controls. Longitudinally, only 
pati ents in HD stage 2 showed a reducti on of visuospati al working memory capacity. Speed 
and accuracy were positi vely correlated, but only in the HD groups. 
Conclusions
Impairment in visuospati al working memory is detectable cross-secti onally in both 
premanifest and manifest stages of HD, but declines in visuospati al working memory at 12 
months were only signifi cant in HD stage 2. Furthermore, in manifest HD there is evidence 
for a “worse-worse phenomenon”, whereby reducti ons were present in both motor speed 
and accuracy. 
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Introducti on
Hunti ngton’s disease (HD) is an autosomal dominant neurodegenerati ve disease, which 
is characterised by progressive motor, psychiatric and cogniti ve symptoms and signs. The 
mean age of disease diagnosis is between 35 and 45 years. Individuals at risk of carrying 
the HD gene can be tested. Those who are found to have the gene but not to have clinical 
disease signs are referred to as premanifest gene carriers. Many studies investi gati ng 
cogniti on in HD have demonstrated progressive cogniti ve decline resulti ng in dementi a 1;2. 
Cogniti ve decline is also detectable in the premanifest gene carriers across a number of 
domains, including executi ve functi ons, memory, emoti on recogniti on and psychomotor 
functi ons 3-5. 
Working memory is a topic of recent att enti on as a possible marker for disease state in 
H D6;7. Many day-to-day acti viti es require retenti on, integrati on and manipulati on of either 
verbally or visually presented informati on, referred to as verbal or visual (or visuospati al) 
working memory8. Poorer working memory has been described as part of the disease 
course of HD. In parti cular, several cross-secti onal studies have demonstrated that HD 
pati ents show poorer spati al or visual working memory in comparison to contro ls6;9;10. 
Longitudinally, visual working memory span was found to decline over a period of 3.6 
years in 22 pati ents with HD11. Verbal working memory has also been found to be impaired 
cross-secti onally i n HD10;12.  
Studies of premanifest gene carriers have identi fi ed mild-to-moderate cogniti ve defi cits 
in a range of domains, including att enti on, memory, psychomotor speed and executi ve 
functi oning, which are among the fi rst cogniti ve functi ons to show decline in the 
premanifest  phase13-19. With regard to working memory, the evidence in premanifest 
HD is unclear. Some studies have reported a decline in both verbal and visual working 
 memory18;20. However, others have suggested that premanifest HD do not diff er from 
controls in either visual or verbal working memory14;21. Limited longitudinal evidence 
is available regarding working memory in premanifest HD. However, in one study of 12 
premanifest gene carriers who were tested with an extensive neuropsychological batt ery 
3 ti mes over a period of 2.5 years, it was suggested that working memory, in parti cular 
visuospati al working memory, may be among the fi rst cogniti ve functi ons to show decline 
in the premanife st phase7. 
Working memory is implemented in complex brain networks which integrate signals 
received by the parietal cortex, and then project these integrated signals onto the 
frontostriatal brain circuits which subsequently drive motor  responses22-24. In healthy 
adults, evidence from functi onal magneti c resonance imaging (fMRI) demonstrates the 
involvement of the parietal cortex in working memory. For example, short-term memory 
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capacity is correlated with parietal cortex blood oxygen level dependent (BOLD) acti v ity 
levels25;26. The underlying brain regions associated with working memory are also among 
the primary regions implicated in the cogniti ve dysfuncti on observed in HD, namely the 
caudate nucleus and putamen, which lie within the frontostriatal bra in circuits12;27-30. 
The brain regions which are involved in working memory overlap considerably with 
those regions shown to be aff ected structurally and functi onally in both premanifest 
and  diagnosed HD31-33. Measures of brain functi oning during performance of working 
memory tasks, such as fMRI or electroencephalography (EEG), have shown that patt erns 
of the underlying brain processes are diff erent in premanifest gene carriers than those of 
controls, even in the absence of diff erences in working memory tas k performance12;34;35. 
Brain atrophy develops prior to disease diagnosis in these premanifest gene carriers, and 
progresses during the disease course, with the most profound and earliest changes found 
in the deep grey matt er structures such as the caudate nucle us and putamen31;32;36;37. 
The integrity of the white matt er is also aff ected in HD38;39. Given that both brain atrophy 
and decline in objecti vely assessed clinical measures have been observed more than ten 
years before esti mat ed disease onset13;15;31;37, it can be expected that defi ciencies in visual 
working memory would develop as these brain regions deteriorate. 
Motor functi oning overlaps with cogniti ve functi oning, in that both are implemented 
in brain structures such as the basal ganglia40, and cogniti ve performance is measured 
through motor outputs such as verbal or butt on-based responses. The most sensiti ve 
assessments of early cogniti ve changes in HD are those with a substanti al psychomo tor 
speed component15;41-43. Therefore, to bett er understand how HD aff ects cogniti on, it is 
important to disti nguish, where possible, the impact of motor functi oning on cogniti ve 
measures. Also, as we move toward treatment-focused studies in HD, it is necessary to 
understand the progression of cogniti ve defi cits in relati on to motor dysfuncti on. This is 
important since pati ent groups are oft en defi ned in terms of their level of motor defi cits. 
The disti ncti on between premanifest and manifest HD is made based on the level of motor 
abnormaliti es. For premanifest groups, stringent exclusion of motor defi cits can facilitate 
disti ncti ons between motor and cogniti ve disease eff ects, although subtle motor changes 
are not eliminated by this approach. Cogniti ve tasks that require minimal motor responses 
are also desirable in this respect. 
The background presence of motor slowing also complicates the interpretati on of 
cogniti ve testi ng in HD. One approach to disentangling the motor and cogniti ve roles is 
to examine the relati onship between performance accuracy and response ti mes. This 
relati onship is oft en observed as a ‘speed-accuracy trade-off ’, which refers to a strategy 
whereby parti cipants use a slower, more cauti ous approach to ensure the accuracy of 
their performance. Conversely, faster responses may be less accurate due to being less 
careful or cauti ous. We hypothesized that HD gene carriers may slow their responses as a 
compensatory strategy in order to maintain sati sfactory cogniti ve performance. Because 
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we wanted to examine whether speed-accuracy trade-off s would appear in relati on to 
working memory performance in HD, we selected a task in which these two aspects of 
performance could be examined separately, allowing their relati onship to be studied in the 
context of HD. 
The aim of this study was to determine, using a large cross-secti onal study, the degree 
of visuospati al working memory dysfuncti on across multi ple disease stages including 
both premanifest gene carriers, and those in early stage HD. Furthermore, we wanted 
to examine visuospati al working memory functi on in HD across diff erent levels of task 
complexity. We expected to fi nd evidence of visuospati al working memory decline in early 
HD and also in the premanifest phase, especially given the progressively widespread grey 
and white matt er brain changes known to occur in HD. We also wanted to disti nguish 
between cogniti ve and motor inﬂ uences in order to clarify whether working memory 
itself, rather than just the motor expression of this cogniti ve functi on, is aff ected in HD. 
By addressing these aims, we can obtain evidence regarding the possibility that a working 
memory task may be suitable as a marker for cogniti ve deteriorati on in early diagnosed or 
premanifest HD.
Methods
Parti cipants
Three hundred and sixty-six subjects were studied as part of the TRACK-HD longitudinal 
observati onal study. Of these, 123 were premanifest gene carriers, defi ned as geneti cally 
confi rmed but without clinically evident symptoms, 120 were pati ents with stage 1 and 2 
HD, and 123 were age- and sex-matched healthy controls. Parti cipants were recruited from 
four study sites: London (UK), Paris (F), Vancouver (CAN), and Leiden (NL). Premanifest 
parti cipants were included only if they did not have substanti al motor signs as indicated by 
total motor scores of ≤ 5 points on the Unifi ed Hunti ngton Disease Rati ng Scale (UHDRS), 
and if they had Disease Burden Sco res of at least 25044. For each premanifest gene carrier, 
we computed an esti mate of the proximity (in years) to predicted disease onset based on 
CAG repeat le ngth and current age45. Then, using a median split (10.8 years to expected 
onset) we divided the group into a further from esti mated onset group (PreHD-A, > 10.8 
years to esti mated onset) and a closer to esti mated onset group (PreHD-B, < 10.8 years 
to esti mated onset). For early stage HD parti cipants, we used Total Functi onal Capacity 
(TFC) scores from the UHDRS to diff erenti ate between pati ents in HD stage 1 (HD1, TFC 
scores 11-13) and HD stage 2 (HD2, TFC scores of 7-10) groups. Parti cipants were studied 
annually, and in the current report we include baseline cross-secti onal data on a visual 
working memory task, the Spot the Change task (SPOT), as well as data from the fi rst 
longitudinal (12-month) visit. For informati on on the full cogniti ve assessment batt ery, 
additi onal examinati ons and detailed inclusion criteria see Tabrizi et al. (2009)5. 
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Spot the change task
The Spot the C hange task (SPOT) was based on the previously described visual array 
comparison task46;47. Using a Lenovo Vantage Thinkpad tablet PC (IBM, New York), 
parti cipants viewed an array of coloured squares (250 ms), followed by a blank display 
(1000 ms), and then second array of coloured squares in which one of the squares 
had been encircled. The positi on of the squares was unchanged between the two 
presentati ons. Parti cipants were then asked to indicate if the colour of the encircled 
square had changed from the fi rst to second display. Using a mouse mounted on a 
stabilising wooden platf orm, the response “same” could be given using the thumb of 
the dominant hand or “diff erent” using the non-dominant thumb. The mouse platf orm 
included labels for the “same” and “diff erent” responses to remind subjects which thumb 
corresponded to which response. Answers could be given up to 8 seconds aft er the 
beginning of the second display. Prior to starti ng the task, instructi ons and a minimum of 
four practi ce trials were given to ensure task comprehension. Three levels of diﬃ  culty, 
based on the number of coloured squares contained in the array, were used. Specifi cally, at 
baseline, the easiest level included three coloured squares (set size 3) and the harder level 
included fi ve coloured squares (set size 5). At the 12-month visit, set sizes 5 and 7 were 
used. The easiest level, set size 3, showed a ceiling eff ect at baseline and was dropped 
from the test batt ery and replaced by set size 7 for the 12-month visit. This design yielded 
cross-secti onal data on set sizes 3, 5 and 7, and longitudinal data at 12 months for set size 
5. Thirty-two trials of each set size were randomly mixed, yielding a total of 64 trials at 
each visit. Both accuracy and response ti me were recorded and analysed separately for 
each of the set sizes. 
Non-response trials were recorded when a parti cipant did not respond within the given 
8 second ti me frame, which occurred 168 ti mes across both visits and study groups 
(0.38% of the trials). In an additi onal seven trials, responses were given within 100 ms 
of the sti mulus; these were considered to be ‘pre-cogniti ve’ or accidental responses and 
were excluded from the analysis. Accuracy measures were corrected for guessing by the 
calculati on of k, a measure of working memory capacity as described by Cowan (2001), 
computed as k = set size n ([number correct hits/number of trials] + [number correct 
rejecti on s/number of trials] -1)46. A k or working memory capacity value close to the set 
size (e.g., 3, 5 or 7) indicates good working memory capacity, whereas working memory 
capaciti es close to or less than zero represent performances closer to chance.  
Of subjects that att ended the visits, only a small number of parti cipants failed to complete 
the SPOT, which was nearly always due to ti me constraints. The SPOT was completed at 
the baseline visit, the 12-month visit, or at both visits by a total of 363/366 (99%) of the 
parti cipants (with 1 control and 2 HD2 parti cipants not completi ng the SPOT at any of the 
visits and were thus excluded from the analysis). The baseline visit had a total of 355 of 
366 who completed the task (97%), yielding missing data for 3 controls, 5 HD1, and 3 HD2. 
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Three hundred and twenty fi ve of 355 (92%) of baseline visit parti cipants returned for the 
12-month visit, with an additi onal 8 completi ng the task who did not do so at baseline. 
Therefore, 333 out of 366 (91%) completed the task during the 12-month visit, yielding 
missing data for 9 control, 1 PreA, 5 PreB, 6 HD1 and 12 HD2 during this visit. 
Stati sti cal analysis 
All working memory capacity (k) data were analysed in a single regression model 
incorporati ng data from all levels of diﬃ  culty and both visits. Working memory capacity, k, 
was the outcome variable. The main predictors were group (controls, PreHD-A, PreHD-B, 
HD1 and HD2) and set size at each visit (set size 3 and 5 at visit 1; set size 5 and 7 at visit 
2).
Response ti mes (RT) were considered separately for correct (correct recogniti ons and 
correct rejecti ons) or incorrect (incorrect recogniti ons and incorrect rejecti ons) trials. The 
distributi ons of RTs were highly skewed and therefore log transformed prior to analysis 
to improve normalisati on of these variables for stati sti cal analysis. Similar to the analyses 
for working memory capacity, all RT data from both visits and from all three set sizes 
were analysed in a separate single regression model with RT as the outcome. The main 
predictors were group (Controls, PreHD-A, PreHD-B, HD1 and HD2), response accuracy 
(correct or incorrect) and set size (set sizes 3 and 5 at the baseline visit; set sizes 5 and 7 at 
the 12-month). 
 
Age, gender, educati on level and study site were included as covariates for both the 
working memory capacity (k) and RT models. The regression models used generalised 
esti mati ng equati ons, which have a working assumpti on of exchangeability an d robust 
standard errors48;49. This allowed for cross-secti onal comparison of each gene-carrier group 
to controls for each set size. We also examined whether groups responded diff erently in 
terms of RTs for correct versus incorrect trials. Longitudinal comparisons of each gene 
carrier group for their set size 5 performance at the second visit (versus their performance 
at the baseline visit) were compared to that of controls at their 12-month visit (versus their 
baseline visit). 
Finally, to examine the direct relati onship between accuracy and RT, we computed 
separate linear regression models for each set size with RT as the outcome measure. For 
this analysis, k and group (controls, PreHD-A, PreHD-B, HD1 and HD2) were the main 
predictors. Again, age, gender, educati on level and study site were covariates. A group 
versus k interacti on was included to allow diff erences in the speed/accuracy relati onship 
between groups to be investi gated. 
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Results
To address our primary objecti ve of examining visual working memory, here we fi rst 
describe k (working memory capacity) in the fi ve groups, including both cross-secti onal 
and longitudinal results. We then present RT fi ndings per set size. Finally, we describe the 
relati onship between RT and accuracy to further characterize the relati onship of visual 
working memory to premanifest and early stage HD. The parti cipant characteristi cs at 
baseline are shown in table 1. 
Table 1 Parti cipant characteristi cs at baseline
Controls PreHD-A PreHD-B HD1 HD2 
Number of participants 122 62 58 77 44
Female/male 68 / 54 33 / 29 33 / 25 46 / 31 19 / 25
Age
a
mean (SD) 46.2(10.1) 41.1 (8.6) 40.6 (9.2) 47.2 (10.3) 51.0 (8.6)
Education level
b
mean (SD) 4.0 (1.3) 4.1 (1.1) 3.8 (1.3) 3.8 (1.3) 3.3 (1.4)
CAG repeat length mean (SD) - 42.1 (1.8) 44.2 (2.5) 43.8 (3.3) 43.5 (2.4)
Expected years to onset
a
mean (SD) - 14 (3.1) 9 (1.3) - -
Disease durationa mean (SD) - - 5 (5.8) 8 (4.5)
Intervisit interval (months) mean (SD) 11.6 (0.8) 11.5 (0.6) 11.5 (0.9) 11.6 (1.0) 11.6 (0.6)
a: Age, expected years to onset and disease duration as at baseline; b: Education level as a proxy for 
Intelligence Quotient, as based on the ISCED education classification system
Working memory capacity (k) was signifi cantly lower for the PreHD-B, HD1 and HD2 groups 
at each visit and for each set size (3, 5 and 7) compared to healthy controls (Table 2 and 
Figure 1). PreHD-A did not show diff erence to controls at either visit for any set size. Set 
size 3 (assessed at the fi rst visit only) demonstrated a ceiling eff ect in controls and both 
premanifest groups, but this ceiling eff ect was not apparent for set size 5 and 7. The 
12-month longitudinal eff ects for set size 5, which was the only set size performed across 
both visits, indicated that for the HD2 group, k decreased by nearly half an item compared 
to controls over the same period (-0.46 decline in k, p = 0.045; 95% confi dence interval: 
-0.01 k to -0.92 k). No other group showed signifi cant decline in performance aft er 12 
months. 
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The RTs in the easiest conditi on, set size 3, were longer in the PreHD-B, HD1 and HD2 than 
in controls when answering correctly, despite the ceiling eff ect. For set size 3 incorrect 
responses, only the HD2 group was signifi cantly slower. At baseline for set size 5 (the 
moderately diﬃ  cult trials), correct responses were slower in the PreHD-B, HD1 and HD2 
than controls. At the 12-month ti me point, only HD1 and HD2 were slower at answering 
correctly than controls. Incorrect responses showed similar sensiti vity. Specifi cally, at 
baseline, only the HD2 group provided slower incorrect responses compared to controls, 
and at 12 months, PreHD-A, HD1 and HD2 groups provided slower incorrect responses 
as compared to controls. In the most challenging conditi on, set size 7 trials, all four 
groups (PreHD-A, PreHD-B, HD1 and HD2) were signifi cantly slower than controls when 
responding correctly, but when responding incorrectly, only HD1 and HD2 were slower. 
The relati onship between motor performance and working memory capacity (k) was 
examined using only three groups to increase power, including controls, a premanifest 
group (PreHD-A and PreHD-B combined) and an early HD group (HD1 and HD2 combined). 
Across all three groups the results showed a signifi cant overall interacti on eff ect between 
trial accuracy and RT, thereby indicati ng that response ti mes diff ered for correct as 
compared to incorrect responses. This is depicted in Figure 1, which shows that RTs for 
correct and incorrect responses converge with increasing severity of disease stage as the 
diﬃ  culty of the task increases. In a separate analysis of the relati onship between speed 
and accuracy, we found no evidence for a relati onship between speed of response and 
accuracy for any of the set sizes in either controls or the premanifest gene carrier group. 
In contrast, we did fi nd that slower response speed was related to lower levels of accuracy 
in the manifest HD group for all set sizes. Specifi cally, longer RTs were associated with less 
accurate responses at baseline for set sizes 3 and 5, and at 12 months for set sizes 5 and 7 
(all p values < 0.001; see Figure 1). 
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Figure 1. Ctrl = healthy controls, PreA = Premanifest gene carriers far from expected disease onset, PreB = 
Premanifest gene carriers close to expected disease onset, HD1 = Pati ents in stage 1 of the disease, H2 = pati ents 
in stage 2 of the disease, Year 1 = baseline visit, Year 2 = 12-month visit.
(a) Working memory capacity for set sizes 3 and 5 at Year 1 (b) and set sizes 5 and 7 at Year 2 for HD gene-carriers 
and healthy controls. (c)Response ti me for set sizes 3 and 5 at Year 1 (d) and set sizes 5 and 7 at Year 2. (e) Speed 
vs. accuracy for set sizes 5 and 7 in controls, premanifest gene carriers (pre HD) and pati ents (set size 3 not shown 
due to ceiling eff ect in controls and premanifest gene carriers) 
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Discussion
This study’s main fi ndings were that cross-secti onally, visuospati al working memory 
capacity is lower in both premanifest HD gene carriers who are within a decade of disease 
onset and in early HD pati ents. Secondly, over a period of one year, manifest HD pati ents 
show longitudinal decline in working memory capacity. Finally, in manifest HD, despite 
observing both working memory decline and slower response ti mes, the relati onship 
between motor response speed and accuracy was not a speed-accuracy trade-off , but 
rather we observed that longer response ti mes corresponded to poorer performance. 
From the cross-secti onal results we conclude that working memory capacity is impaired 
in premanifest gene carriers close to expected disease onset (i.e. within 10.8 years of 
expected diagnosis) and in stage 1 and 2 HD pati ents as compared to healthy controls. 
All groups responded very similarly to the moderately diﬃ  cult trials at both visits. These 
fi ndings confi rm the presence of dysfuncti on in visual working memory which has 
previously been found in HD pati ents i n cross-secti onal studies50;51, and extends these 
fi ndings to premanifest HD. Furthermore, despite the report by Lemiere et al. (2004) 
of a longitudinal decline in general working memory over two and a hal f years in pre 
manifest HD7, we did not fi nd a decline in visual working memory in premanifest HD in 
our 12-month follow up. Our results add to current literature in that we report, for what 
we believe is the fi rst ti me, that decline in visuospati al working memory can be observed 
over a period of just 12 months in pati ents with stage 2 HD. We did not fi nd a change over 
12-month in premanifest gene carriers or pati ents at stage 1 of the disease, which could 
be related to a slower progression of cogniti ve changes at these stages of the disease. 
Furthermore, the task used in the current study taxed various levels of working memory 
capacity and our results demonstrate lower working memory capacity at all complexity 
levels of the task. 
Response ti me results indicated that premanifest and diagnosed parti cipants were slower 
than controls at responding to the task correctly. This is parti cularly relevant as the 
premanifest gene carriers were restricted to only those who were free of clinically evident 
motor signs. Given the lack of signifi cant motor signs in this group, we believe that the 
slowing observed may indicate slowed cogniti on or informati on processing rather than 
evidence of slowed motor processing. Our fi nding is consistent with previous fi ndings of 
psychomotor sl owing in premanifest groups15;41. We also note that the working memory 
task included a long response ti me frame (8 seconds), to allow parti cipants, even those 
with early HD who have proven motor defi cits, to respond to the trials within the ti me 
frame. The task design therefore eliminated any potenti al diff erences in response ti me 
being att ributed to missing data in the manifest group. 
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A key strength of the current paper is that in combining assessment of the response speed 
and accuracy, we can examine how slowing and accuracy are related within a working 
memory task, whereas in previous studies, psychomotor speed and working memory 
have been examined in separate tasks. In premanifest gene carriers and controls, we 
found that response ti mes and working memory capacity were not signifi cantly related 
to each other. More specifi cally, we did not fi nd evidence for a speed-accuracy trade-off  
in any parti cipant group. A speed-accuracy trade-off  would have been apparent if faster 
responders showed generally less accuracy than slower responders52. On the contrary, 
we found evidence that in manifest HD the opposite is true, such that slower responses 
were associated with less accurate performances and thus lower visual working memory 
capacity. 
Our fi ndings show that declines in visuospati al working memory in early HD are 
accompanied by both slower speed of responses and lower accuracy.  This kind 
of relati onship between speed and accuracy, can be described as a “worse-worse 
phenomenon”, and cannot be explained as an epiphenomenon of HD. An epiphenomenon 
describes a relati onship between two defi cits in a disease that occur simultaneously but 
are in fact not related or caused by each other; however, because they occur together 
they seem related. The premanifest HD data from this study discount an epiphenomenon 
as the explanati on because although the premanifest gene carriers demonstrated 
signifi cantly slower response ti mes as well as a poorer working memory capacity, there 
was no stati sti cal evidence of a relati onship between the two. Additi onally, because motor 
slowing can be present at the same ti me as poor cogniti ve performance in the absence of 
a relati onship between the two, as is seen in the premanifest gene carriers, the presence 
of motor slowing does not directly implicate it as a primary cause of poorer cogniti ve 
performance. Therefore, the presence of a “worse-worse phenomenon” indicates that 
poor cogniti ve performance cannot be explained by slow responses ti mes only.
The visual working memory task applied in this study included a reasonably large number 
of trials, thereby providing relati vely robust esti mates of working memory capacity across 
three diﬃ  culty levels. The task can be argued to assess visuospati al rather than verbal 
working memory because it uses a random selecti on of colours and locati on of squares 
between trial pairs, which makes the use of verbal encoding strategies unlikely. This design 
also appears to have minimal practi ce eff ects. 
One limitati on is that it is not possible to eliminate defi cits in basic att enti on as a cause for 
poor task performance. However, the short trial durati on was designed to limit the impact 
of short att enti on spans on task performance. It is also important to realise that att enti onal 
functi ons are interlinked with working memory, and the role of att enti on in cogniti ve 
processing is complex. In fact, Cowan (2001) argue that working memory tasks, such 
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as Spot the Change task, assess the scope of att enti on, a key factor that l imits working 
memory capacity46. As HD progresses, there may be a decrease in the ability to adequately 
att end to and extract relevant informati on from the task at hand. Therefore, although 
att enti on span is not directly assessed by this task, att enti on processes play a role in the 
task outcome. This could be reﬂ ected in the “worse-worse phenomenon” whereby it may 
be more diﬃ  cult for pati ents with HD to extract the needed informati on from the sti muli, 
as well as being slower at integrati ng the informati on from the fi rst and second arrays. 
In summary, we conclude that visual working memory impairment can be detected in 
both premanifest gene carriers and early stage HD pati ents using the Spot the Change 
task. In the early stages of HD we observed a “worse-worse phenomenon” whereby lower 
accuracy was associated with slower responses; the opposite of a speed-accuracy trade-
off . Importantly, the longitudinal results demonstrated that visual working memory task 
shows detectable decline across 12 months in stage 2 HD. Our fi ndings, together with 
other reports in the literature, suggest that working memory tasks are useful markers 
of cogniti ve deteriorati on in HD. Such deteriorati on may be most sensiti vely detected in 
early HD, especially in stage 2, using moderate to higher working memory loads along 
with measures of working memory capacity and response ti mes for correct trials. This sort 
of cogniti ve task may be applicable in short term trials (of 12 or more month durati on) 
of disease modifying or symptomati c treatments for parti cipants in HD stage 2. Future 
examinati on of longitudinal eff ects in the most diﬃ  cult conditi on, set size 7, once such 
data become available from the TRACK-HD study, may reveal added task sensiti vity for 
premanifest gene carriers or stage 1 HD. 
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Abstract
In Hunti ngton’s disease (HD) atrophy of the caudate nucleus and putamen has been 
described many years before clinical manifestati on. Volume changes of the pallidum, 
thalamus, brainstem, accumbens nucleus, hippocampus, and amygdala are less well 
investi gated, or reported with contradicti ng results. The aim of our study is to provide 
a more precise view of the specifi c atrophy of the subcorti cal grey matt er structures in 
diff erent stages of Hunti ngton’s disease, and secondly to investi gate how this inﬂ uences 
the clinical manifestati ons. All TRACK-HD subjects underwent standardised T
1
-weighted 
3T MRI scans encompassing 123 manifest HD (stage 1, n = 77; stage 2, n = 46), 120 
premanifest HD (close to onset, n = 58; far from onset, n = 62) and 123 controls. Using 
FMRIB’s FIRST and SIENAX tools the accumbens nucleus, amygdala, brainstem, caudate 
nucleus, hippocampus, pallidum, putamen, thalamus and whole brain volume were 
extracted. Results showed that volumes of the caudate nucleus and putamen were 
reduced in premanifest HD far from predicted onset (> 10.8 years). Atrophy of accumbens 
nucleus and pallidum was apparent in premanifest HD in the close to onset group (0–10.8 
years). All other structures were aff ected to some degree in the manifest group, although 
brainstem, thalamus and amygdala were relati vely spared. The accumbens nucleus, 
putamen, pallidum and hippocampus had a strong signifi cant correlati on with functi onal 
and motor scores. We conclude that volume changes may be a sensiti ve and reliable 
measure for early disease detecti on and in this way serve as a biomarker for Hunti ngton’s 
disease. Besides the caudate nucleus and putamen, the pallidum and the accumbens 
nucleus show great potenti al in this respect.
eve_manuscript_0108.indd   64 1-8-2012   13:14:07
  |65Early Atrophy
Introducti on
Hunti ngton’s disease (HD) is an autosomal dominantly inherited, slowly progressive, 
neurodegenerati ve disease localised on chromosome four. The pathophysiological 
mechanism is complex and although impaired energy metabolism and neuronal 
excitotoxicity are named as major contributors1;2, it is sti ll not fully understood, but the 
main result is neuronal dysfuncti on and loss in the brain. The disease is characterised by 
clinical symptoms in the motor, cogniti ve, and psychiatric domains. 
Loss of brain cells and their connecti ons, referred to as atrophy, can be visualised with 
Magneti c Resonance Imaging (MRI) techniques and has been the focus of many studies 
in search of objecti ve biomarkers for tracking disease progression. The striatum has 
been the primary region of interest, due to previous fi ndings in pathological studies that 
demonstrated the most severe loss of neurons in this region3. In manifest HD, the evidence 
for widespread atrophy is extensive, whereby several MRI studies showed striatal4-12 and 
corti cal atrophy13;14. The striatal atrophy occurs in the premanifest stages of HD, with 
atrophy of the caudate nucleus and putamen present up to a decade or more before 
clinical manifestati on15-20.
Other subcorti cal grey matt er structures have been examined to a lesser degree. 
Thalamic4;5;9;21 and pallidum9;10;22;23 atrophy is apparent in the manifest stages of HD; 
however, fi ndings are controversial in the premanifest stage, as not all studies are in 
agreement16-19;22;24. Atrophy of the hippocampus, amygdala, accumbens nucleus, and 
brainstem has only been reported in the manifest stage in a very limited number of 
studies9;22. Whole brain atrophy has been demonstrated in HD25;26. However, the rate of 
volume reducti on of the subcorti cal structures as compared to whole brain atrophy has 
not been reported in any of the above menti oned studies and is of importance as this 
regional atrophy may very well only be a reﬂ ecti on of whole brain atrophy. Correlati on 
studies have been performed for volume reducti ons and global clinical measures in 
manifest HD8;9;22. However, reports on the relati onship of atrophy with clinical measures of 
all these structures in diff erent disease stages in one large cohort has not been previously 
reported. 
With the possibiliti es of new therapies for HD, there has been increasing interest in 
the development of robust, reproducible biomarkers to assess the eﬃ  cacy of potenti al 
treatments. The TRACK-HD study is an internati onal multi -centre study investi gati ng 
candidate biomarkers for HD and encompasses a large, well defi ned, sample of HD gene 
carriers26. Applicati on of a fully automated MRI-analysis tool to this study sample provides 
the opportunity to study brain atrophy in detail within a very large HD cohort. The aim of 
this study is to provide a more precise overview of the specifi c atrophy of the subcorti cal 
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grey matt er structures in diff erent disease stages, whilst taking into account whole brain 
atrophy and provide bett er targets for biomarker research. Secondly, we aim to examine 
the relati onship of all subcorti cal grey matt er structure volumes to clinical measures for 
HD. 
Methods
Subjects
The TRACK-HD study recruited 366 parti cipants from four centres (the Nati onal Hospital for 
Neurology and Neurosurgery in London, the Department of Medical Geneti cs at University 
of Briti sh Columbia in Vancouver, the Department of Geneti cs and Cytogeneti cs at the 
Hôpital de la Salpetrière-Université Pierre and Marie Curie in Paris and the Department of 
Neurology at Leiden University Medical Center in Leiden) totalling 123 early manifest HD, 
120 premanifest HD and 123 control subjects. Inclusion criteria for the early manifest HD 
group consisted of geneti c confi rmati on of an expanded CAG repeat of ≥ 40, presence of 
motor disturbances on the Unifi ed Hunti ngton’s Disease Rati ng Scale (UHDRS), defi ned as 
a diagnosti c motor confi dence score of 4 and a total motor score (TMS) of > 5, and a Total 
Functi onal Capacity (TFC) of ≥ 7. Inclusion criteria for the premanifest group consisted of 
geneti c confi rmati on of an expanded CAG repeat of ≥ 40, absence of motor disturbances 
on the UHDRS, defi ned as a TMS of ≤ 5. Furthermore, premanifest gene carriers required a 
burden of pathology score > 250, based on CAG length and age27, to ensure a premanifest 
HD sample close to onset. Spouses or partners of premanifest and aff ected subjects or 
gene-negati ve siblings were recruited as healthy control subjects. The control group was 
age-and gender-matched to the combined premanifest and manifest HD group. Further 
subdivision of the premanifest group was performed on the basis of predicted years to 
diagnosis into preHD-A (10.8 or more years to disease onset) and preHD-B (closer than 
10.8 years to disease onset) based on Langbehn’s et al. (2004) survival analysis formula28;29. 
The early manifest HD subjects were also divided into two groups based on disease stage 
by means of TFC score, the HD1 group (TFC score: 11-13) and the HD2 group (TFC score: 
7-10)30. The study was approved by the local ethical committ ees and writt en informed 
consent was obtained from each subject. For full details on study design see Tabrizi et al. 
(2009)26. 
Clinical measures
From the total TRACK-HD assessment batt ery, the UHDRS motor scale and TFC were used 
for this study. The UHDRS TMS is a representati on of the severity of motor disturbances, 
scores potenti ally range from 0-124, with higher scores indicati ng more severe motor 
abnormaliti es. The TFC is a scale used for assessment of global impairments within daily 
acti viti es, ranging from 0-13, with lower scores indicati ng impaired global functi oning.
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MRI acquisiti on
All parti cipants underwent 3Tesla MRI scanning. T
1
-weighted image volumes were 
acquired using a 3D MPRAGE acquisiti on sequence on a 3.0T Siemens or a 3.0T Phillips 
whole body scanner with the following imaging parameters: TR = 2200ms (Siemens) / 
7.7ms (Philips), TE=2.2ms (Siemens) / 3.5ms (Philips), FA=10° (Siemens) / 8° (Philips), FOV= 
28cm (Siemens) / 24cm (Philips), matrix size 256x256 (Siemens) / 224x224 (Philips), 208 
(Siemens) / 164 (Philips), sagitt al slices to cover the enti re brain with a slice thickness of 
1.0 mm with no gap between slices.
Post-processing
All T
1
-weighed scans were analysed using soft ware provided by FMRIB’s Soft ware Library 
(FSL)31. Eight subcorti cal regions were assessed using FMRIB’s integrated registrati on and 
segmentati on tool (FIRST)32-34, namely the accumbens nucleus, amygdala, brainstem, 
caudate nucleus, hippocampus, pallidum, putamen, and the thalamus. Total brain ti ssue 
volume was esti mated with SIENAX35;35;36;36. For details on MRI post-processing please 
see the Supplementary Material. The whole brain volume was used to calculate rati os 
of atrophy of the subcorti cal structures to whole brain atrophy. The obtained rati o was 
divided by the control group value in order to obtain an easily interpretable rati o whereby 
1.00 is the control (normal) value rati o. The following formula was used: 
[volume structure / (whole brain volume - volume structure)] / control group value
A value below 1.00 demonstrates that the structure displays more atrophy than the overall 
whole brain atrophy. A value greater than 1.00 demonstrates that the overall whole brain 
atrophy is greater than the atrophy of the structure at hand.
Stati sti cs
Analysis of variance for group comparison was performed for volumes and rati os of the 
eight diff erent subcorti cal structures, whilst correcti ng for intracranial volume, study 
site, age and gender. (Note that each site used a diff erent MRI Scanner model, and thus 
potenti al scanner eff ects can not be diff erenti ated from site eff ects.) Comparisons of 
each structure were made for each disease group as compared to the control group, and 
as compared to the previous disease stage group, e.g. the preHD-B group was, besides 
comparison to the control group, also compared to the preHD-A group. We calculated 
parti al correlati ons between the various subcorti cal structures and total motor score 
and total functi onal capacity from the UHDRS batt ery. These correlati ons used volumes 
corrected for intracranial volume and were further controlled for age, site, and gender 
by “parti aling” these covariates out during the correlati on calculati ons. The UHDRS TMS 
and TFC analyses were performed on the basis of a two-way group division, namely the 
premanifest gene carriers and the manifest HD group in order to keep suﬃ  cient power to 
perform this analysis. The signifi cance level was set at p value < 0.05.
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Results
Characteristi cs
The clinical characteristi cs of the fi ve study groups are shown (Table 1). The progressive 
nature of HD inherently leads to a higher age of the manifest HD groups. Except for 
the HD2 group, which displayed lower levels of educati on, there were no signifi cant 
diff erences in educati on level between the disease groups and the controls. For full details 
on group characteristi cs we refer to the recent baseline TRACK-HD paper26.
Table 1: Group characteristics
Control PreHD-A PreHD-B HD1 HD2
N 123 62 58 75 46
Leiden 30 16 14 76 14
London 30 14 16 19 11
Paris 30 14 16 25 4
Vancouver 33 18 12 15 17
Age (SD)
(range; years)
46.1 (10.2) 
(23.0–65.7)
41.1 (8.6) 
(18.6–59.4)
40.6 (9.2) 
(22.3–64.1)
46.9 (10.2) 
(22.8–64.1)
51.4 (8.6) 
(33.3–63.3)
Women (%) 68 (55%) 33 (53%) 33 (57%) 45 (60%) 21 (46%)
Educati on (SD) 
levels 1-6
4.0 (1.3) 4.1 (1.1) 3.8 (1.3) 3.8 (1.3) 3.2 (1.4)
Disease-burden 
score (SD)
n.a. 259.1 (30.1) 333.1 (30.0) 364.1 (75.0)
397.6 (67.5)
Descripti ve stati sti cs of the fi ve diff erent groups. Data are mean (SD, range) or number (%).
Volumes
Examples of a typical output from the segmentati on by the FIRST and SIENAX tools are 
depicted (Figure 1), for the FIRST examples only the left  hemisphere segmentati ons are 
shown, however both sides were segmented for the analysis. 
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Figure 1: FSL-FIRST and SIENAX. A. Example segementati ons by FSL FIRST. Dark blue = brainstem, blue = 
pallidum, light blue = thalamus, green = caudate nucleus, dark red = accumbens nucleus, red = putamen, copper 
= hippocampus, pink = amygdala. B. Example output from the FSL SIENAX tool. Red depicts the fi nal sienax 
segmentati on results.
Volume comparisons for eight subcorti cal structures in fi ve groups are shown (Table 2). 
Furthermore, fi gure 2 shows the amount of volume reducti on in terms of percentage 
of the control value. The putamen and the caudate nucleus show a similar patt ern of a 
smaller volume in the preHD-A group and in every subsequent disease stage group with 
a conti nuous decline in volume. The accumbens nucleus and pallidum show a decreased 
volume in the preHD-B group and from every following disease stage group as compared 
to the controls as well as to the previous disease stage group except for the accumbens 
nucleus between HD1 and HD2.
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The brainstem and thalamus show signs of reduced volume in preHD-B, HD1 and HD2 as 
compared to the control group. 
The amygdala showed no reduced volume as compared to the control group. The 
hippocampus showed volume reducti on in stages preHD-B, HD1 and HD2 as compared to 
controls. In terms of percentages of volume reducti on as compared to the control group 
value it is apparent that the pallidum and accumbens nucleus show marked atrophy with 
only 62% and 60% of the normal volume remaining in the HD2 group, respecti vely. These 
structures are closely followed by the putamen and the caudate nucleus with 67% and 
70% remaining volume, respecti vely. Percentages for all structures in the four disease 
stages are also available in the supplementary material.
Rati os
Comparisons for volume rati o of eight structures as compared to whole brain atrophy are 
shown (Table 3). A smaller rati o indicates that the volume of this specifi c structure declines 
faster than the overall brain atrophy. The putamen atrophy rati o showed a conti nuous 
smaller value across subsequent disease stage groups. The caudate nucleus atrophy 
rati o showed a similar patt ern, except within the manifest stage this rati o did not show 
a signifi cant diff erence across HD1 and HD2. The accumbens nucleus and the pallidum 
atrophy rati o showed a decrease over disease stages from the preHD-B group onwards. 
The rati o of whole brain atrophy to amygdala atrophy is comparable or slightly higher 
to the control group rati o. The atrophy rati o for the brainstem and thalamus shows no 
or slightly higher rati os as compared to the control group, stati ng that atrophy of these 
structures is comparable or slower to whole brain atrophy. Finally, the hippocampus 
atrophy rati o shows a drop in value in HD2 as compared to control and HD1.
Clinical measures
The UHDRS total motor score in the premanifest stage is most strongly correlated to the 
atrophy of the caudate nucleus (R=-0.272, p=0.003) and putamen (R=-0.240, p=0.009), but 
also to the atrophy of accumbens nucleus, pallidum and thalamus. The TFC demonstrates 
a strong ceiling eff ect in the premanifest stage and no signifi cant correlati ons are to be 
found. In the manifest stage of the disease the UHDRS total motor score is most strongly 
related to the putamen (R=-0.530, p <0.0001), pallidum (R=-0.390, p <0.0001) and 
accumbens nucleus (R<-0.380, p<0.0001), but also to the hippocampus, thalamus, and 
brainstem.
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The TFC is most strongly correlated to atrophy of the putamen (R=0.270, p=0.004), 
hippocampus (R=0.240, p=0.01) and pallidum (R=0.230, p=0.01) and a weak correlati on to 
accumbens nucleus and brainstem.
Figure 2: Percentage of volume for eight structures as compared to the control value. PreHD-A = premanifest 
gene carriers far from expected disease onset, preHD-B = premanifest gene carriers close to disease onset, HD1 = 
manifest HD stage 1, HD2 = manifest HD stage 2. 
Discussion
The aim of this study was to provide a comprehensive overview of the atrophy of 
subcorti cal structures, with respect to disease stage while taking into account whole brain 
atrophy. The main fi ndings show that all subcorti cal grey matt er structures at some point 
have a reduced absolute volume. However, the accumbens nucleus, the caudate nucleus, 
the pallidum and the putamen display a true progressive decline in volume reducti on 
which is disproporti onate to overall whole brain atrophy and this is already visible in the 
premanifest stages of HD. Conversely, the amygdala, brainstem and thalamus do show 
reduced volumes, but this merely reﬂ ects the overall whole brain atrophy rate. The 
hippocampus is excepti onal in the fact that only in the manifest stage a true rapid decline 
in this structure is observed. Furthermore, the volume reducti ons of the accumbens 
nucleus, putamen, pallidum and hippocampus have a severe impact on clinical measures 
in manifest HD. 
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The atrophy of the caudate nucleus and putamen in the premanifest stages confi rms 
earlier studies. The fact that this happens a decade or more before esti mated ti me to 
onset is in accordance with the fi ndings of Aylward et al. (1996)37, the fi ndings of the 
PREDICT-HD study20;20 and with the results reported in TRACK-HD baseline paper26.
Atrophy of the pallidum and thalamus in the premanifest stages of HD is controversial. 
Campodonico et al. (1998) and Harris et al. (1999) report no signifi cant reducti on in 
volume of the pallidum18;24, while others do report this fi nding16;17;19. With regard to the 
thalamus in the premanifest stage, reports of reduced volume are available in favor16;24 and 
in dispute19;38 of thalamic involvement. Our fi ndings, using 3T MRI and in the largest cohort 
reported thus far, confi rms that atrophy in the pallidum is apparent in the premanifest 
stage closer to predicted disease onset, but not in the further from predicted onset stage. 
Although thalamic atrophy is also apparent in the premanifest close to onset stage, this 
merely reﬂ ects the whole brain atrophy. 
The brainstem, thalamus, and amygdala follow the normal atrophy rate of the whole brain 
in the manifest stages of the disease. In fact, in HD stage 1 the brainstem and the amygdala 
show signs of being relati vely spared. The hippocampus shows a diff erent patt ern 
of atrophy as it starts to show signs of atrophy in preHD-B stage, but really becomes 
signifi cant in terms of volume loss in HD stage 2. To some degree the above described 
fi ndings have been reported by Rosas et al. (2003) and Douaud et al. (2006) 9;22. The added 
value of our study lies not only in the large sample size facilitati ng the further specifi cati on 
of the premanifest and manifest groups, but parti cularly in the fact that the atrophy 
described takes into account whole brain atrophy. It should be noted that some cauti on is 
appropriate when interpreti ng the rati o to whole brain atrophy, as this method does not 
necessarily imply that the volume reducti on of a certain structure has to be greater than 
the whole brain atrophy to be of signifi cance in terms of clinical symptoms. 
The clinical impact of atrophy of subcorti cal grey matt er is diﬃ  cult to assess as many 
brain structures are involved in complex functi onality. We have demonstrated that of 
the subcorti cal grey matt er structures, specifi cally volume reducti ons of the accumbens 
nucleus, putamen and pallidum have the greatest inﬂ uence on predicti ng the motor 
disturbances in manifest HD, and perhaps surprisingly, the impact of the caudate nucleus 
is minimal. The role of the pallidum in motor functi on is underesti mated and surpasses the 
caudate nucleus and the thalamus. However, the putamen is the most important structure 
for this clinical symptom. Our study shows that decreased global functi oning of manifest 
HD was mainly related to volume loss of the hippocampus, putamen and pallidum. 
Cogniti ve and motor defi ciencies have been shown in a number of separate studies, all 
examining only part of the deep grey matt er structures, to relate to volume reducti ons 
of the basal ganglia, thalamus and frontal lobe4;6;11;18;19;24;39;40. Within one small cohort 
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examinati on of clinical measures with the TFC was carried out by Rosas et al. (2003) who 
provided evidence for an associati on between each separate structure and the TFC in the 
manifest stage22, which, apart from some diff erences between studies, is largely confi rmed 
by our study. All these studies show that there is an associati on between volumes and 
clinical measures; however, we hope by examining all structures within one large, well 
defi ned cohort we can provide evidence for which structure has the most contributi on (or 
at least the strongest correlati on) to global functi oning and motor disturbances.
TRACK-HD is a longitudinal observati onal biomarker study aimed at providing essenti al 
methodology for the assessment of therapeuti c interventi ons. In respect to this goal 
we can add that the accumbens nucleus and pallidum show similar biomarker potenti al 
in additi on to the well recognised structures putamen and caudate nucleus. The 
hippocampus is also of importance as it has a high correlati on with clinical symptoms. 
The important role of the caudate nucleus in the premanifest stage of the disease seems 
to diminish aft er manifestati on, as was also suggested by the TRACK-HD baseline paper26. 
It is possibly fair to say that at diff erent disease stages diff erent structures play a role. 
A biomarker would ideally show sensiti vity across all disease stages and would reﬂ ect 
the underlying pathologic processes. From this cross-secti onal analysis it is not possible 
to draw any defi niti ve conclusions, however, the putamen possibly shows the greatest 
potenti al. Longitudinal evaluati on has to be performed to confi rm the putamen’s true 
potenti al. Furthermore we would like to stress how taking whole brain atrophy into 
account aids our interpretati on of regional atrophy rates and in this way their potenti al as 
biomarkers can be assessed more eff ecti vely. 
A limitati on of our study could be the use of a relati vely new soft ware package from FSL 
used for segmentati on, which hasn’t specifi cally been validated in HD. Visual inspecti on, 
however, did not reveal any signifi cant mismatches. The method applied gives structure 
segmentati on on an individual basis and can therefore be used to compare groups. In 
contrast to this limitati on several clear reasons exist in favor of using FIRST; fi rst of all, 
compared to manual segmentati on the automated segmentati on uses voxel intensity in 
contrast to the someti mes diﬃ  cult visual contrast diff erences, reducing a rater dependent 
bias. Secondly this automated technique is suitable for implantati on on large datasets, 
whereas manual segmentati on is labour intensive and prone to human error.
In conclusion, we have demonstrated that atrophy of the pallidum and the accumbens 
nucleus exists in the premanifest stages of the disease and confi rmed the well known 
atrophy of the caudate nucleus and putamen. Furthermore, we have shown the important 
correlati on of the accumbens nucleus, putamen, pallidum and hippocampus with clinical 
symptoms. The importance of the remaining subcorti cal structures should be regarded 
when taking into account that they show similar amounts of atrophy as the brain as a 
whole. These fi ndings have implicati ons for biomarker research, as several subcorti cal 
structures now show great potenti al for use as a disease progression measure. 
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Supplementary Material
Table 1: Percentage of the volume as compared to the control group value for 
eight separate structures.
PreHD-A PreHD-B HD1 HD2
Accumbens Nucleus 97.4 % 86.4 % 72.6 % 60.3 %
Amygdala 99.6 % 100.0 % 97.0 % 87.1 %
Brainstem 99.1 % 95.7 % 92.4 % 87.7 %
Caudate Nucleus 91.5 % 82.8 % 73.1 % 69.8 %
Hippocampus 99.7 % 96.4 % 91.1 % 78.6 %
Pallidum 98.1 % 86.2 % 75.6 % 62.3 %
Putamen 93.5 % 84.1 % 73.4 % 67.5 %
Thalamus 100.3 % 97.0 % 90.2 % 84.9 %
Values represent percentage of the volume as compared to the control group value for eight separate subcorti cal 
structures. PreHD-A = premanifest gene carriers far from expected disease onset, preHD-B = premanifest gene 
carriers close to disease onset, HD1 = manifest HD stage 1, HD2 = manifest HD stage 2. 
Methods: MRI Postprocessing 
All T
1
-weighed scans were analysed using soft ware provided by FMRIB’s Soft ware Library 
(FSL)1. Eight subcorti cal regions were assessed using FMRIB’s Integrated Registrati on 
and Segmentati on Tool (FIRST)2-4, namely the accumbens nucleus, amygdala, brainstem, 
caudate nucleus, hippocampus, pallidum, putamen, and the thalamus. Using FIRST, the 
T
1
-weighted images were fi rst registered to MNI (Montreal Neurological Insti tute) 152 
standard space, using linear registrati on with 12 degrees of freedom5-6. FIRST draws upon 
a vast library of manually segmented images, which were transformed into deformable 
surface meshes. These meshes were applied to our dataset to be used as subcorti cal 
masks to locate the specifi c structures. Subsequently, segmentati on was carried out using 
the voxel intensiti es and mesh models. Finally a boundary correcti on was applied to 
prevent overlap with adjacent structures. Aft er registrati on and segmentati on the absolute 
volume was calculated having taken into account the obtained informati on from previous 
steps. A visual inspecti on of all registrati ons was performed and of the fi nal segmentati ons 
20% were selected at random and visually inspected for accuracy.Total brain ti ssue volume 
was esti mated with SIENAX7-8.This program extracts brain and skull images from the 
single whole-head input data9.The brain images were then aﬃ  ne-registered to MNI152 
space, using the skull images to determine the registrati on scaling. Next, ti ssue-type 
segmentati on with parti al volume esti mati on was carried out10.
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Abstract 
Background
Hunti ngton’s Disease (HD) is a geneti c disorder aff ecti ng the brain. Atrophy of deep grey 
matt er structures has been reported and it is likely that underlying pathologic processes 
occur before or in concurrence with volumetric changes. Measurement of metabolite 
concentrati ons in these brain structures has the potenti al to provide insight into 
pathological processes. We aim to gain understanding of metabolite changes with respect 
to the disease stage and pathophysiological changes. 
Methods
We studied fi ve brain regions using magneti c resonance spectroscopy (MRS) using a 
7-Tesla MRI scanner. Localised proton spectra were acquired to obtain fi ve metabolite 
concentrati ons. MRS was performed in the caudate nucleus, putamen, thalamus, 
hypothalamus and frontal lobe in 44 control subjects, premanifest gene carriers and 
manifest HD.
Results
In the caudate nucleus HD pati ents display lower NAA (p=0.009) and lower creati ne 
concentrati on (p=0.001) as compared to controls. In the putamen, manifest HD pati ents 
show lower NAA (p=0.024), lower creati ne concentrati on (p=0.027) and lower glutamate 
(p=0.013). Although absolute values of NAA, creati ne and glutamate were lower, no 
signifi cant diff erences to controls were found in the premanifest gene carriers. 
Conclusion
The lower concentrati ons of NAA and creati ne in the caudate nucleus and putamen of 
early manifest HD suggest defi cits in neuronal integrity and energy metabolism. The 
changes in glutamate could support the excitotoxicity theory. These fi ndings not only 
give insight in neuropathological changes in HD, but also indicate that MRS can possibly 
be applied in future clinical trials to evaluate medicati on targeted at specifi c metabolic 
processes.
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Introducti on
Hunti ngton’s Disease (HD) is a neurodegenerati ve autosomal dominant disorder. The 
causati ve gene mutati on is located on the short arm of chromosome 4 and consists of an 
expanded Cytosine-Adenine-Guanine (CAG) repeat within the Htt -gene. This expansion 
results in the synthesis of an abnormal hunti ngti n protein that causes neuronal damage, 
brain atrophy, ulti mately leading to functi onal disturbances of motor, cogniti on and 
behavior. 
HD research has revealed widespread changes throughout the brain1. Controversy remains 
as to which structures are aff ected at diff erent disease stages. Atrophy of the striatum is 
regarded as the hallmark of the pathologic fi ndings in HD2. MRI studies demonstrate that 
the caudate nucleus and putamen begin to show atrophy up to a decade before clinical 
manifestati ons occur3. Structures such as the thalamus, hypothalamus, the frontal lobe, 
white matt er and corti cal grey matt er have all been implicated to some degree at this pre-
manifest stage, although fi ndings diff er1;4-6. 
The pathophysiological mechanism leading to neuronal damage remains unclear. 
Currently the two most accepted hypotheses describe impaired energy metabolism and 
the excitotoxicity of neurons7;8. Both hypotheses can potenti ally be explored by means of 
non-invasive in vivo measurements of metabolites such as creati ne and glutamate, using 
localised magneti c resonance spectroscopy (MRS). However, previous studies measuring 
the changes in the metabolite levels related to the damaging processes in HD have 
reported conﬂ icti ng results. In one study a lower level of N-acetylaspartate (NAA) was 
confi rmed post-mortem in the putamen and cortex in manifest HD9. In vivo altered levels 
of NAA, creati ne, choline and glutamate have been reported in both premanifest and 
manifest HD in several brain structures, such as the striatum and thalamus using MRS10-16. 
However, in contrast, other studies using localised MRS did not detect changes in these 
metabolite levels in either manifest or premanifest HD17-19.
One of the factors that might explain discrepancies between previous studies is the 
relati vely poor spati al and/or spectral resoluti on of localised spectra. Improvement in MRS 
methodology in terms of spectral resoluti on in combinati on with small voxel size and total 
scanning ti me can be achieved using a high fi eld MRI scanner20;21. This allows metabolite 
quanti fi cati on in small, well defi ned anatomical structures, such as the caudate nucleus 
and putamen. 
The major aims of the present study were to assess metabolite diff erences between 
manifest HD pati ents or premanifest HD gene carriers and controls, and to assess the 
associati on between these metabolite diff erences and clinical measures of disease severity 
in order to obtain a greater understanding of the pathophysiological changes in HD with 
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respect to the disease stage. The hypotheses were as follows; as the neuronal integrity 
and the energy metabolism would be compromised, we expected the NAA and creati ne to 
be lower in premanifest and manifest HD, especially in the striatum. Possible changes in 
glutamate could be expected based on the excitotoxicity theory, with higher levels in both 
premanifest and manifest HD. 
Materials and Methods
Subjects 
Parti cipants were recruited from the outpati ent neurology clinic of the Leiden University 
Medical Center. Inclusion criteria for the early manifest HD consisted of geneti c 
confi rmati on with a CAG repeat ≥ 39, and the presence of motor disturbances as measured 
by the Unifi ed Hunti ngton’s Disease Rati ng Scale ’99 (UHDRS) defi ned as a total motor 
score (TMS) > 5 and a Total Functi onal Capacity (TFC) ≥ 7. All parti cipants received a 
diagnosti c confi dence rati ng of 4, representi ng “motor abnormaliti es that are unequivocal 
signs of HD (>99% confi dence)”. Inclusion criteria for the premanifest HD parti cipants 
consisted of geneti c confi rmati on with a CAG repeat ≥ 39, and the absence of motor 
disturbances on the UHDRS defi ned as a TMS ≤ 5. Healthy gene negati ve family members 
or partner/spouses were recruited as control subjects in an eff ort to reduce inﬂ uences 
of environmental factors. Exclusion criteria for all parti cipants consisted of signifi cant 
(neurological) comorbidity, a major psychiatric diagnosis, history of severe head injury or 
incompati bility for MRI. In total 44 subjects were recruited to undergo MRS in one or more 
regions of interest (ROI). Time constraints and HD related issues (such as pati ent moti on) 
accounted for not all parti cipants completi ng the MRS protocol in all fi ve of the ROI’s. 
The study was approved by the local Medical Ethical Committ ee of the Leiden University 
Medical Center. All parti cipants provided writt en informed consent.
Clinical measures
Clinical evaluati on for all subjects consisted of the UHDRS motor scale (score 0-124) 
and TFC, a global scale of impairment in daily life acti viti es, score 0 -13. Furthermore, 
a short cogniti ve batt ery was administered, consisti ng of the Mini Mental State Exam 
(MMSE), Stroop test word reading card (Stoop-II), the Symbol Digit Modality Test (SDMT), 
Trail making Test part B (TMT-B), the Wechsler Memory Scale (MQ) and premorbid IQ 
esti mati on using the Dutch Adult Reading Test (DART)22. Behavioural disturbances were 
evaluated with the Beck Depression Inventory 2nd version (BDI-II)23 and the Problem 
Behaviour Assessment short version (PBA-s). Predicted years to onset were calculated 
from current age and CAG repeat length using the formula by Langbehn et al. (2004)24.
MRI/MRS acquisiti on: 
MRI and MRS were performed on a Philips 7-Tesla Achieva whole body scanner (Philips 
Healthcare, Best, The Netherlands) with a NOVA Medical quadrature transmit coil and 
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16 channel receive coil array. For accurate planning, a high resoluti on, three-dimensional 
T
1
-weighted GRE scan was acquired (TR/TE = 11/5.4 ms, voxel size 0.44 x 0.44 x 0.84 mm, 
total scan ti me 1:46). Localised proton spectra were acquired using a sti mulated echo 
acquisiti on mode (STEAM) sequence. The voxel was placed within the region of interest 
with the maximum volume containing only ti ssue from the intended structure, minimising 
the contributi on from surrounding ti ssue, and also parti al volume eff ects. Regions of 
interest consisted of the caudate nucleus, putamen, thalamus, hypothalamus and the 
prefrontal white and corti cal grey matt er. For the prefrontal voxel, positi oning included 
approximately 50% white and 50% corti cal grey matt er. Only for the hypothalamus voxel 
was some cerebral spinal ﬂ uid (CSF) necessarily present since the voxel was placed 
bilaterally. For each voxel in each ROI a water reference signal was acquired for adequate 
quanti fi cati on. The following scan parameters were used for the STEAM spectra: TR/TE/TM 
= 2000/19/25 ms, BW 4 kHz, 2048 complex data points and 128 signal averages, giving a 
data acquisiti on ti me of approximately 5 minutes per spectrum. The chemical shift  arti fact 
was minimal (<1 mm), which is shown in fi gure 1. Water suppression was performed using 
a frequency-selecti ve RF pulse and gradient spoiling, six saturati on bands were additi onally 
applied to suppress signal from surrounding ti ssue. All scans included a reference scan 
without water suppression for quanti fi cati on. When an MRS scan failed (for example due 
to moti on) it was standard protocol to try the same ROI again: however, this did, in some 
cases, result in insuﬃ  cient ti me for the full protocol to be completed since the ti me for 
each pati ent in the magnet was strictly limited to one hour.
MRS post-processing
MRS data were analysed with LCModel25;26, using the unsuppressed water as an internal 
reference to calculate the concentrati ons of metabolites. Concentrati ons of choline, 
creati ne, glutamine+glutamate (Glx), total NAA (N-acetylaspartateglutamate + NAA), myo-
inositol and lactate were calculated for analysis. 
Figure 1. Example of chemical shift s at 7-Tesla using STEAM provided for an actual planning. Red box = NAA, white 
box = metabolite as stated below each fi gure. Only a minimal chemical shift  exists. The chemical shift  of water is 
almost zero, as the separate water fi le is planned according to the NAA-voxel. NAA= N-acetylaspartate
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Stringent quality control was enforced to exclude data with high esti mated errors. A signal 
to noise rati o of ≤ 3 and very high values of residual errors in the LCmodel fi tti  ng were 
applied as initi al spectral exclusion criteria. Furthermore, the LCModel fi t for metabolites 
were required to have a Cramér-Rao Lower Bound (CRLB) of 20% or less. This was required 
for all metabolites within a single spectrum, with the excepti on of lactate. For lactate 
CRLB above 100% were excluded from further analysis. If lactate was not quanti fi ed with 
CRLB <100% in at least 50% of analysed spectra, the analysis of lactate was deemed not 
detectable; this method was fi rst presented by Tkac et al. (2009)20. In total 30 spectra 
were included in the analysis for the hypothalamus , 36 of the thalamus, 28 of the caudate 
nucleus, 27 of the putamen and 32 subjects of the prefrontal region.
Stati sti cs
Stati sti cal analyses were performed using SPSS for Windows (SPSS version 17.0, SPSS inc, 
Chicago, IL). All clinical variables were assessed between groups with a one-way analysis 
of variance (ANOVA), with post-hoc testi ng. To compare all metabolites in the fi ve brain 
regions between the manifest and premanifest HD group versus the control group, an 
ANOVA with planned comparisons was performed. The nature of this study is exploratory, 
and therefore in order to prevent inﬂ ati on of type II errors and avoid important results 
going unreported, no correcti on for multi ple testi ng was performed, as is accepted practi ce 
in such types of study27. To examine the relati onship between metabolic concentrati ons 
and clinical measures in gene carriers (manifest and premanifest HD), parti al Pearson 
correlati on analysis corrected for age was performed.
Results
Demographics
No diff erences in age, educati on level or IQ were present between the manifest HD and 
control group, or between the premanifest HD and control group. No signifi cant diff erence 
exists in CAG repeat length between the premanifest and the manifest HD group. For all 
other clinical assessments variables we refer to the results in table 1.
Voxel planning
Typical examples of localised proton spectra for the fi ve examined regions, along with 
metabolite identi fi cati on, are shown in fi gure 2. The voxel locati on is shown on the left  
side, for clarity the voxel is only shown in one orientati on. Actual planning of the voxel 
required oblique planning in all three dimensions. Figure 3 provides a typical example 
spectrum and fi t from the LCmodel.
Voxel sizes were individually set, based upon the diff erent sizes of structures in diff erent 
individuals, although the voxel size was never below 1.0 ml. With these sizes it was 
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possible in all cases to include only the intended (grey matt er) structure, without 
contaminati on of other (white matt er) structures, the excepti on being the prefrontal 
region. The voxel size ranged from 1.0 ml in the caudate nucleus for a manifest HD 
parti cipant to a maximum of 3.4 ml for the putamen of a parti cipant in the control group. 
Metabolite analysis
The concentrati ons of the six metabolites (NAA, creati ne, choline, glutamate, lactate and 
myo-inositol) in the fi ve brain regions are shown in table 2 for the three groups. In the 
caudate nucleus the manifest HD group demonstrated signifi cantly lower NAA (F = 8.12, 
p= 0.009) and lower creati ne concentrati on (F = 13.60, p= 0.001) compared to control 
subjects. In the putamen, manifest HD showed signifi cantly lower NAA (F = 5.81, p= 0.024), 
lower creati ne concentrati on (F = 5.58, p= 0.027) and glutamate/glutamine (F = 7.21, p= 
0.013) compared to controls.
Table 1: Demographic variables and scores on clinical assessments for the 
three groups.
Control
n: 18 (m:9 f:9)
Premanifest
n: 14 (m:6 f:8)
Manifest
n:12 (m:5 f:7)
 Mean SD Mean SD Mean SD
Age 47.7 7.4 42.9 11.0 48.6 7.0
Years of educati on 15.9 3.2 14.3 3.3 15.3 2.7
IQ 106.7 7.8 102.2 12.5 102.3 9.5
CAG 20.3 c 2.9 43.1 3.4 43.7 2.3
Disease burden n.a. n.a. 306.4 87.0 385.4 e 72.5
Predicted YTO n.a. n.a. 10.4 8.2 n.a. n.a.
UHDRS TMS 2.0 2.4 2.6 1.3 20.9 a 14.1
UHDRS TFC 12.9 0.2 12.6 0.6 11.3 a 1.9
PBA-s 5.9 1.4 5.0 1.3 13.2 a 3.8
BDI-II 3.9 4.6 5.2 5.5 6.4 6.1
MMSE 29.5 0.7 28.5 1.7 28.3 b 1.6
SDMT 59.2 8.9 48.5 10.8 37.3 d 6.7
TMT-B 46.7 15.1 67.8 27.8 101.4 a 51.2
Stroop II 104.0 15.4 95.1 19.4 79.3 b 19.9
MQ 127.3 11.5 115.5 23.2 99.7 b 13.2
SD = Standard Deviati on. CAG = CAG repeat length of larger allele. Predicted YTO = predicted years to onset. 
UHDRS TMS = Unifi ed Hunti ngton’s Disease Rati ng Scale Total Motor Score, PBA-s = Problem Behaviour 
Assessment short version, TFC = Total Functi onal Capacity, BDI-II = Beck Depression Inventory 2nd version, MMSE 
= Mini Mental State Exam, TMT = Trail Making Test part B, SDMT = Symbol Digit Modality Test, MQ = Memory 
Quoti ent, Stroop II = Stroop word reading card, n.a.=not applicable. a = signifi cant diff erences between early 
HD compared to both premanifest and controls. b = signifi cant diff erences between early HD and controls. 
c=signifi cant diff erences between control and both premanifest and manifest HD. d=signifi cant diff erences 
between all three groups. e=signifi cant diff erence between premanifest and manifest HD
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No signifi cant diff erences were found in the hypothalamus, thalamus or prefrontal region. 
Comparison of the premanifest gene carrier group and the control group did not show any 
signifi cant diff erences in any of the regions. However, the absolute values of NAA, creati ne 
and glutamate were lower in the caudate nucleus and putamen in the premanifest gene 
carrier group, but did not reach signifi cance.
Table 2: Metabolite concentrations from ﬁ ve brain regions in HD
Control Premanifest Manifest
N Mean SD N Mean SD N Mean SD
Hypothalamus 11 10 9
Creati ne 10.7 2.1 9.4 2.0 9.3 1.7
Choline 3.7 0.7 3.4 0.6 3.3 0.8
NAA 12.1 1.9 11.9 1.5 11.3 2.1
Glx 12.5 3.0 12.0 4.0 11.0 4.8
Myo-inositol 13.4 4.8 12.7 3.1 13.3 2.8
Lactate 1.5 1.0 1.1 1.1 1.0 1.4
Thalamus 14 13 9
Creati ne 12.7 3.5 12.8 3.6 12.1 1.6
Choline 3.1 0.8 3.0 0.7 3.1 0.4
NAA 17.8 6.0 15.8 2.6 15.9 1.6
Glu/Gln 14.8 5.1 15.1 3.4 12.8 3.4
Myo-inositol 8.5 4.1 7.3 2.6 9.5 4.4
Lactate 1.1 1.0 0.5 0.7 1.8 0.9
 Caudate nucleus 12 11 5
Creati ne 12.5 1.7 11.7 2.2 8.9* 1.2
Choline 3.1 0.7 2.8 0.5 2.6 0.6
NAA 12.1 2.3 10.8 2.0 9.0** 1.1
Glx 15.4 5.2 13.3 5.7 10.8 1.6
Myo-inositol 6.2 1.4 7.1 2.0 7.9 2.0
Lactate 1.2 0.9 1.5 0.9 0.5 0.8
Putamen 13 9 5
Creati ne 13.6 2.3 12.1 2.2 10.9* 0.9
Choline 3.4 0.8 3.1 0.5 3.0 0.4
NAA 14.8 1.6 14.4 1.7 12.8* 0.9
Glx 16.3 3.4 14.2 3.4 11.4* 3.8
Myo-inositol 7.3 2.1 6.5 3.1 10.5 4.0
Lactate 0.8 0.6 1.0 1.3 0.3 0.4
Prefrontal 13 9 10
Creati ne 9.1 2.4 9.2 1.6 9.9 2.1
Choline 2.3 0.5 2.4 0.4 2.3 0.5
NAA 11.7 2.4 11.6 1.5 11.9 3.0
Glx 11.3 2.8 9.8 2.2 13.3 4.0
Myo-inositol 9.5 2.4 8.8 1.9 11.9 4.9
Lactate 1.2 1.1 1.5 1.5 0.8 0.9
Concentrati ons of metabolites in the three groups. Since the water concentrati on and the T
1
 and T
2
 relaxati on 
ti mes of the individual metabolites in the specifi c voxels of interest are unknown at the fi eld strength of 7 Tesla, 
data are expressed as relati ve values to the water peak in arbitrary units (AU). NAA = N-acetylaspartate, Glx = 
glutamate + glutamine, *p<0,05, ** p<0.005
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Relati onship to clinical measures 
The associati on of metabolite levels with clinical measures is shown in table 3. TFC was 
associated with creati ne levels in caudate nucleus and putamen and with NAA in the 
putamen, showing decreased metabolite levels corresponding to poorer clinical scores. 
The NAA concentrati on in the putamen was associated with higher scores on the UHDRS 
TMS, indicati ng lower NAA to correspond to more motor disturbances. Lower glutamate/
glutamine related to poorer scores on the cogniti ve tests SDMT and TMT. Finally, a higher 
PBA score, indicati ng more behavioural disturbances, corresponded to lower creati ne in 
the caudate nucleus.
Table 3: Relationship of the clinical measures with metabolite concentration 
in the caudate nucleus and putamen
Caudate nucleus Putamen
Creati ne NAA Creati ne NAA Glx
Disease burden
R -0,266 -0,473 0.168 0.284 -0.400
p 0.339 0.075 0.584 0.347 0.157
UHDRS TMS
R -0.280 -0.228 -0.324 -0.415 -0.255
p 0.157 0.253 0.106 0.035* 0.200
PBA-s
R -0.545 -0.207 -0.063 0.064 0.052
p 0.003* 0.300 0.758 0.754 0.797
TFC
R 0.409 0.106 0.440 0.556 0.095
p 0.034* 0.598 0.025* 0.003* 0.636
BDI-II
R -0.256 -0.022 0.005 0.206 0.152
p 0.197 0.914 0.983 0.323 0.457
MMSE
R -0.196 -0.106 -0.070 -0.108 -0.223
p 0.328 0.598 0.735 0.601 0.265
TMT-B
R 0.310 0.270 0.185 0.049 0.438
p 0.115 0.173 0.366 0.813 0.022*
SDMT
R 0.171 0.133 0.239 0.125 0.555
p 0.404 0.518 0.250 0.552 0.003*
MQ
R 0.151 0.078 -0.049 -0.013 0.326
p 0.451 0.700 0.811 0.951 0.097
Stroop II
R -0.196 -0.106 -0.070 -0.108 -0.223
p 0.328 0.598 0.735 0.601 0.265
Correlati on analysis of metabolite concentrati on with clinical measures. UHDRS TMS = Unifi ed Hunti ngton’s 
Disease Rati ng Scale Total Motor Score, PBA-s = Problem Behaviour Assessment short version, TFC = Total 
Functi onal Capacity, BDI-II = Beck Depression Inventory 2nd version, MMSE = Mini Mental State Exam, TMT = Trail 
Making Test part B, SDMT = Symbol Digit Modality Test, MQ = Memory Quoti ent, Stroop II = Stroop word reading 
card, R = parti al r correlati on coeﬃ  cient.*p<0.05
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Figure 2: Localised proton MR spectra from diff erent regions of the brain On the left  side the voxel is displayed 
in the transverse directi on, a typical spectrum of that structure is shown on the right side for the three groups. 
Five diff erent regions are displayed: hypothalamus, thalamus, caudate nucleus, putamen, prefrontal region. 
Cho=choline, Cr=creati ne, NAA=N-acetylaspratate, mI=myo-inositol, Glx=glutmate+glutamine, Lac=lactate, 
PPM=parts per million. A Gaussian fi lter of 4 Hz was applied. 
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Figure 3: LCmodel output example. The black line is the raw spectrum, the red line is the fi t by LCmodel. PPM = 
parts per million
Discussion
The major fi ndings of this study are lower concentrati ons of creati ne and NAA in the 
caudate nucleus and the putamen, and a reducti on of glutamate in the putamen in 
manifest HD. A relati onship between diff erences in these metabolic levels and clinical 
measures of disease severity, especially global functi oning, was demonstrated. No 
stati sti cally signifi cant diff erences in any metabolite concentrati on were observed when 
the premanifest group was compared to controls, although the absolute lower values 
could indicate a subtle decline. 
As creati ne is considered an important marker for brain energy metabolism28, the fi nding 
of lower creati ne levels suggests impaired energy metabolism in manifest HD. In the 
healthy populati on, the concentrati on of creati ne in the brain is considered to be fairly 
stable, however, specifi c pathology has been shown to inﬂ uence creati ne concentrati ons28. 
The fi nding of lower creati ne in putamen and caudate nucleus is supported by fi ndings 
of Sanchez et al. (1999), who observed a reducti on of both creati ne and NAA in the 
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striatum10. Reynolds et al. (2005) went on to propose creati ne as a possible biomarker, 
when they demonstrated lower levels in the caudate nucleus in premanifest HD18. 
Contrary to our fi ndings, Reynolds et al. (2005) did not report altered creati ne levels in 
the putamen. Results from the TRACK-HD study reported by Sturrock et al. (2010) show 
similar lower values of creati ne in the putamen as our study29. Jenkins et al. (1998) found 
additi onal evidence for impaired energy metabolism as displayed by elevated lactate levels 
in HD within the occipital cortex11;12. However, our study did not show elevated lactate 
in any of the examined structures. This fi nding can possibly be explained by the fact that 
Jenkins et al. (1993) used a more severely aff ected HD populati on with a lower mean 
TFC score of 7.311. Moreover, the region analysed by Jenkins et al. (1993, 1998)11;12 did 
not consist of the basal ganglia, but of the occipital cortex, which is a very metabolically 
acti ve area of the cortex and is also severely atrophied in HD30. Although, these studies 
are not completely comparable on the basis of methodology and results, they do all point 
towards the importance of assessment of metabolic changes and specifi cally the energy 
metabolism markers such as creati ne. 
NAA is a marker for the integrity of neurons and axons28 and lower NAA levels suggest 
a decrease in neuronal integrity. As atrophy of numerous brain structures is apparent in 
manifest HD, it is likely that neurons are aff ected and decrease in NAA may occur. This 
hypothesis was previously confi rmed within the striatum10;11;17. Again the recent report 
from Sturrock et al. (2010) is similar to our fi ndings of lower NAA in the putamen29. 
Our study confi rms the fi nding of decreased NAA in the striatum (caudate nucleus plus 
putamen), and more importantly, our data show that neuronal damage may be present 
in both the caudate nucleus and putamen separately. The ability to acquire spectra from 
relati vely small voxels is an important advantage of higher magneti c fi elds in localised MR 
spectroscopy. 
Glutamate is of interest in light of the excitotoxicity theory which states that an 
oversti mulati on of neurons causes cell damage and eventually cell death. In neurons this 
can occur either due to increased levels of glutamate (and/or its precursor glutamine) or 
due to an increase in sensiti vity of the glutamate receptors, both resulti ng in the same 
eff ect7;8. Taylor et al. (1994,1996) described increased levels of glutamate, supporti ng 
this theory14;15. However, the glutamate levels in these studies were expressed as a rati o 
to creati ne, and could also be inﬂ uenced by changes of the creati ne level. Our study 
demonstrates reduced glutamate levels in the putamen. An explanati on may be that the 
number of viable neurons is decreased to an extent where glutamate is lowered along with 
the neuron count. Also, the sensiti vity of glutamate receptors could be altered, resulti ng in 
altered levels of glutamate. However, without further investi gati on these propositi ons are 
highly speculati ve.
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In the premanifest HD group no changes in any of the examined metabolites levels could 
be demonstrated. This was an unexpected fi nding, as previous studies have reported 
structural abnormaliti es, e.g. atrophy, at this stage1;31;32 and some reports exist of lowered 
levels of metabolites in premanifest HD gene carriers10;18. Sanchez-Pernaute et al. (1999) 
did report lower NAA and lower creati ne in the striatum in 4 premanifest gene carriers; 
however the arti cle already stated that there were soft  motor signs present in two 
out of four in this group10. Reynolds et al. (2005) reported on lower values of creati ne 
and NAA, yet he concluded that there was no pathognomonic profi le in metabolite 
changes, but stated that there was great heterogeneity in this respect18. Nonetheless, 
we did hypothesize that premanifest HD would show altered levels of metabolites as 
atrophy (which is already present more than a decade before disease onset3;30-32 is 
logically the result of underlying processes. We must therefore conclude that either we 
cannot (yet) measure these changes or the processes involved are more complex than 
simple linear correlati on between metabolite levels and disease severity. For instance 
the excitotoxicity theory can possibly be a process measured by increased (damaging 
eff ects) or decreased (loss of healthy neurons) levels of glutamate depending on the 
individual disease stage. When performing group analysis, these measurements can 
become diluted. Individual assessment of longitudinal changes could shed more light on 
these changes. An explanati on as to why no signifi cant diff erences in our premanifest 
populati on were found, may be that our premanifest group was too heterogeneous in 
terms of proximity to disease onset. When taking into considerati on the ‘disease burden 
score’, a proven correlate of striatal damage and thereby proximity to onset33, a range of 
121.5 to 450.5 exists within our premanifest HD sample. This large range suggests a great 
deal of variability in striatal damage and therefore of possible metabolite diff erences. 
Even so, despite this large range in disease burden score, a decline in absolute values of 
NAA and creati ne was observed in the premanifest group, although this did not reach 
stati sti cal signifi cance. A second explanati on could be our very stringent inclusion criteria. 
Only premanifest parti cipants were included when there was no evidence of motor 
symptoms, as quanti fi ed by an UHDRS motor score of 5 or less, whereas other studies may 
have allowed parti cipati on of premanifest gene carriers with a higher degree of clinical 
abnormaliti es. 
Our data show that metabolite levels are associated with clinical measures of disease 
severity. This fi nding highlights the feasibility of MRS in clinical trials, whereby metabolite 
levels could be target outcome measures. Endeavours using creati ne as a treatment for HD 
with MRS as a monitoring tool have demonstrated the feasibility of this method34. 
This study shows the clinical applicati on of high fi eld 7-Tesla MRI. The spectral resoluti on 
in combinati on with small voxel size and total scanning ti me is a clear improvement in 
MRS methodology21;35. This allows the examinati on of metabolites in small, well defi ned 
anatomical structures, such as the caudate nucleus and putamen for HD, and can be used 
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in the examinati on of many other disorders where spectral and spati al resoluti on is of 
great importance.
A limitati on of our study was the fact that the premanifest group was not uniformly 
distributed according to expected disease onset, which may have lead to a relati vely large 
spread of the metabolite concentrati ons. A more homogeneous group close to onset could 
possibly reveal more signifi cant results already in the premanifest stage of the disease. 
Also the small number of parti cipants included in the manifest groups could be seen 
as a limitati on. However, despite the small amount of parti cipants the results were sti ll 
signifi cant. Furthermore, the hypothalamus region (bilaterally) included some CSF in the 
voxel, especially in the manifest HD group, as a result of atrophy, which could account for 
less reliable measurements. This was not a problem for any of the other regions. Finally, 
the frontal region consisted of approximately 50% of both grey and white matt er, which 
could lead to false negati ve fi ndings if grey or white matt er would be unequally aff ected.
In conclusion, in manifest HD, lower NAA and creati ne were found in the caudate nucleus 
and putamen, supporti ng the theory of impaired energy metabolism as part of the 
pathophysiology of Hunti ngton’s disease. Glutamate levels were lowered in the putamen, 
however to which extent this fi nding supports the excitotoxicity theory remains unclear. 
The relati onship with clinical measures of functi on makes MRS a potenti al disease monitor 
and could also possibly be used to evaluate therapeuti cs targeted at metabolic processes 
in HD.
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Abstract 
Objecti ves
To investi gate the functi on-structure relati onship of white matt er within diff erent stages of 
Hunti ngton’s disease using diff usion tensor imaging (DTI).
Experimental design
From the TRACK-HD study, an early stage HD group and a pre-manifest gene carrier group 
(PMGC) were age-matched to two healthy control groups; all underwent 3T MRI scanning 
of the brain. Region of interest (ROI) segmentati on of the corpus callosum, caudate 
nucleus, thalamus, prefrontal cortex and sensorimotor cortex was applied, and the 
apparent fi ber pathways of these regions were analysed. Functi onal measures of motor, 
oculomotor, cogniti on, and behavior were correlated to DTI measures.
Principle observati ons 
In PMGC versus controls, higher apparent diff usion coeﬃ  cient (ADC) was seen in white 
matt er pathways of the sensorimotor cortex (p<0.01) and in the ROI of corpus callosum 
(p<0.017). In early HD, fi ber tract analysis showed higher ADC in pathways of the 
corpus callosum, thalamus, sensorimotor and pre-frontal region (p<0.01). ROI analysis 
showed higher diff usivity in the corpus callosum and caudate nucleus (p<0.017). Motor, 
oculomotor, cogniti on, and probability of onset within 2 and 5 years, correlated well 
with ADC measures of the corpus callosum ( p<0.01 – p<0.005), sensorimotor (p<0.01 – 
p<0.005) and prefrontal region (p<0.01). 
Conclusions
Disturbances in the white matt er connecti ons of the sensorimotor cortex can be 
demonstrated not only in manifest HD but also in pre-manifest gene carriers. Connecti vity 
measures are well related to clinical functi oning. DTI measures can be regarded as a 
potenti al biomarker for HD, due to their ability to objecti fy changes in brain structures and 
their role within brain networks.
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Introducti on
Hunti ngton’s disease (HD) is a neurodegenerati ve geneti c disorder characterised by 
a progressive deteriorati on of motor control, cogniti ve functi oning, and mood and 
behavioral functi oning. The presence of an abnormal expansion of CAG repeats in the 
HTT gene, on chromosome four is responsible for the disease. The eff ect of the HD gene is 
seen in the brain as progressive cerebral atrophy of the basal ganglia and cortex1-4. It has 
been shown that the onset of atrophy may already be present in gene carriers up to 10 
years prior to disease manifestati on4;5. On the contrary, less is known about white matt er 
changes in HD. Some reports demonstrate global atrophy of the white matt er in manifest 
HD6;7, whereas others show regional diff erences only8;9. A global volume reducti on of white 
matt er was seen only in one study of premanifest gene carriers10. The specifi c impact of 
HD on specifi c white matt er pathways, and the clinical relevance of these changes, remains 
unclear. 
The development and clinical applicati on of magneti c resonance diff usion tensor 
imaging (DTI) has increased knowledge of grey and white matt er structure in a variety 
of neurodegenerati ve diseases11. In pati ents with HD, a few studies have applied DTI to 
characterise changes in the macrostructure and microstructure of the basal ganglia. Lower 
fracti onal anisotropy (FA) values were found for premanifest gene carriers in the putamen, 
caudate nucleus12 and thalamus3. On the contrary, Rosas et al. (2006) found higher FA in 
the putamen and pallidum14. In healthy subjects, FA values of grey matt er structures are 
generally below 0.15. In white matt er, values tend to be much higher ranging from 0.2 
up to 115. In general, the higher the FA value the more directi onal the organisati on of the 
ti ssue is regarded to be - as seen in white matt er fi ber tracts. For this reason FA is generally 
accepted as an indicati on of ti ssue integrity. 
In white matt er, lower FA and increased apparent diff usion coeﬃ  cient (ADC) values have 
been found in the internal capsule and corpus callosum in premanifest and manifest HD 
compared with healthy control subjects13;14. In several of neurodegenerati ve disorders, 
such as Alzheimer’s and Parkinson’s Disease, ADC values have been found to higher, 
indicati ng that degenerati on negati vely aff ects the brain ti ssue structure16-18. Higher ADC 
values indicate that the microstructure of the ti ssue allows a faster movement of water 
molecules. These higher values were also found in manifest HD19-22. To fi nd white matt er 
diff erences that are related to the earliest changes in HD, specifi c white matt er fi ber tracts 
that are related to HD symptomatology should preferably be investi gated. A reducti on 
in cogniti ve, motor, oculomotor performance is present up to a decade before clinical 
manifestati on of HD5;23;24, therefore, it can be hypothesized that the fi bers associated with 
these functi on may also be aff ected in the premanifest phase. The direct nature of this 
relati onship is unknown, and therefore, the aim of the present study is, fi rst, to investi gate 
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early FA and ADC changes in white matt er fi ber bundles running to and from brain 
areas known to be aff ected by HD (e.g. caudate nucleus) or those related to the clinical 
characteristi cs of HD (e.g sensorimotor cortex or prefrontal cortex). Second, to investi gate 
to which extent changes in brain ti ssue structure and integrity in white matt er fi bers are 
related to clinical functi oning.
Method
Parti cipants 
As part of the Track-HD study 90 parti cipants were included at the Leiden University 
Medical Centre study site (for details see Tabrizi et al., 20094). Diff usion tensor magneti c 
resonance imaging was added to the standard MRI protocol. DTI was not performed 
because of claustrophobia in 10 parti cipants, and another nine were excluded from 
analysis due to movement arti facts. Of the remaining 71 subjects, 16 subjects had early 
HD, 27 were premanifest gene carriers and 28 were healthy control subjects. Inclusion 
criteria for premanifest HD gene carriers were a CAG repeat ≥ 40 with a total motor score 
on the Unifi ed Hunti ngton’s Disease Rati ng Scale 1999 (UHDRS) ≤ 5. Inclusion criteria for 
the early manifest HD pati ents were a CAG repeat ≥ 40, with a UHDRS motor score > 5 
and a total functi onal capacity (TFC) score ≥ 7. Healthy gene negati ve family members 
or partners were recruited as control subjects. Because the early HD group is inherently 
older than the premanifest group, the control group was split into two separate groups 
of each 14 subjects to achieve age-matching. The younger healthy control subjects 
were age matched to the premanifest gene carriers (control group A). The older healthy 
controls subjects were age-matched to the manifest group (control group B). None of the 
parti cipants suff ered from a neurological disorder, a major psychiatric diagnosis, or had a 
history of severe head injury. The study was approved by the Medical Ethical Committ ee of 
the Leiden University Medical Centre. All parti cipants gave informed consent. 
DTI acquisiti on
MRI acquisiti on was performed on a 3 Tesla whole body scanner (Philips Achieva, 
Healthcare, Best, the Netherlands) with an eight channel SENSE head coil. T
1
-weighted 
image volumes were acquired using a 3D MPRAGE acquisiti on sequence with the following 
imaging parameters: TR = 7.7 ms, TE = 3.5 ms, FOV = 24 cm, matrix size 224x224, number 
of slices = 164, slice thickness = 1.00 mm, slice gap = 0. A volumetric T
2
-weighted image 
(VISTA) was acquired with the same parameters for fi eld of view, acquisiti on matrix, and 
slice thickness as the T
1
-weighted images, with TE = 250 ms and TR = 2500 ms. A single-
shot echo-planar DTI sequence was applied with 32 measurement directi ons and the 
following scan parameters: TR = 10004 ms, TE = 56 ms, FOV = 220 x 220 x 128 with an 
acquisiti on matrix of 112 x 110, 2.00 mm slice thickness, transversal slice orientati on, 
slice gap = 0, ﬂ ip angle = 90°, single reconstructi on voxel dimensions were 1.96 x 1.96 x 
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2.00 mm, number of slices = 64, B factor = 1000, halfscan factor = 0.61. Parallel imaging 
(SENSE) was used with a reducti on factor of 2, NSA = 1 and fat suppression was applied. 
DTI acquisiti on ti me was 6.55 minutes.
Regions of interest segmentati on
A priori, the caudate nuclei, thalami, and the corpus callosum were determined as regions 
of interest (ROI). A semiautomati c segmentati on and analysis procedure was used as 
part of the soft ware program FibreTrak (release 2.5.3, Philips Medical Systems, Best, the 
Netherlands). The caudate nucleus and thalamus were segmented separately on each 
side, but considered as one ROI during data analysis. On the DTI scans, special cauti on was 
taken to prevent inclusion of any non grey matt er voxels, as both the caudate nucleus and 
thalamus are laterally bordered by the internal capsule. All analyses and segmentati ons 
were performed blinded to group status. For more detailed informati on on segmentati ons 
see the supplementary material. 
 
Fiber tract analysis
Fiber analysis of fi bers running through the following fi ve structures was performed: the 
corpus callosum (Figure 1A), sensorimotor cortex (Figure 1B), caudate nucleus (Figure 1C), 
superior prefrontal cortex (Figure 1D) and thalamus (Figure 1E). To analyse fi bers running 
through the corpus callosum, caudate nucleus and thalamus, the previously segmented 
ROIs were used. Additi onal segmentati ons for ROIs of the superior prefrontal cortex and 
sensorimotor cortex were performed. The superior prefrontal region was segmented on 
the basis of Brodmann areas 9 and 10. The sensorimotor cortex on Brodmann areas 1, 2, 3 
and 412. To calculate the average ADC and FA of the fi ve white matt er pathways FibreTrak 
was used (release 2.5.3, Philips Medical Systems, Best, The Netherlands). The soft ware 
applies fi ber assignment by conti nuous tracking25. The following standard parameters were 
implemented: minimum FA value 0.10, maximum angle change 27º, minimum fi ber length 
10 mm. For more detailed informati on on the applicati on of the fi ber tracking soft ware see 
the supplementary material.
Clinical Assessments
From the extensive assessment batt ery in the TRACK-HD study, specifi c tasks were chosen 
that gave a representati on of functi oning in each symptom domain. Furthermore, these 
were tasks that had been proved to provide sensiti ve outcome measures for group 
comparisons, even in the premanifest stages4: index fi nger speeded tapping and sustained 
tongue force measures (motor), anti -saccade latency and error rate (oculomotor), symbol 
digit modaliti es test, the Stroop word reading test, trail making task part B, and a visual 
working memory task – the spot the change task (cogniti on); Beck’s depression inventory 
2nd version (BDI-II) and the frontal systems behavior inventory which yields three subscores 
of disinhibiti on, executi ve functi oning and apathy (psychiatry). CAG repeat length and 
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probability of onset within 5 years and Burden of pathology ((CAG – 35.5) x age))26 were 
also added to the analysis. For the complete set of clinical assessments and variables see 
Tabrizi et al. (2009)4. 
Stati sti cs
Stati sti cal analyses were performed with the Stati sti cal Package for Social Sciences 
(SPSS for Windows; version 17.0.2, SPSS inc, Chicago, IL). Distributi ons and assumpti ons 
were checked. Independent student’s t-tests and Chi-square tests were applied where 
appropriate in the analysis of group diff erences based on descripti ve data; age, CAG, 
Dutch adult reading test (IQ), TFC and UHDRS. To test for diff erences in FA and ADC in 
the three ROIs and the fi ve white matt er fi ber bundles between premanifest or manifest 
gene carriers and their corresponding control groups, analyses were performed using 
independent student’s t-tests. Correcti on for multi ple comparisons was applied to each 
analysis. Each analysis of ADC in the basal ganglia ROIs, the FA in the basal ganglia ROIs, 
the FA of the fi ber pathways, and the ADC of the fi ber pathways was regarded as a 
separate analyses. Therefore a Bonferroni correcti on was applied to each analysis. For the 
ADC and FA ROI analysis this lead to 0.05/3 = 0.017, and for the ADC and FA fi ber pathways 
analysis this lead this to 0.05/5 = 0.01. The number of voxels in each seed ROI was 
compared between groups. Parti al Pearson correlati ons analysis was performed to explore 
and test for possible associati ons between measures of white matt er fi ber pathway 
integrity and clinical measures. Age and gender were added into this analysis as covariates. 
The number of voxels in a ROI were also correlated to the clinical variables in order to 
examine the possibility that grey matt er volume explains any possible correlati ons. The 
ADC and FA values of the white matt er fi ber pathways were correlated to each other to 
examine other explanati ons for possible results.
Results
Premanifest
No diff erences in age, gender, IQ, TFC, and UHDRS motor score between the premanifest 
gene carriers and their controls were present (Table I). The ADC and FA values of the ROIs 
and fi ber pathways are shown in Table I. Premanifest gene carriers showed increased ADC 
values in the corpus callosum compared with controls. A signifi cant increase in ADC of 
the white matt er fi bers of the sensorimotor cortex was also found between premanifest 
gene carriers and controls. No diff erences in ADC were found in the regions of the caudate 
nucleus and thalamus. No diff erence in FA was found in any of the three regions between 
the two groups. Also, no FA or ADC diff erences were found in any of the fi ber pathways 
between the two groups. The number of voxels in the caudate nucleus ROI of premanifest 
group is signifi cantly lower than the number in the control group ROI.
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Early HD
The demographic data of the early HD and control group B showed no diff erences in age, 
gender or IQ. TFC and UHDRS diff ered signifi cantly (Table II). In the corpus callosum and 
the caudate nucleus, the ADC values were larger in early HD when compared with controls. 
Between the two groups, no diff erence in FA was found in any of the ROIs. ADC values 
were signifi cantly increased in fi bers from all regions, except for the caudate nucleus 
fi bers. FA was decreased in fi bers running to and from the prefrontal cortex in early HD 
pati ents. No diff erence in FA was found in fi bers passing through the corpus callosum, 
caudate nucleus, thalamus and sensorimotor cortex. The number of voxels of the caudate 
nucleus as well as in the corpus callosum was signifi cantly lower in the pati ent group than 
in the control group (Table II). 
Clinical correlati ons
The correlati on analysis between the ADC of the fi ber bundles with geneti cs, probability of 
onset within fi ve years, burden of pathology, motor, oculomotor, cogniti on and behavior in 
all parti cipants are shown in Table III. 
Tapping was moderately associated with the diff usivity (ADC) of bundles through the 
corpus callosum, thalamus, sensorimotor cortex and prefrontal cortex. For the tongue 
force, similar but weaker associati ons were found. Latency of anti -saccades and the 
percentage of anti saccade errors in the oculomotor task were found to correlate with 
increased diff usivity of the corpus callosum, sensorimotor cortex and prefrontal cortex 
fi bers. All cogniti ve measures were moderately to strongly associated with the ADC 
of fi bers through the corpus callosum, sensorimotor cortex and to a lesser extent the 
prefrontal cortex. In premanifest gene carriers, probability of expected onset within 5 
years and burden of pathology showed a high positi ve correlati on with the diff usivity of 
the corpus callosum fi bers and with those of the sensorimotor cortex, whereby a loss of 
integrity related to a higher probability of onset within fi ve years and higher burden of 
pathology. No associati on in any cogniti ve domain with fi bers of the thalamus was found. 
CAG repeat length and behavioral measures did not show associati on with the ADC of 
any of the fi ber bundles studied. No measures showed associati on with the fi bers of the 
caudate nucleus. FA of the corpus callosum and sensorimotor cortex fi bers negati vely 
correlated with the latency (r = -0.52, p < 0.001) and percentage of errors 
(r = -.038, p= 0.001) in the anti -saccade oculomotor task. FA did not demonstrate any 
signifi cant correlati on with geneti cs, motor, cogniti on, and behavior.
The results from a correlati onal analysis between number of voxels in a seed region and 
clinical variables showed fi ve signifi cant moderate correlati ons. Only one of these also 
showed a signifi cant correlati on in the analysis of ADC values with clinical variables. This 
was the correlati on between the caudate nucleus and TMT task performance (r = -0.36, 
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p< 0.01). Directly correlati ng the ADC and FA values of the white matt er pathways with 
each other revealed a number of signifi cant correlati ons which is shown in table IV in the 
supplementary material. The direct correlati on of ADC and FA of the same fi ber bundle 
shows that the ADC and FA of the sensorimotor cortex and prefrontal white matt er 
pathways are correlated. 
Figure 1. Typical example of ROIs (A) and subsequent white matt er fi ber pathways in a premanifest gene carrier of 
the corpus callosum (B), sensorimotor cortex (C), caudate nucleus (D), prefrontal cortex (E) and thalamus (F). 3D 
crosses depict orientati on, whereby H = head, F = feet, A = anterior, P = posterior, R = right, L = left .
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Table 1. Group demographics, ADC and FA values, and number of seed 
voxels per region of interest for the premanifest gene carriers and their 
controls. 
Control group A 
n: 14, male: 7
Premanifest gene carriers
n: 27, male: 16
Mean (SD) range Mean (SD) range
Age (yrs) 46 (7,5) 35 - 58 43 (8,3) 26 - 61
CAG - (-) - 43 (2,5) 39 – 50
IQ 105,6 (11,3) 88 - 130 101,3 (11,3) 76 - 118
TFC 13 (0) 13 - 13 12,6 (0,8) 10 - 13
UHDRS 1,9 (1,8) 0 - 6 2,4 (1,4) 0 - 4
ADC ROI # voxels ± SD mean ± SD # voxels ± SD mean ± SD p
Corpus Callosum 1884 ± 378 0.78 ± 0.028 1767 ± 319 0.81 ± 0.033* 0.014
Caudate Nucleus 58 ± 13 0.73 ± 0.071 47 ± 11*** 0.76 ± 0.053 0.160
Thalamus 2700 ± 843 0.73 ±0.023 2601 ± 657 0.73 ± 0.023 0.994
FA ROI
Corpus Callosum 1884 ± 378 0.76 ± 0.019 1767 ± 319 0.75 ± 0.021 0.461
Caudate Nucleus 58 ± 13 0.17 ± 0.015 47 ± 11*** 0.18 ± 0.023 0.058
Thalamus 2700 ± 843 0.34 ± 0.025 2601 ± 657 0.33 ± 0.022 0.368
ADC Fiber pathway # voxels ± SD mean ± SD # voxels ± SD mean ± SD
Corpus Callosum 1884 ± 378 0.89 ± 0.049 1767 ± 319 0.91 ± 0.054 0.206
Caudate Nucleus 58 ± 13 0.98 ± 0.116 47 ± 11*** 0.94 ± 0.075 0.166
Thalamus 2700 ± 843 0.87 ± 0.055 2601 ± 657 0.89 ± 0.071 0.476
Motor cortex 595 ± 86 0.78 ± 0.017 580 ± 71 0.80 ± 0.029** 0.009
Prefrontal cortex 1136 ± 183 0.88 ± 0.044 1117 ± 322 0.89 ± 0.037 0.631
FA Fiber pathway
Corpus Callosum 1884 ± 378 0.49 ± 0.015 1767 ± 319 0.49 ± 0.016 0.785
Caudate Nucleus 58 ± 13 0.36 ± 0.017 47 ± 11*** 0.35 ± 0.031 0.683
Thalamus 2700 ± 843 0.42 ± 0.018 2601 ± 657 0.41 ± 0.021 0.515
Motor cortex 595 ± 86 0.40 ± 0.017 580 ± 71 0.39 ± 0.020 0.190
Prefrontal cortex 1136 ± 183 0.41 ± 0.018 1117 ± 322 0.40 ± 0.021 0.120
SD: standard deviati on, CAG: CAG repeat length, IQ: esti mate of premorbid intelligence quoti ent. TFC: Total 
Functi onal Capacity score.UHDRS: Unifi ed Hunti ngton’s Disease Rati ng Scale total motor score. ROI: Region 
of interest analysis. ADC: Apparent Diff usion Coeﬃ  cient in μm2/ms, FA: Fracti onal Anisotropy (no unit), Fiber 
pathway: fi ber pathways analysis between the listed region and the rest of the brain. *p <0.017, **p<0.01 
(adjusted for multi ple comparisons). # voxels: mean number of voxels in the listed seed region. ***Number of 
voxels diff ers signifi cantly from healthy controls
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Table 2. Group demographics, ADC and FA values, and number of seed 
voxels per region of interest for the early HD patients and their controls.
Control group B
n: 14, male: 7
Early HD
n: 16, male: 12
Mean (SD) range Mean (SD) range
Age (yrs) 51.4 (7.9) 42 - 65 48.2 (10) 31 - 63
CAG - (-) - 43 (1.6) 41 - 46
IQ 102.6 (6.6) 88 - 115 99.6 (12) 72 - 118
TFC 12.9 (0.3) 12 - 13 10.6§ (2) 7 - 13
UHDRS 3.1 (2.8) 0 - 7 18.3§ (10.4) 6 - 45
ADC ROI # voxels ± SD mean ± SD # voxels ± SD mean ± SD p
Corpus Callosum 1934 ± 312 0.80 ± 0.031 1445 ± 371*** 0.85 ± 0.040* 0.000
Caudate Nucleus 57 ± 12 0.74 ± 0.048 40 ± 7*** 0.83 ± 0.069* 0.001
Thalamus 2480 ± 531 0.74 ± 0.032 3102 ± 1062 0.74  ± 0.034 0.863 
FA ROI
Corpus Callosum 1934 ± 312 0.75 ± 0.012 1445 ± 371*** 0.73 ± 0.033 0.046 
Caudate Nucleus 57 ± 12 0.17 ± 0.018 40 ± 7*** 0.19 ± 0.019 0.072
Thalamus 2480 ± 531 0.33 ± 0.021 3102 ± 1062 0.32 ± 0.034 0.95
ADC Fiber pathway # voxels ± SD mean ± SD # voxels ± SD mean ± SD
Corpus Callosum 1934 ± 312 0.89 ± 0.051 1445 ± 371*** 0.95 ± 0.067** 0.008
Caudate Nucleus 57 ± 12 0.88 ± 0.107 40 ± 7***  0.97 ± 0.079 0.023
Thalamus 2480 ± 531 0.85 ± 0.080 3102 ± 1062 0.93 ± 0.063** 0.007
Motor cortex 589 ± 117 0.79 ± 0.023 593 ± 110 0.82 ± 0.027** 0.001
Prefrontal cortex 1118 ± 239 0.88 ± 0.023 1202 ± 274 0.95 ± 0.056** 0.000
FA Fiber pathway
Corpus Callosum 1934 ± 312 0.48 ± 0.013 1445 ± 371*** 0.47 ± 0.017 0.027 
Caudate Nucleus 57 ± 12 0.35 ± 0.027 40 ± 7*** 0.35 ± 0.021 0.592
Thalamus 2480 ± 531 0.41 ± 0.016 3102 ± 1062 0.41 ± 0.024 0.644
Motor cortex 589 ± 117 0.38 ± 0.019 593 ± 110 0.37 ± 0.024 0.059
Prefrontal cortex 1118 ± 239 0.39 ± 0.016 1202 ± 274  0.38 ± 0.014** 0.006
SD: standard deviati on, CAG: CAG repeat length, IQ: esti mate of premorbid intelligence quoti ent. TFC: Total 
Functi onal Capacity score. UHDRS: Unifi ed Hunti ngton’s Disease Rati ng Scale total motor score. §Signifi cant 
diff erence from control group, p< 0.01. ROI: Region of interest analysis. ADC: Apparent Diff usion Coeﬃ  cient in 
μm2/ms, FA: Fracti onal Anisotropy (no unit), Fiber pathway: fi ber pathways analysis between the listed region 
and the rest of the brain. *p <0.017, **p<0.01 (adjusted for multi ple comparisons). # voxels: mean number of 
voxels in the listed seed region. ***Number of voxels diff ers signifi cantly from healthy controls.
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Discussion
The main fi nding of this study is that in premanifest gene carriers, the white matt er 
pathway of the sensorimotor cortex is impaired. Furthermore, our data show that in 
the early manifest phase of the disease impairment is more widespread and present in 
the white matt er pathways of the sensorimotor cortex, corpus callosum, thalamus, and 
prefrontal cortex. Finally, a relati onship is seen between the changes in white matt er 
pathways and functi onality in the domains of motor, oculomotor and cogniti on. Moreover 
this study confi rms fi ndings of regional diff erences in the corpus callosum of premanifest 
and the caudate nuclei and corpus callosum of early HD14;27.
In the premanifest phase of the disease, our study demonstrated a reducti on of integrity 
of only the sensorimotor cortex fi bers pathway, therefore this suggests that this pathway 
may be one of the fi rst to be aff ected by HD. This is supported by the positi ve relati onship 
between a higher probability of onset within 5 years, and a higher burden of pathology, 
with the loss of integrity of the sensorimotor cortex fi bers. This premanifest cohort is ‘free’ 
of motor symptoms, and therefore these fi ndings in a truly ‘premotor’ premanifest group 
further support the idea that these white matt er changes are among the fi rst to occur. 
This study is the fi rst to demonstrate this change across the whole pathway; however, 
other studies examining this area do provide support for this fi nding. The fi ndings of the 
voxel–by–voxel white matt er analysis of Reading et al. (2005)12 found diff erences in a 
cluster of voxels coinciding with the primary motor cortex (Brodmann area 4). Atrophy of 
the sensorimotor cortex was demonstrated as the only corti cal region to be aff ected in 
premanifest gene carriers far from predicted onset4. Furthermore diff erences have been 
reported in functi ons that uti lise this area in premanifest gene carriers, such as measures 
of motor functi on5;28. The other important fi nding of our study in premanifest gene carriers 
is the diff erences in diff usivity in the corpus callosum, thereby replicati ng previous fi ndings 
by Rosas et al. (2006,2009)14;27. However we add that these diff erences are not seen in the 
white matt er projecti ons specifi cally going to and from the corpus callosum. Therefore, 
when looking beyond the main structure it can be suggested that the loss of integrity of 
the main structure is apparent, but not spread over its enti re network, as is the case in 
manifest HD. 
In the early manifest phase of HD, our data show that the diff usivity of the fi ber pathways 
of the thalamus, corpus callosum, sensorimotor, and prefrontal cortex was higher in HD 
than in healthy controls. This suggests a disintegrati on of these structures. Of the fi ve 
white matt er pathways examined in HD all were found to be aff ected except the pathways 
of the caudate nuclei. The absence of aff ected white matt er from the caudate nucleus 
should be interpreted with some cauti on. It may suggest that the magnitude of integrity 
loss may not be the same for a structure as for its fi bers at a given stage of the disease. 
However the variance of these measurements is larger than that of the other fi bers 
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pathways. The remaining results, such as that of reduced integrity of the prefrontal cortex 
fi bers, fi nd support in the regional diff erences demonstrated by Rosas et al. (2006)14. Our 
results show changes in ADC and almost no changes in FA. This suggests that of these 
two closely related measures, ADC is more sensiti ve in demonstrati ng changes across 
large pathways in HD. The results of the regional analysis showed higher diff usivity in the 
caudate nucleus and corpus callosum in HD than in healthy controls. This was not the case 
in the thalamus, whereby similar diff usion properti es were seen in both HD and controls. 
Our fi ndings concur with previous cross-secti onal and longitudinal fi ndings of a widespread 
eff ect of HD on white matt er14;20;22;29. The fi nding that a region was not aff ected, but its 
fi bers were, demonstrates the need to embrace the full potenti al of DTI measures for HD, 
as this shows that despite a structure not showing integrity diff erences, the fi bers that are 
needed for this structure to communicate with the brain may well be aff ected. In the case 
of the thalamus this is especially relevant to the clinical expression of the disease as this 
structure is vital to a large number of functi onal processes. 
The previously discussed outcomes demonstrate that almost all fi ber pathways that we 
examined are aff ected in early manifest HD and that one specifi c pathway is also aff ected 
in premanifest gene carriers. In exploring the clinical implicati ons of these fi ndings we 
see strong relati onships between both motor, oculomotor and cogniti ve measures, and 
diff usivity measures of the pathways of the corpus callosum, thalamus, sensorimotor and 
prefrontal cortex. Although one cogniti ve measure does correlate to the prefrontal cortex 
fi ber the cogniti ve measures are most strongly related to the sensorimotor cortex fi bers. 
This fi nding can be explained with two complementary hypotheses. First, as seen in the 
premanifest group, the fi bers of the sensorimotor cortex are the fi rst to show decreased 
integrity. This suggests that these are the most severely aff ected fi bers in the earliest 
(premanifest) stages of HD; therefore, it is not surprising that the clinical measures of 
decline relate to these fi bers. Second, HD eff ects both cogniti on and motor functi on, 
and all cogniti ve tests require a motor response. A consequent fi nding in cogniti ve HD 
literature is that cogniti ve tests sensiti ve to psychomotor speed are the most sensiti ve 
tasks. A great deal of voluntary motor functi oning is initi ated in the sensorimotor cortex. 
Because of this we were not enti rely surprised that cogniti ve tests relate strongly to the 
fi bers of the sensorimotor cortex. The tasks chosen for analysis were those that provide 
meaningful outcomes for all study groups, and did not show ceiling or ﬂ oor eff ects. 
Therefore, we can conclude that fi bers associated with higher order cogniti ve and motor 
coordinati on are aff ected in a manner that is congruent to clinical manifestati ons and 
that for this reason, DTI measures can be applied to characterise the structure-functi on 
relati onship of white matt er. This conclusion is supported in other studies of white and 
grey matt er and clinical measures6,30. In another study of eye movements and fi ber 
tracking, similar results were found as ours, especially fi nding a relati onship between eye 
movements and fi ber FA31. We did not show a relati onship between CAG repeat length 
or behavioral processes and changes in white matt er integrity. The CAG repeat length is 
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not dependent on disease progression or white matt er pathways and this stable quality 
may, in part, explain this fi nding. A possible explanati on for the absence of a relati onship 
between behavioral measures and diff usivity may be the complex pathophysiological 
and psychological process underlying these behavioral changes that may not be primarily 
dependent on white matt er. Alternati vely, the use of medicati on may be a factor in the 
level of symptoms reported (full details of medicati on use are outlined in Tabrizi et al. 
(2009)4 leading to an underesti mati on of neuropsychiatric problem behavior. However, 
a recent study has shown that behavioral changes in premanifest HD remain stable32, 
thereby reinforcing the idea that degenerati ve processes are not at the root of these 
neuropsychiatric diff erences. Therefore we conclude that behavioral changes may not be 
directly reﬂ ected by white matt er changes. 
This study examined and demonstrated diff erences in white matt er pathways of fi ve HD 
relevant regions, this restricti on is a limitati on of the study. Diff erences were found in 
the number of seed voxels in the caudate nucleus in premanifest gene carriers and in the 
caudate nucleus and corpus callosum in manifest HD. On the contrary, diff erences were 
not seen in the number of voxels in the thalamus, sensorimotor region, or prefrontal 
regions in the pati ent group. These reducti ons do seem to reﬂ ect expected atrophy, but 
do not follow the patt ern of diff erences found in ADC. Therefore these diff erences do 
not seem to explain the diff erences in diff usivity. The results from a correlati on analysis 
between number of voxels in a seed region and clinical variables reveal only fi ve signifi cant 
moderate correlati ons. This is in contrast to the analysis of relati onship between average 
ADC and the clinical variables whereby 25 moderate to high correlati ons were signifi cant. 
Furthermore only one of these fi ve was the same as one of the 25 clinical correlati ons. 
These results suggest the volume of the seed region does not explain the observed original 
correlati ons. With this possibility excluded, it can be stated with more certainty that the 
relati onships observed reﬂ ect the underlying changes in structure of the white matt er 
pathways. Furthermore, direct correlati on of the ADC and FA of the white matt er pathways 
also supports this conclusion. It can be seen that only signifi cant relati onships between 
the ADC and FA of the same pathways were apparent for pathways that showed (nearly) 
signifi cant group diff erences. Overall, the results call for further examinati on of white 
matt er pathways. The fi ndings warrant confi rmati on with longitudinal follow-up.
In conclusion, we demonstrated that the sensorimotor cortex fi bers are aff ected already in 
the premanifest phase of HD and therefore may be a good target for following progression 
of the disease. Our data show that impairment is seen in corpus callosum, nuclei and fi ber 
projecti ons of HD relevant brain regions in both premanifest and early manifest HD. These 
impairments relate to proven correlates of clinical dysfuncti on. Overall, the fi ndings of this 
study confi rm the feasibility and use of DTI measures in HD research, whereby we show 
that ADC is a good measure in characterising the impaired functi on-structure relati onship 
present in HD.
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Supplementary Material
Supplementary Methods
Segmentati on
Based on the anatomical co-registrati on images, the ROIs were segmented in nati ve space 
for each individual. This was done by two experienced radiographers, blinded to pati ent 
group. Two types of ROIs were defi ned. Basal ganglia ROIs for analysis, and seed-ROIs as 
starti ng point for fi ber tracking. The basal ganglia ROIs were segmented as follows. For 
the caudate nucleus all voxels clearly bounded by the lateral ventricle and the anterior 
limb of the internal capsule were selected. The putamen segmentati on included all voxels 
within the structure bounded on the medial side by the globus pallidus and the anterior 
limb of the internal capsule, and on the lateral side by the capsula extrema. The thalamus 
segmentati on was performed by allocati ng all voxels to the ROI that medially bordered 
the third ventricle, were superiorly bordered by the lateral ventricle, and were laterally 
bordered by the internal capsule. The seed ROIs were corti cally based, and because these 
areas were not as clearly anatomically bounded as the other structures, Brodmann areas 
were used to defi ne the segmentati on. Reading et al. (2005) defi ned areas of the cortex 
in their analysis of presymptomati c HD by means of these Brodmann areas1. The superior 
prefrontal region was segmented on areas 9 (frontal porti on) and 10. Brodmann area 10 
is medially bound by the superior rostral suclus, and dorsally by the inferior frontal suclus 
and the frontomarginal sulcus. Area 9 bordered inferiorally by area 10 and dorsally by the 
superior frontal sulcus. Aft er all ROIs were drawn, the radiographers switched scans and 
carefully checked the segmentati ons for potenti al miss-segmentati on. Aft er all scans had 
been segmented a random 20% were selected for verifi cati on by a neurologist specialised 
in neuro-imaging. Any segmentati on voxels that were felt to be outside of the targeted 
anatomy were discussed unti l a consensus was formed and these few voxels were changed 
accordingly.
Analysis
We applied the soft ware supplied by the manufacture by transferring the raw DTI data 
and the anatomic co-registrati on images to an off -line manufacturer provided console. In 
doing so the data were loaded into the Philips Research Image-processing Development 
Environment (PRIDE) (Philips Medical Systems). Then the diff usion tensor and derived 
measures, including ADC and FA, were calculated using the Philips PRIDE Fiber Tracking 
tool (version 2.5.3). This allows fi ber tracking based on the Fiber Assignment by 
Conti nuous Tracking (FACT) algorithm2. The algorithm values for restricti ng fi ber tracking 
were kept at default and were: minimum FA value of 0.10, maximum angle change: 27°, 
and a minimum fi ber length of 10mm. This same method and soft ware has been applied in 
a number of disorders of both brain and muscle, such as developmental CNS anomalies3, 
corti cospinal tract stroke4, lateral patellar dislocati on5 and Lissencephaly6.
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Supplementary Results
Table 4. Cross tabulation of correlation coefﬁ cients of the FA and ADC of the 
white matter ﬁ ber pathways with each other.
 Corpus 
Callosum
Caudate 
Nucleus
Thalamus Motor 
cortex
Prefrontal 
cortex
ADC FA ADC FA ADC FA ADC FA ADC FA
Corpus 
Callosum
ADC - -.123 .482 -.262 .705 .069 .644 -.312 .572 -.432
FA - .002 .136 -.065 .472 -.439 .581 -.272 .516
Caudate 
Nucleus
ADC - .028 .594 .153 .185 .091 .206 -.077
FA - -.116 .404 -.052 .190 -.352 .046
Thalamus
ADC - .034 .476 -.145 .353 -.183
FA - -.021 .290 -.050 .126
Motor 
cortex
ADC - -.604 .548 -.530
FA - -.492 .473
Prefrontal 
cortex
ADC - -.483
FA -
ADC: Apparent Diff usion Coeﬃ  cient, FA: Fracti onal Anisotropy. Bold = signifi cant correlati on
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Abstract
Increased iron in subcorti cal structures in pati ents with Hunti ngton’s Disease (HD) has 
been suggested as a causal factor of neuronal degenerati on. The present study examines 
iron accumulati on, measured using magneti c resonance imaging (MRI), in premanifest 
gene carriers and in early HD pati ents as compared to healthy controls. In total 27 early 
HD pati ents, 22 premanifest gene carriers and 25 healthy controls, from the Leiden site of 
the TRACK-HD study, underwent 3T MRI including high resoluti on 3D T
1
- and T
2
-weighted 
and asymmetric spin echo (ASE) sequences. Magneti c Field Correlati on (MFC) maps of 
iron levels were constructed to assess magneti c fi eld inhomogeneiti es and compared 
between groups in the caudate nucleus, putamen, globus pallidus, hippocampus, 
amygdala, accumbens nucleus, and thalamus. Subsequently the relati onship of MFC value 
to volumetric data and disease state was examined. Higher MFC values were found in 
the caudate nucleus (p<0.05) and putamen (p<0.005) of early HD compared to controls 
and premanifest gene carriers. No diff erences in MFC were found between premanifest 
gene carriers and controls. MFC in the caudate nucleus and putamen is a predictor of 
disease state in HD. No correlati on was found between the MFC value and volume of these 
subcorti cal structures. We conclude that Hunti ngton’s disease pati ents in the early stages 
of the disease, but not premanifest gene carriers, have higher iron concentrati ons in the 
caudate nucleus and putamen. We have demonstrated that the iron content of these 
structures relates to disease state in gene carriers, independently of the measured volume 
of these structures. 
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Introducti on 
Hunti ngton’s Disease (HD) is an autosomal dominant neurodegenerati ve disorder 
characterised by brain atrophy and clinical deteriorati on in the domains of motor functi on, 
cogniti on and behaviour. HD is caused by an expanded CAG repeat in the HTT gene on 
the short arm of chromosome 4. Geneti c testi ng can be performed in those at risk, prior 
to disease onset, to ascertain that they carry the gene and will develop the disease in 
the future. Histological reports describe profound cellular structure deteriorati on of the 
putamen and caudate nucleus1-3, as well as iron accumulati on4. Autopsy brain ti ssue 
extracti ons confi rmed these fi ndings in end-stage pati ents by demonstrati ng increased 
absolute iron levels in these structures5. 
MRI has been shown to be a valuable tool for esti mati ng iron levels in vivo6;7. Several 
MRI techniques have been used to assess the distributi on of iron in the brain in normal 
aging8-10 and in neurodegenerati ve diseases11-14. These include T
2
 and T
2
* mapping, as well 
as suscepti bility weighted imaging (SWI). Each of these techniques is simple to perform, 
but have signifi cant potenti al limitati ons. A confounding factor of both T
2
- and T
2
*-
based imaging is that measurements are also aff ected by changes in the water content, 
associated for example with destructi ve brain processes15, and can mask the changes in 
iron content6;9;14;16;17. Ex vivo histological staining of putamen samples from HD pati ents 
demonstrated elevated putamen iron levels18 but there was litt le correlati on to T
2
-
weighted imaging of these samples. To overcome these limitati ons T
2
 can be measured at 
two diff erent fi eld strengths to remove the fi eld independent contributi on to T
2
 changes. 
Because the T
2 
value of water is relati vely fi eld strength independent19, this method is a 
more sensiti ve measurement of iron content. However, scanning subjects on two diff erent 
MRI systems is clinically impracti cal. MRI approaches based on changes in T
2
* relaxati on 
ti me have also been widely applied16. In additi on to the sensiti vity of the measurement to 
water content, a specifi c limitati on of T
2
* imaging techniques is that measurements are 
aff ected by local background sources of magneti c fi eld inhomogeneiti es that cause signal 
loss unrelated to the internal iron content of the ti ssue6. SWI is a technique that provides 
an additi onal measure for detecti ng iron related changes by combining magnitude 
and phase data into a single image20. Because changes in the magneti c fi eld also lead 
to changes in the MRI signal phase, it has been suggested as a more sensiti ve method 
for detecti ng neurodegenerati ve disease related iron changes17. However SWI is not a 
quanti tati ve method and the limitati ons menti oned above for T
2
* techniques are also true 
for SWI. Hence, the limitati ons posed by the above described methods demonstrates the 
need for further development and applicati on of existi ng and new techniques12. 
The recently developed quanti tati ve technique of magneti c fi eld correlati on (MFC) imaging 
has the potenti al to solve the limitati ons of previously applied MRI techniques in HD. 
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MFC is sensiti ve to spati ally inhomogeneous magneti c fi elds, such as those generated by 
iron-rich regions. An advantage is that this technique is insensiti ve to changes in water 
concentrati on. For this reason MFC has previously been used to study increased iron 
concentrati ons in the basal ganglia in pati ents with aceruloplasminemia21, pati ents with 
traumati c brain injury22 and in pati ents with multi ple sclerosis23. The relati onship between 
the measured MFC values and magneti c fi eld inhomogeneiti es is more direct compared 
to other relaxometry measurements, allowing for a clearer physical interpretati on of MFC 
measurements21;24. Furthermore, MFC imaging can be implemented practi cally in a single 
short scan at one fi eld strength. 
Previous MRI studies have suggested that increased iron in the striatum could be a causal 
factor of the symptoms of HD11;19. Given that both prior to, and aft er, disease onset, brain 
changes in the form of volumetric reducti ons have been systemati cally reported25-28, it 
is possible that iron levels change both in the premanifest and in the manifest stages of 
the disease. However, this hypothesis has only been examined previously in one group 
of premanifest gene carriers of HD29. It has been suggested that increases in iron could 
promote neurotoxicity through the inducti on of oxidati ve reacti ons12;30. A questi on 
sti ll debated is whether these iron changes are causal or secondary factors of disease 
processes. With this current study we aim to determine at which disease stage iron 
accumulati ons increase in HD. 
It remains unclear to what extent iron changes are independent of volume decreases in 
both the premanifest and manifest phases of the disease, or whether iron levels alter as a 
direct result of volumetric change25;28;31. Volume decreases may concentrate the iron that 
is already present, or alternati vely more iron may accumulate as the disease progresses. 
It is important for our understanding of HD, as well as for future research, to diff erenti ate 
between these pathophysiological mechanisms. For this reason, the second aim of this 
study is to examine and relate the potenti al iron changes to the amount of atrophy present 
in the related subcorti cal grey matt ers structures. 
The current reports of iron in HD examined only a selecti on of the subcorti cal grey 
matt er structures. However, recently atrophy has been demonstrated in seven major 
subcorti cal structures in the progressive stages of HD27. In this current study we investi gate 
in both premanifest and early HD the extent to which elevated iron may be present. 
We hypothesize that iron concentrati ons will be higher in these subcorti cal grey matt er 
structures in HD pati ents. Furthermore, we expect that iron may play a role in HD that is 
not explained by volumetric diff erences. 
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Material and Methods
Parti cipants
Parti cipants were recruited from the Leiden University Medical Centre (LUMC) study site 
of the longitudinal TRACK-HD study28, 27 manifest gene carriers in the early disease stages 
one or two (early HD)32, 22 premanifest gene carriers (prior to disease onset) and 25 
healthy controls underwent 3T MRI scanning including an asymmetric spin echo sequence 
and functi onal assessment. 
Inclusion criteria for the early HD group were a positi ve geneti c test for the HTT gene with 
40 or more CAG repeats, the presence of motor disturbances quanti fi ed by more than fi ve 
points on the Unifi ed Hunti ngton’s Disease Rati ng Scale – motor score (UHDRS-TMS), and 
a minimum Total Functi onal Capacity (TFC) score of seven points32. Inclusion criteria for 
premanifest gene carriers consisted of 40 or more CAG repeats, and the absence of motor 
disturbances with fi ve or less points on the UHDRS-TMS. A burden of pathology score 
greater than 25033 was required. Age- and gender-matched gene-negati ve relati ves of HD 
gene carriers were included as healthy controls. Level of educati on in accordance to the 
Internati onal Standard Classifi cati on of Educati on (ISCED) was recorded. The study was 
approved by the Medical Ethical Committ ee and all parti cipants gave informed consent. 
MRI protocol
An MRI protocol including high-resoluti on 3D T
1
-weighted and asymmetric spin echo (ASE) 
sequences was applied using a 3 Tesla whole body scanner (Achieva, Philips Healthcare, 
Best, The Netherlands) with an eight channel receive array head coil. Parti cipants were 
positi oned carefully with the applicati on of strapping or cushioning where needed, to 
reduce the potenti al occurrence of involuntary head movement.
A 9.5 minute isotropic 1 mm3 3D T
1
-weighted scan was acquired with the following 
parameters: repeti ti on ti me (TR)/ echo ti me (TE) = 7.7 ms/3.5 ms, fi eld-of-view (FOV) 
= 24x24x16.4 cm3. A T
2
-weighted image (turbo spin echo) was acquired with the same 
volumetric spati al resoluti ons as the T
1
-weighted images, with TE = 250 ms and TR = 2500 
ms, also with a durati on of 9.5 minutes. The T
2
-weighted image for this study was only 
used to exclude any possible comorbidity. An 8 minute ASE sequence was implemented 
with the following scan parameters: TR/TE/ﬂ ip angle = 1005 ms/38 ms/90°. The FOV was 
22x19x7cm3 with a voxel size of 1.9x1.7x2mm3 for 18 slices with an interslice gap of 2 mm, 
positi oned through the basal ganglia and an acquisiti on bandwidth of 290 Hz. The positi on 
of the refocusing radiofrequency pulse was shift ed from its original positi on towards the 
excitati on radiofrequency pulse by several ti me shift s = 0, 2.3, 6.9, 11.5 and 13.8 ms, thus 
varying the sensiti vity of the sequence to magneti c fi eld variati ons. 
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Post-processing of MRI images
Magneti c ﬁ eld correlati on
Prior to post-processing all images were screened for arti facts and clinical abnormaliti es 
by a clinical neuroradiologist from the radiology department of the LUMC. Furthermore 
structural images were subjected to external quality control by a contract research 
organisati on (IXICO Ltd, London, UK). ASE images were fi tt ed to a theoreti cal model 
relati ng the signal decay to the homogeneity of the magneti c fi eld24. The resulti ng MFC 
maps display the amount of magneti c fi eld inhomogeneiti es present for each voxel. 
Higher MFC values correspond to a more inhomogeneous magneti c fi eld. A correcti on was 
applied to the MFC maps to account for the contributi ons of macroscopic magneti c fi eld 
inhomogeneiti es21 using the non shift ed image and the fi rst asymmetric echo image of 2.3 
ms. These macroscopic fi eld inhomogeneiti es arising from, for example, the cavernous 
sinus and the skull are unrelated to iron content. The contributi ons from such areas were 
corrected to retain the underlying microscopic variati ons, such as those caused by iron, in 
the magneti c fi eld in the remaining brain ti ssue.
Image Segmentati on
Segmentati on of the accumbens nucleus, amygdala, caudate nucleus, hippocampus, 
globus pallidus, putamen and thalamus was performed on the T
1
-weighted scans using the 
FIRST tool34 from FMRIB’s Soft ware Library (FSL, Oxford). Based on these segmentati ons, 
the absolute volume of each structure was calculated with FSLstats (FSL, Oxford), where 
the resulti ng value represents the total bi-lateral volume of a single structure. The 
volumetric analysis procedure, including a correcti on for intracranial volume, was identi cal 
to that described previously27 making use of the FSL tools (FSL oxford). The segmentati on 
masks were registered to the MFC maps using the T
1
-weighted scans and the quality of 
the registrati on was visually inspected. Average MFC values were calculated for each 
segmented bilateral structure. 
Stati sti cs
To examine diff erences in MFC and volume between the groups, one-way Multi variate 
Analyses of Covariance (ANCOVA) were performed with the MFC value, or volumetric value 
(corrected for intracranial volume), of each subcorti cal structure as the outcome variable, 
while controlling for age and gender. The p value aft er post-hoc Bonferroni correcti on was 
considered signifi cant at p<0.05. 
To determine the independent potenti al for MFC value as a marker of disease state in HD, 
again only gene carriers were examined (premanifest+early HD, n=49). Logisti c regression 
analysis was performed with disease state (premanifest vs. early HD) as the variable to 
be predicted. Age, gender, CAG repeat length, MFC value and volume of the relevant 
subcorti cal structures were included as predictor variables19;35. These were entered in one 
block (ENTER method) during analysis. All stati sti cal analyses were performed with the 
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SPSS 17.0 package (SPSS Inc., Chicago, USA). 
Subsequently, two analyses were performed to investi gate the potenti al correlati on 
between MFC values in any aff ected regions and volume changes in all gene carriers 
(premanifest + early HD). First, to investi gate the direct relati onship between MFC value 
and volume of the individual subcorti cal structures, Pearson’s parti al correlati on analysis 
was performed, whilst controlling for the same covariates as in the logisti c regression, 
namely age, gender and CAG repeat length. Secondly, to test for the potenti al inﬂ uence 
of the interacti on term (MFC value*volume) between MFC value and volume on disease 
state (premanifest or early HD), a general linear model univariate analysis of variance was 
performed. 
To understand the potenti al relati onship between iron levels and clinical measures, 
Pearson’s parti al correlati on analysis was performed between iron in regions showing 
aberrant levels and clinical measures while controlling for age, gender and CAG repeat 
length. This was performed in the gene carrier group for the Unifi ed Hunti ngton’s Disease 
Rati ng Scale – Total Motor Score (UHDRS), the Unifi ed Hunti ngton’s Disease Rati ng Scale 
- Total functi onal Capacity measure (TFC), the number of correct answers on the Symbol 
Digit Modaliti es Test (SDMT), the number of correct answer on the Stroop word reading 
test (SWR) and the Beck’s Depression Inventory 2nd Editi on (BDI-II). For the premanifest 
gene carriers only an additi onal analysis was performed to understand any relati onship 
between iron levels and the number of years to predicted disease onset, calculated 
according to the method by Langbehn et al. (2004)35. Pearson correlati on was applied 
without covariates, as it is not appropriate to include covariates that are used in the 
predicti on of expected disease onset. The p value was Bonferroni corrected for multi ple 
comparisons. 
Results
MFC value
No signifi cant group diff erences were found for age, gender or educati on levels 
between controls, premanifest gene carriers, and early HD (table 1). The early HD group 
demonstrated lower scores on the TFC and higher total scores on the UHDRS (p<0.001) 
compared to the healthy control group and premanifest gene carriers. 
Typical examples of the brain structure segmentati ons (fi gure 1a) and MFC maps in a 
healthy control (fi gure 1b), a premanifest gene carrier (fi gure 1c) and an early manifest 
pati ent (fi gure 1d) are shown in fi gure 1. This fi gure demonstrates the spati al distributi on 
of the magneti c fi eld inhomogeneiti es, with the highest values visible in the caudate 
nucleus, putamen, and globus pallidus. Higher MFC values were observed in the early 
HD group: the MFC group averages can be found in table 2 and are displayed in fi gure 
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2. The MFC values in the caudate nucleus and putamen of HD pati ents were found to 
be signifi cantly higher than in healthy controls (p = 0.03 and p = 0.003, respecti vely). 
No signifi cant diff erences were found between premanifest gene carriers and controls. 
No other nuclei showed diff erences either between early HD pati ents and controls, or 
between premanifest gene carriers and controls. 
Table 1. Demographic informati on of controls, premanifest gene carriers, and early 
Hunti ngton’s disease
Healthy 
Controls
Premanifest
Gene Carriers
Early Manifest 
Pati ents
N 25 22 27
Gender Female/Male 13/12 13/9 19/8
Age
Mean yrs ± SD
Range (min – max)
50.3 ± 8.3
36 - 66
45.6 ± 8.5
27 - 62
50.0 ± 9.9
30 - 64
Educati on level Mean ISCED level ± SD 3.4 ± 1.1 3.8 ± 1.1 3.2 ± 1.3
UHDRS Mean total score ± SD 2.1 ± 1.7 2.6 ± 1.4 25.2 ± 15.4*
TFC Mean ± SD; Range: 0-13 12.9 ± 0.2 12.5 ± 0.8 9.8 ± 2.8*
N = number of parti cipants, SD = Standard Deviati on, ISCED = Internati onal Standard Classifi cati on of Educati on 
(range 0-6), UHDRS = Unifi ed Hunti ngton’s Disease Rati ng Scale – Total Motor Score, TFC = Total Functi onal 
Capacity, * Signifi cantly diff erent from both healthy controls and premanifest HD at p<0.001. 
Figure 1. Typical example of magnitude images
A) Magnitude image showing segmentati on of caudate nucleus (yellow), putamen (brown) and globus pallidus 
(orange). The corresponding MFC maps for a healthy control (B), premanifest gene carrier (C) and early 
Hunti ngton’s disease pati ent (D). High MFC values are found in the subcorti cal grey matt er structures, known to 
correspond with high iron concentrati ons. Highest values are found in the early HD pati ent. The high MFC values 
found laterally near the ti ssue-skull interface are caused by macroscopic magneti c fi eld inhomogeneiti es from the 
skull ti ssue interface that could not be properly corrected. The distance to the areas of interest is so large that no 
interference with measurements in the deep gray matt er structures is expected. 
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Figure 2. Groups diff erences in MFC 
Figure 2: MFC group averages for controls, premanifest and manifest HD. All images were registered to standard 
space and averaged. The resulti ng average is a visual display of the values shown in table 2, however more 
localised informati on is present in this visual display. High MFC values are found in the subcorti cal grey matt er 
structures, known to correspond with high iron concentrati ons.
Volume
The volumes of the caudate nucleus and putamen were smaller in early HD pati ents 
compared to premanifest gene carriers and controls, and also smaller in premanifest gene 
carriers as compared to controls (all p<0.0001). Smaller volumes of the accumbens nucleus 
(p<0.0001), globus pallidus (p<0.0001) and thalamus (p=0.001) were also found in early HD 
as compared to healthy controls only (table 2). 
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Table 2. Average MFC values and subcorti cal grey matt er volumes per subcorti cal nucleus 
per study group
Mean MFC(s-2) SD Volume (ml) SD
Accumbens nucleus
Control group 385.6 101.2 1.10 .25
Premanifest 343.2 93.7   .98* .19
Early HD 450.3 219.1      .76**§ .17
Amygdala
Control group 446.6 122.0 2.54 .44
Premanifest 419.0 108.6 2.46 .45
Early HD 412.2 111.9 2.29 .42
Caudate nucleus
Control group 398.6 55.0 6.96 .91
Premanifest 372.4 76.8   5.86** .72
Early HD     478.1*§§ 153.1     4.72**§§ .76
Hippocampus
Control group 452.0 102.8 7.91 .82
Premanifest 400.0 59.8 7.80 .80
Early HD 409.6 102.2  7.21 .86
Globus pallidus
Control group 643.7 120.8 3.54 .42
Premanifest 715.3 215.2 3.27 .47
Early HD 807.4 368.9      2.67**§§ .44
Putamen
Control group 481.8 120.6 4.83 .71
Premanifest 491.8 154.0   4.14** .50
Early HD     632.1**§ 190.6     3.28**§§ .50
Thalamus
Control group 388.4 60.3 15.23 1.45
Premanifest 377.8 92.9 14.80 1.39
Early HD 373.6 82.1   13.67** 1.39
MFC values represent average value in s-2. Volumetric analysis performed with correcti on for intercranial volume, 
volumes reported represent absolute total volume of each left  and right nucleus. 
* Signifi cantly diff erent from healthy controls (p<0.05)
** Signifi cantly diff erent from healthy controls (p<0.005)
§ Signifi cantly diff erent from premanifest gene carriers (p<0.05)
§§ Signifi cantly diff erent from premanifest gene carriers (p<0.005)
Predicti ng disease state
Logisti c regression was performed to assess the predicti ve quality of subcorti cal 
MFC values of the caudate nucleus and putamen to disease state in all gene carriers 
(premanifest or early HD) as shown in table 3. The MFC values and volumes of the caudate 
nucleus, and putamen were signifi cant predictors of disease state. In contrast, age, gender 
and CAG repeat length were not signifi cant contributors to the predicti on of disease state. 
Figure 3 shows the relati onship between volume and MFC value for the caudate nucleus 
and putamen. In assessing further the independence of these two signifi cant predictors 
the Pearson’s parti al correlati on showed that the MFC value and volume were not related 
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to one another in the caudate nucleus (r=-0.105, p=0.486) or putamen (r=-0.132, p=0.382) 
in gene carriers (premanifest + early HD). The univariate analysis of variance assessing any 
potenti al interacti on eff ect of MFC and volume on disease state also showed no interacti on 
(caudate nucleus: p=0.916; putamen: p=0.992).
Table 3. Logisti c regression model for predicti ng disease state (premanifest vs. early 
manifest) in all gene carrying parti cipants
Total model Level of stati sti cal signifi cance
(p value)
χ2 DF p MFC value Volume
Caudate nucleus 33.3 5 <0.0005 0.02 0.01
Putamen 40 5 <0.0005 0.04 0.01
Table shows only those predictors that signifi cantly contributed to the model. MFC values represent average 
value per subcorti cal nucleus. DF = degrees of freedom. Volumes included are total volume of left  and right 
nucleus per subcorti cal structure. 
Relati onship to clinical measures
The relati onship between clinical measures and iron levels in the caudate nucleus and 
putamen was examined for both gene carriers groups. No relati onship was found between 
UHDRS total motor score, TFC, SDMT, SWR or BDI-II and iron levels in the putamen or 
caudate nucleus. For the premanifest group only correlati on no signifi cant relati onship 
between predicted years to onset and iron in the caudate nucleus or putamen was 
shown. Individual iron levels versus a measure of disease load, namely burden of disease 
pathology33, are displayed for individual gene carriers in fi gure 4. 
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Figure 3: Individual MFC values set out against volumetric data for (A) caudate nucleus and 
(B) putamen. 
Figure 4: Burden of disease pathology scores ((CAG - 35.5) * age) versus MFC values for all 
gene carriers (premanifest + manifest) in the caudate nucleus and putamen. 
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Discussion
This study’s main fi ndings show increased levels of iron, as demonstrated by higher MFC 
values, in caudate nucleus and putamen in pati ents with early HD. MFC values were not 
signifi cantly diff erent to controls in premanifest gene carriers. For clarity and consistency 
with other studies, we will refer to changes in the measured iron-dependent quanti ty, 
namely MFC values, as changes in iron11;16;36. The iron levels in the putamen and caudate 
nucleus are not related to the volume of these structures. Furthermore, iron levels appear 
to predict the disease state (premanifest or early manifest) of HD gene carriers. 
In early HD the caudate nucleus and putamen show signifi cantly higher MFC values. This 
is in line with in vivo11;19 and ex vivo5;18  fi ndings. The relati ve MFC values in the healthy 
controls correspond to ex-vivo-determined levels of iron, whereby the globus pallidus 
showed highest values for all parti cipant groups, which is in agreement with previous 
studies of both aging and neurodegenerati on36-38. 
No signifi cant diff erences in iron were observed between premanifest gene carriers and 
healthy controls. The only other report in premanifest gene carriers found elevated iron 
in the globus pallidus29. However, this report was based on a group with less stringent 
inclusion criteria of individuals, namely without overt motor signs as opposed to a UHDRS 
cut-off  point of 5. The correlati on which Jurgens et al. (2010) found between the number 
of hypointense pixels and total motor score, demonstrates that all of the parti cipants 
with higher iron levels would have been classifi ed as having early manifest HD under our 
criteria29. It is certainly possible that the iron levels are not high enough for MFC, or any 
other existi ng imaging techniques, to pick up small changes in premanifest gene carriers, 
or that abnormal iron depositi ons do not occur unti l later in the disease process. The 
volumetric decreases of the caudate nucleus and putamen in premanifest gene carriers 
found in this present study are in line with previous reports25-27. 
This study has demonstrated that the individual iron content of the caudate nucleus and 
putamen independently predicts disease state in gene carriers (premanifest versus early 
manifest), also when taking into considerati on the predicti ve value of other commonly 
related factors, such as volume, CAG repeat length or age. Furthermore the iron content in 
the putamen and caudate nucleus is not directly related to the volume of these structures, 
and there is no interacti on eff ect present that explains disease state. Therefore, our results 
indicate that volumetric decrease and iron increase are two independent processes in HD, 
with iron accumulati on not occurring as a direct result of volume decrease (Figure 4). This 
is an important fi nding as it reiterates the need for increasing our understanding of the 
pathophysiological processes related to iron in HD. When considering this conclusion it is 
important to exclude the possibility of epiphenomenonological results, especially in early 
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HD. We addressed this by accounti ng for those factors most commonly found to explain 
the variance between premanifest and manifest gene carriers33;35. We propose that iron 
levels may be regarded as a marker of disease state, as iron does not diff erenti ate those 
prior to disease onset from controls, but does disti nguish between premanifest gene 
carriers and those in the earliest stages of HD. Reproducti on and longitudinal evaluati on 
of potenti al iron accumulati on may demonstrate the capacity to predict symptom 
progression or, as previously suggested, the age of disease onset39. 
Iron content in early HD was not found to be higher than in controls in the amygdala, 
hippocampus, nucleus accumbens or thalamus. This both replicates and also adds to 
previous fi ndings in which no diff erences were found in the hippocampus and thalamus19. 
We have measured a patt ern of elevated iron in early HD that could be toxic or an 
accelerated process of normal aging. However, oxidati ve stress related mechanisms, as a 
result of higher free radicals cannot be excluded40. It may be that iron depositi ons primarily 
aff ect nuclei that consist of the same types of cells, such as the medium spiny neurons 
common to the putamen and caudate nucleus, or as demonstrated in HD pati ents and 
mice, the microglia4. Many hypotheses on the role of iron in neurodegenerati on have been 
formulated but the exact mechanisms remains unclear12;41;42. 
Globus pallidus iron depositi ons showed an increase in the early HD group as compared to 
controls: however, this was not stati sti cally signifi cant. This may be related to the sequence 
parameters, and not due to an intrinsic absence of higher iron levels, especially as another 
study in manifest HD19 found higher iron in the globus pallidus. The chosen ASE parameters 
could be subopti mal for measurements in areas of very high iron concentrati on as a 
result of the pronounced signal reducti on. As a result a higher standard deviati on can be 
expected in the MFC maps within the globus pallidus, which was indeed the case. Future 
research at ultra high fi eld strength (7 Tesla and above) could increase the sensiti vity of the 
MFC method. 
We believe that the technique used in our study is a more direct measure of iron than 
conventi onal T
2
-, T
2
*- and SWI based methods that have been used extensively to study 
the distributi on of iron in the brain8;9;14, due primarily to the robustness with respect to 
any altered water concentrati ons. In the study by Bartzokis et al. (2007) T
2
 relaxati on 
values were obtained by scanning pati ents at two diff erent fi eld strengths and signifi cant 
diff erences were found in iron concentrati on of the putamen, globus pallidus, and caudate 
nucleus in manifest HD pati ents19. This is comparable to the results of our study. Vymazal 
et al. (2007) measured T
2
 relaxati on values at a single fi eld strength and found changes 
in the globus pallidus and white matt er only in HD pati ents16. The discrepancy between 
these and our results can potenti ally be explained by the sensiti vity of T
2
 measurements to 
water content, which is thought to change during disease progression due to, for example, 
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breakdown of the structural integrity of myelin9;15;19. Although we cannot defi niti vely 
exclude all potenti al sources of magneti c fi eld variati on43, we believe that based on ex-
vivo studies4;14 the changes observed in our and previous studies are related primarily to 
increased iron. An advantage of MFC measurements is that the macroscopic component of 
the fi eld inhomogeneiti es can be separated from the microscopic components, which is a 
confounding factor for T
2
* based techniques. 
A possible limitati on could be the inﬂ uence of other sources of magneti c fi eld variati on, 
such as the cavernous sinus or skull. However all possible steps were taken to prevent 
this inﬂ uence. Aft er correcti on a remainder of macroscopic fi eld variati ons is sti ll present 
located laterally near skull-ti ssue interface and around large vessels. However, upon visual 
inspecti on, the macroscopic contributi on of these regions around the basal ganglia are 
adequately corrected. 
In conclusion, we have demonstrated that pati ents with early HD have higher magneti c 
fi eld inhomogeneiti es in the caudate nucleus and putamen. This is not found in 
premanifest gene carriers. The iron content of the caudate nucleus, putamen seems 
to independently predicts disease state in HD gene carriers. Futhermore, we have 
demonstrated that increased iron accumulati on is an independent disease process not 
related to structural atrophy.
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Abstract
Background
Hunti ngton’s disease (HD) is characterised by both regional and generalised neuronal 
cell loss in the brain. Investi gati ng functi onal brain connecti vity patt erns in rest in HD has 
the potenti al to broaden the understanding of brain functi onality in relati on to disease 
progression. This study aims to establish whether brain connecti vity during rest is diff erent 
in premanifest and manifest HD as compared to controls. 
Methods
At the Leiden University Medical Centre study site of the TRACK-HD study, 20 early HD 
pati ents (disease stage 1 and 2), 28 premanifest gene carriers and 28 healthy controls 
underwent 3T MRI scanning. Standard and high-resoluti on T
1
-weighted images and 
a resti ng state fMRI scan were acquired. Using FSL, group diff erences in resti ng state 
connecti vity were examined for eight networks of interest using a dual regression 
method. With a voxelwise correcti on for localised atrophy, group diff erences in functi onal 
connecti vity were examined. 
Results
Brain connecti vity of the left  middle frontal and pre-central gyrus, and right post central 
gyrus with the medial visual network was reduced in premanifest and manifest HD 
as compared to controls (0.05>p>0.0001). In manifest HD connecti vity of numerous 
widespread brain regions with the default mode network and the executi ve control 
network were reduced (0.05>p>0.0001).
Discussion
Brain regions that show reduced intrinsic functi onal connecti vity are present in 
premanifest gene carriers and to a much larger extent in manifest HD pati ents. These 
diff erences are present even when the potenti al inﬂ uence of atrophy is taken into account. 
Resti ng state fMRI can potenti ally be used for early disease detecti on in the premanifest 
phase of HD and for monitoring of disease modifying compounds. 
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Introducti on
Hunti ngton’s disease (HD) is an autosomal dominant neurodegenerati ve disease 
characterised by progressive motor-, behavioural- and cogniti ve-dysfuncti on. The 
expansion of the HTT gene on chromosome 4 is eventually responsible for neuronal 
loss and dysfuncti on throughout the brain1;2. Previous studies have demonstrated that 
atrophy of both the deep grey matt er structures and of the cortex are apparent in pati ents 
with HD, and also to a lesser degree in HD gene carriers prior to disease onset3-6. These 
premanifest gene carriers, who do not show symptoms of the disease but are certain of 
eventual disease onset, have also been found to show reduced integrity of white matt er7-9. 
In pati ents with HD, both extensive white matt er integrity loss and atrophy of white matt er 
has been shown9-11. 
Clinical assessments in multi ple functi onal domains have extensively objecti fi ed the 
impairments reported by pati ents and their companions12-15. Also in premanifest gene 
carriers numerous tests of functi oning have shown diminished performance16-18. In an 
eff ort to bridge the gap between the observed clinical deteriorati ons and structural brain 
defi cits, a number of studies have applied clinical assessments whilst observati on of brain 
acti vity was performed using functi onal magneti c resonance imaging (fMRI).
Four task-based fMRI studies in manifest HD demonstrated a fairly homogenous profi le, 
with reducti ons in brain acti vati on in numerous corti cal and sub-corti cal brain regions19-22. 
However the results from the limited number of task-based fMRI studies in premanifest 
HD report a more heterogeneous patt ern. Increased acti vati on in several brain regions 
was found in premanifest gene carriers far from expected disease onset, and reduced 
acti vati on was reported in premanifest gene carriers close to expected disease onset23;24. 
These task-based fMRI studies all challenged the brain during the MRI scanning yielding 
assessment and performance dependent results. An alternati ve approach is to examine 
the brain connecti vity patt erns without taxati on. 
Brain functi on depends on large-scale brain interacti ons25. Functi onal brain connecti vity 
patt erns can be examined at rest with fMRI and this approach is recognised as an 
important step towards understanding functi onal brain networks26. Hence, recent reports 
have incorporated resti ng state (RS) fMRI to examine the brain during both normal 
aging and disease27-30. Currently the earliest detectable brain changes in HD are atrophy 
of subcorti cal grey matt er structures17;31. Given that cell loss presents as the result of a 
pathologic cascade it is plausible to expect functi onal brain changes prior to cell loss. In 
carriers of the APOE-4 gene, alterati ons in intrinsic functi onal connecti vity have been 
observed even in the absence of changes in brain structure32. Such interacti ons have not 
been studied in premanifest HD. Functi onal brain changes may also occur in HD, either 
prior to, or as a result of brain atrophy. RS fMRI has the potenti al to give insight into 
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potenti al functi onal changes. RS fMRI could be implemented for early disease detecti on 
and could evaluate the eff ect of future neuroprotecti ve or therapeuti c compounds. This 
study aims to establish whether functi onal brain connecti vity at rest is altered in both 
premanifest HD gene carriers and early manifest pati ents. 
Methods
Parti cipants
At the Leiden University Medical Centre study site of the TRACK-HD study, subjects 
parti cipati ng in the longitudinal TRACK-HD study underwent MRI scanning including fMRI 
during the baseline visit. Of the 90 parti cipants included, 11 did not undergo the additi onal 
fMRI scan due to ti me constraints. Furthermore aft er quality control of the fMRI data, 
both visually and by means of the scan analysis reports generated during post-processing 
of the MRI data, three manifest HD parti cipants were excluded from the analysis because 
of excessive moti on (>4mm). In total 20 stage 1 and 2 HD pati ents, 28 premanifest gene 
carriers and 28 healthy controls were included in the fMRI analysis (table 1). 
Inclusion criteria for HD pati ents included a positi ve geneti c test for the HTT gene with 
40 or more CAG repeats; the presence of motor disturbances defi ned as more than fi ve 
points on the Unifi ed Hunti ngton’s Disease Rati ng Scale – total motor score (UHDRS-
TMS), and a Total Functi onal Capacity score (TFC) greater than or equal to seven points, 
thereby only including pati ents in the earliest two disease stages33. Inclusion criteria for 
premanifest gene carriers consisted of a positi ve geneti c test with 40 or more CAG repeats, 
and the absence of motor disturbances with fi ve or less points on the UHDRS-TMS. 
Finally, a burden of pathology score ((CAG repeat length -35.5) x age) greater than 25034 
was required. Age- and gender-matched gene-negati ve relati ves of HD gene carriers and 
unaff ected spouses were included as healthy controls. Exclusion criteria for all parti cipants 
included previous signifi cant head injury, any other neurological or major psychiatric 
disorder, or unwillingness to undergo MRI scanning. The study was approved by the 
Medical Ethical Committ ee of the Leiden University Medical Centre. All parti cipants gave 
writt en informed consent. For full details of study parameters see Tabrizi et al. (2009)31.
During further medical history taking, handedness was recorded by means of the 
Edinburgh Inventory 2nd version (Oldfi eld, 1970). For early HD pati ents, the rater’s esti mate 
of disease onset was determined, based on the rater’s observati ons, reports by the 
pati ents and informati on from companions or relati ves. With this informati on the current 
disease durati on was calculated. For premanifest gene carriers the esti mated number of 
years unti l disease onset was calculated based on their current age and CAG repeat length, 
by means of the formula developed by Langbehn et al. (2004)35.
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MRI protocol
MRI acquisiti on was performed on a 3 Tesla whole body scanner (Philips Achieva, 
Healthcare, Best, The Netherlands) with an eight channel receive array head coil. An 
anatomical T
1
-weighted scan was acquired using an ultrafast gradient echo 3D acquisiti on 
sequence with the following imaging parameters: repeti ti on ti me (TR) = 7.7 ms, echo ti me 
(TE) = 3.5 ms, fi eld-of-view = 24 x 24 x 16.4 cm, matrix size 224 x 224, with a durati on of 
9 minutes. For post-processing registrati on purposes, a high resoluti on T
1
-weighted scan, 
with the following parameters was collected; repeti ti on ti me (TR) = 2200 ms, echo ti me 
(TE) = 30 ms, fi eld-of-view = 220 x220x168 mm, ﬂ ip angle = 80°, matrix size= 112x109mm, 
with a durati on of 46 seconds. A RS fMRI scan with the following parameters was also 
obtained: repeti ti on ti me (TR) = 2200 ms, echo ti me (TE) = 30 ms, fi eld-of-view = 220 x 220 
x 10.4 cm, resoluti on = 1.96 x 1.96 x 2, no slice gap, ﬂ ip angle = 80°, matrix size 80 x 79, 
with a durati on of 7.5 minutes. To reduce unnecessary sensory input that could inﬂ uence 
the results, parti cipants were not allowed to listen to music during the RS fMRI scan, and 
to ensure a wakeful dispositi on parti cipants were asked to keep their eyes open with 
normal background light. 
Pre-processing for RS fMRI analysis
Pre-processing of the RS fMRI data using the standard procedure was carried out using FSL 
4.1.836. The following steps were preformed: head moti on correcti on37, brain extracti on38, 
spati al smoothing using a Gaussian kernel of 5 mm full width at half maximum (FWHM). 
All volumes were normalised based on mean intensity and high-pass temporal fi ltering 
(Gaussian-weighted least-squares straight line fi tti  ng, FWHM = 100s). The middle 
(reference scan) of each individuals RS fMRI ti me series was aﬃ  ne registered to MNI152 
standard space (Montreal Neurological Insti tute, Montreal, QC, Cananda): initi ally, it was 
registered to the high resoluti on T
1
-weighted scan. This high resoluti on T
1
-weighted scan 
was subsequently registered to the anatomical T
1
-weighted scan. Finally, the anatomical 
scan was registered to MNI152 standard space. By fi rst registering the functi onal data to 
the high resoluti on scan and then to the anatomical T
1
-weighted scan allows for bett er 
registrati on of the data. These three registrati on matrices were combined to obtain a 
matrix for transforming fMRI data from nati ve space to standard space, using interpolati on 
to 2x2x2 mm voxels. Visual quality control was performed to ensure correct registrati on. 
Stati sti cal analyses
Stati sti cal analysis of group demographic was compared using SPSS (version 17, SPSS, 
USA). Where appropriate either Analysis of Variance or Chi-squared tests were applied. 
Resti ng state connecti vity was examined using a dual regression method32;39;40. In doing 
so the similarity of the haemodynamic response patt erns (fMRI signal) for each brain 
voxel was compared to the fMRI signal in eight pre-defi ned, well established, networks 
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of interest (NOIs)41. These networks encompass over 80% of the enti re brain volume. The 
NOIs represent spati al template maps corresponding to medial visual (NOI1), lateral visual 
(NOI2), auditory (NOI3), sensorimotor (NOI4), the default mode (NOI5), executi ve control 
(NOI6), visual-spati al memory (NOI7), and working memory (NOI8) networks. 
First, a spati al regression was applied: The eight NOIs and a CSF mask were used as spati al 
regressors in a general linear model (GLM) to obtain the nine corresponding dynamic 
patt erns of fMRI signal ﬂ uctuati ons in each network from each individual’s RS fMRI scan. 
Next, these nine ti me series, together with six moti on correcti on parameters derived 
during preprocessing (three translati ons and three rotati ons) were used as temporal 
regressors in a second (temporal) GLM. For each voxel, the z-score corresponding to each 
of these 15 temporal regressors was obtained. A GLM was applied, resulti ng in spati al 
z-score maps for each individual’s RS fMRI scan, for each NOI. This dual-regression method 
thereby generated eight z-scores maps reﬂ ecti ng the connecti vity strength of each voxel 
in the brain to each of the eight NOIs. A voxel with a high z-score demonstrated a highly 
similar patt ern of fMRI ﬂ uctuati on to the voxels in the NOI.
These z-score maps were constructed to compare the groups. The group stati sti cal 
analysis was performed to determine which brain regions showed stati sti cally signifi cant 
diff erences in connecti vity to any of the NOIs between groups by applying three 
independent sample t-tests. This was performed with a voxel-wise correcti on for 
localised grey matt er concentrati on to rule-out any potenti ally confounding impact of 
local structural loss on brain connecti vity, as described by Oakes et al. (2007)42. In short, 
per individual the anatomical T
1
-weighted scans were processed to provide voxel-based 
intensity maps of grey matt er concentrati on, which were included as a voxel-wise covariate 
in the mixed eff ects model group analysis. Non-parametric permutati on based stati sti cal 
inference was used with 5000 repeated permutati ons per NOI for the comparisons; 
controls vs premanifest, controls vs manifest HD and premanifest vs manifest HD. 
Correcti on for multi ple comparisons was applied using threshold free cluster enhancement 
based correcti on whereby all results under the threshold of p<0.05 were considered 
stati sti cally signifi cant43. This provided spati al informati on per NOI of brain regions 
demonstrati ng diff erent connecti vity patt erns between the study groups. 
Results
The groups did not diff er in terms of age, gender, handedness and educati on level. Early 
HD pati ents had signifi cantly higher UHDRS motor scores, CAG repeat lengths and lower 
TFC scores than premanifest gene carriers and/or healthy controls. 
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Table 1: Group characteristi cs of the study groups
Healthy
controls
Premanifest 
gene carriers
Early HD 
pati ents
N 28 28 20
Gender M/F 13/15 11/17 5/15
Age 
(years) Mean (SD)
48.5 (8.5) 43.21 (8.2) 46.5 (10.6)
CAG repeat length
Mean (SD)
n/a 42.5 (2.5) 44.1 (2.6) §
Total Functi onal Capacity
Mean (SD)
12.9 (1.9) 12.6 (0.8) 10.2 (1.9)*§
UHDRS - Motor
Mean (SD)
2.5 (2.5) 2.4 (1.4) 20.3 (11.0)*§
Expected disease onset 
(years) Mean (SD)
n/a 11,6 (4.4) n/a
Disease durati on 
(years) Mean (SD)
n/a n/a 6.8 (7.4)
N = number of parti cipants, SD = Standard deviati on, n/a = not applicable, UHDRS – Motor = Unifi ed Hunti ngton’s 
Disease Rati ng Scale – total motor score, * signifi cantly diff erent to controls at p< 0.05, § signifi cantly diff erent to 
premanifest gene carriers at p< 0.05. 
In both premanifest gene carriers and early manifest HD the same regions in the left  
frontal lobe and the right parietal lobe displayed reduced connecti vity with the NOI1 
(medial visual network), as compared to controls (0.05>p>0.0001). The area in the left  
frontal lobe comprised the grey matt er near the pre-central and middle-frontal gyri. The 
area in the parietal lobe was localised in the post-central gyrus (fi gure 1). Premanifest 
gene carriers only, also displayed reduced connecti vity bi-laterally of the cingulate gyrus 
with NOI1 compared to the controls. This area of reduced connecti vity was not found in 
the early HD group. The manifest HD group demonstrated additi onal areas of reduced 
connecti vity with NOI1 that were not observed in the premanifest gene carrier group. 
These areas were located bi-laterally within the superior occipital lobe, within a large fi eld 
in the deep grey matt er, including the putamen, globus pallidus, thalamus, and bi-laterally 
in the cortex of the frontal orbital region (fi gures 1).
The connecti vity of the left  parietal lobe, the pre-frontal cortex in both hemispheres, and 
regions of grey and white matt er in the both temporal lobes with NOI5 (the default mode 
network) was reduced in early HD only as compared to controls (0.05>p>0.0001) (fi gure 1). 
Connecti vity of a small region in the thalamus and the left  supramarginal gyrus with 
NOI6 (executi ve control network) was reduced in manifest HD as compared to controls 
(0.05>p>0.0001) (fi gure 1). No diff erences between any of the study groups were found in 
the connecti vity with the other NOIs. 
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Figure 1. Group comparisons of functi onal brain connecti vity shown in three orientati ons. 
Green areas show the voxels encompassing the network of interest (NOI) with which the connecti vity decreases 
are present. Blue - light blue areas show the areas of reduced connecti vity with the NOI between premanifest 
gene carriers and controls, red-yellow areas show the areas of reduced connecti vity with the NOI between 
early manifest HD and controls. Some are of blue and red overlap is present, here the functi onal connecti vity is 
reduced in both premanifest and manifest HD. 
Discussion
Reducti ons in intrinsic functi onal connecti vity are apparent in both premanifest gene 
carriers and pati ents with early HD. The earliest areas to show a reducti on in connecti vity 
are regions within the left  frontal and right parietal and bilateral visual lobes. These areas 
also demonstrated reduced connecti vity in the early manifest group. Further connecti vity 
reducti ons were also apparent in many other brain regions in early HD such as subcorti cal 
grey matt er and the occipital lobes. These observed diff erences to healthy controls are not 
explained by brain atrophy. 
In premanifest gene carriers our fi ndings show reduced connecti vity of the medial 
visual network (NOI1) with the left  frontal, right parietal and bilateral cingulate gyrus 
during rest. The only known other report of RS fMRI in HD is a methodological report 
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describing the stability and suitability of RS fMRI over a one year follow up period in 
premanifest gene carriers. No group diff erences in any of their prespecifi ed interregional 
fMRI correlati ons were found44. The prespecifi ed two seed regions used for interregional 
correlati on were diff erent to the networks applied in the current paper, and this 
methodological dissimilarity may explain the variati on in outcome. Carriers of genes 
resulti ng in neurological diseases other than HD have been found to show aberrant 
intrinsic functi onal connecti vity in the absence of disease signs32;45, thus supporti ng the 
occurrence of functi onal brain changes prior to a disease manifestati on. Results from other 
studies using task based fMRI in HD also support our fi ndings23;24;46-48. These studies show 
disrupted acti vati on (either increased or decreased) in areas that do not form an identi cal 
spati al match to our results, but do show great similarity of involved brain areas. Some 
regions with altering between region connecti ons in this study, such as the left  frontal 
lobe, specifi cally in the middle frontal gyri and pre-central gyrus, have also shown locally 
decreased task related fMRI acti vati on23;24;46-48. Task based fMRI studies also demonstrated 
the implicati on of the post central gyrus48, and the bilateral cingulated cortex23;24;48. 
Further support for our fi nding is found in results using a diff erent imaging technique that 
measures blood perfusion during rest. Cerebral blood ﬂ ow was found to be altered in 
premanifest gene carriers in prefrontal brain regions49. Our results demonstrate that early 
reducti ons in intrinsic functi onal connecti vity are present prior to the clinical manifestati on 
of HD. This is an important fi nding as therapeuti c interventi ons may wish to monitor 
the functi onal impact of a compound on the brain in the absence of clinical outcome 
measures. 
In the early HD group, our fi ndings of reduced connecti vity encompass more and larger 
regions in the brain than of premanifest gene carriers. Some, but not all of these regions 
have previously been shown to show disturbed acti vati on during task based fMRI. The 
disrupted acti vati on was reported in the same brain areas with which we found reducti ons 
in connecti vity of the medial visual network (NOI1); left  frontal lobe20;50, right parietal 
lobe20;50, superior occipital20 and frontal orbital22 regions in both hemispheres, and specifi c 
subcorti cal structures such as the putamen22;48. However, no previous literature describes 
involvement of the globus pallidus, or thalamus. The brain regions demonstrati ng reduced 
connecti vity with the default mode network (NOI5) were also reported to show altered 
acti vati on during performance, such as with the left  parietal50, and bilateral prefrontal 
corti ces21;48 and temporal lobes22. The reducti on of connecti vity of the left  supermarginal 
gyrus and thalami with the executi ve control network (NOI6) during rest, does not fi nd 
support in other studies of connecti vity or brain acti vati on during task executi on. Despite 
the diff erent nature of RS fMRI versus task based fMRI, our current fi ndings do seem 
complementary to the task-based fMRI results. With RS fMRI overall brain connecti vity is 
examined that is not limited to task related brain regions, and we have demonstrated that 
the connecti vity of multi ple brain networks is aff ected in HD. 
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The brain regions demonstrati ng reduced connecti vity as compared to healthy controls 
showed overlap between premanifest gene carriers and early HD pati ents, possibly 
indicati ng progressive functi onal defi cits. The regions demonstrati ng reduced connecti vity 
generally occur bilaterally and throughout the brain, especially in manifest HD. 
It is unknown whether reduced connecti vity patt erns reﬂ ect connecti vity that is limited or 
non-existent due to neuronal death or whether such results reﬂ ect intact but abnormally 
functi oning neurons in HD. The results from this current study suggest that the latt er may 
be a more accurate reﬂ ecti on, given that atrophy reﬂ ects (advanced) volume loss as a 
result of neuronal death, and that our results remain valid when taking into considerati on 
MRI detectable regional atrophy. Therefore, it is not likely that reducti ons in functi onal 
connecti vity can be explained solely by neuronal death in HD.
The strengths of this study lay in the comprehensive and exploratory nature of the fMRI 
analysis. As this study was performed in a single sample of strictly selected premanifest 
and early manifest HD the results reﬂ ect varying stages of disease progression. 
Furthermore, by taking atrophy into considerati on the potenti al inﬂ uence of cell loss on 
connecti vity results was reduced. Examinati on of brain networks encompassing almost 
the enti re brain allowed for a hypothesis generati ng approach. Therefore the brain 
regions found to display reduced connecti vity may be targeted in future studies of HD. 
The limitati ons of this study lay in the potenti al for the inﬂ uence of moti on artefacts 
due to chorea. However, every eff ort was made to prevent moti on during scanning and 
furthermore strict quality control was applied to prohibit the inclusion of poor quality 
scans. This resulted in the exclusion of three scans from the manifest HD group. Also, the 
inﬂ uence of excessive moti on was reduced by including a strictly selected early HD group 
where chorea is generally limited. Other limitati ons are the novelty of the technique 
and the cross-secti onal design. To further understand if connecti vity patt erns are indeed 
aff ected by the progressive nature of this degenerati ve disease, study reproducti on and 
longitudinal follow-up is essenti al in all study groups. Longitudinal follow-up using RS fMRI 
has the advantage over task-based fMRI that it is easier to standardise for cross-site, cross-
cultural studies. In the multi -site follow up of the TRACK-HD study the evaluati on of RS 
fMRI as a biomarker for HD is ongoing.  
In conclusion, we have demonstrated that in the absence of processes that put demand 
on the brain, the HD brain functi ons diff erently. These fi ndings are not explained by 
the presence of cerebral atrophy. We have shown that these functi onal diff erences are 
present not only aft er disease manifestati on but also in the preceding ‘premanifest’ phase. 
Functi onal connecti vity measures can potenti ally be used for early disease detecti on and 
for monitoring of disease modifying compounds. 
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Conclusions 
The aims of this thesis were to gain further insight into specifi c disease processes in 
HD and to identi fy promising biomarkers. To achieve these aims, cogniti ve functi oning, 
structural brain characteristi cs and intrinsti c functi onal brain connecti vity of premanifest 
and early HD subjects were examined.
Understanding disease processes
Following a review of the current literature on cogniti ve functi oning in premanifest 
and manifest HD, we concluded, in chapter 2, that cogniti ve defi cits show a diff erenti al 
progression. During late disease stages all cogniti ve domains show moderate or severe 
disturbances. The global profi le of cogniti ve functi oning in premanifest HD is characterised 
by subtle defi cits of psychomotor speed, negati ve emoti on recogniti on and some 
executi ve functi ons. In manifest HD these defi cits progressively worsen and are eventually 
accompanied by memory dysfuncti on. Global cogniti ve abiliti es and language capaciti es 
are the last to show deteriorati on. Finally, these cogniti ve defi cits in HD result in a 
generalised dementi a.
In chapter 3 we demonstrated that visuospati al working memory is not only defi cient in 
early manifest pati ents but also in premanifest gene carriers. Contrary to our expectati ons 
we found worsened accuracy and performance speed in early HD pati ents. Pati ents did not 
slow their performance in order to maintain accuracy. The absence of this ‘speed accuracy 
trade off ’ and the presence of a ‘worse-worse’ phenomenon generates the hypothesis 
that advice such as ‘pace yourself, take your ti me’ may not have the desired eff ect in HD. 
Furthermore, it suggests that pati ents may need more ti me to integrate visually presented 
informati on. 
The frontostriatal circuit encompasses the brain structures thought to be involved in the 
performance of complex cogniti ve processes such as visuospati al memory1;2. The frontal 
cortex, the striatum, and the white matt er connecti ng the two comprise the frontostriatal 
circuit3. In this thesis, these brain structures were examined in terms of structure (chapters 
4 and 7), metabolism (chapter 5) and functi on (chapter 8).
Since the earliest assessments of brain changes in HD, disti nct grey matt er deteriorati on 
or loss of striatal volume have repeatedly been found in HD4-6. In chapter 4, we 
concluded that atrophy of subcorti cal nuclei show a diff erenti al deteriorati on profi le. In 
premanifest gene carriers within approximately 11 years to onset we found atrophy of the 
hippocampus, accumbens nucleus, globus pallidus, thalamus, and brainstem, alongside the 
well established atrophy of the caudate nucleus and putamen7;8. In manifest HD, further 
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atrophy of these structures was observed, with marked loss of hippocampal volume. 
Interesti ngly, atrophy of the brainstem and thalamus was found to correlate with whole 
brain atrophy, and therefore the volume loss of these grey matt er structures may not 
reﬂ ect an accelerated degenerati ve process, as seems to be the case for the hippocampus, 
accumbens nucleus, thalamus, caudate nucleus and putamen. 
Ex vivo studies have demonstrated iron accumulati on in the caudate nucleus and 
putamen9; where cellular structure deteriorati on in HD was also shown5;10. The relati onship 
between atrophy and iron accumulati on in vivo has not been previously examined. In 
chapter 7 we demonstrated that iron accumulati on is present in the early stages of HD 
and that iron accumulati on and atrophy seem to reﬂ ect independent disease processes. 
Increased magneti c fi eld inhomogeneiti es suggesti ve of elevated iron accumulati on were 
found in the putamen and caudate nucleus of early HD pati ents. In premanifest gene 
carriers elevated iron accumulati on was not found in any of the examined subcorti cal 
structures. The thalamus, hippocampus, globus pallidus, amygdala and accumbens nucleus 
were also not aff ected in early manifest HD. Aft er assessing the volume of the subcorti cal 
structures, we examined the relati onship of atrophy to iron accumulati on in these 
structures. Both volume is lost and iron accumulates in the caudate nucleus and putamen, 
however, we established that these processes are independent. 
 
In chapter 5 magneti c resonance spectroscopy was used to examine metabolic levels in 
the caudate nucleus, putamen, thalamus, hypothalamus, and frontal lobe. The caudate 
nucleus and putamen show reduced creati ne in early manifest HD suggesti ve of reduced 
energy metabolism11. Furthermore, N- acetylaspartate reducti ons in the caudate nucleus 
and putamen suggests that the integrity and vitality of neurons is negati vely aff ected 
in early manifest HD11 . This fi nding is reinforced by the reduced structural integrity, as 
measured with DTI, of the caudate nucleus (chapter 6). Therefore, not only the absolute 
volume of the subcorti cal structure, but also the functi on and integrity of the remaining 
ti ssue is reduced in early HD.
Structural and functi onal connecti vity of brain regions are of importance as adequate 
brain functi oning relies on their extensive interacti ons12. Disturbed integrity proved to be 
relevant not only for grey matt er structures, but also along functi onal pathways connecti ng 
these structures to the rest of the brain. In premanifest gene carriers the integrity of the 
white matt er pathway of the sensorimotor cortex was reduced (chapter 6). In line with 
these fi ndings we also found evidence that the intrinsic functi onal connecti vity of left  
middle frontal and pre-central gyri, and right post central gyrus with the medial visual 
network was reduced prior to disease onset (chapter 8). In manifest HD, a similar but 
more widespread patt ern of reduced integrity of white matt er pathways (chapter 6) and 
functi onal connecti vity of corti cal regions was observed (chapter 8). 
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When all structural and functi onal brain changes are considered together, a broad picture 
of multi -level defi cits begins to emerge. Corti cal, subcorti cal and the intermediate white 
matt er brain ti ssue show evidence of structural and functi onal decline. This is supported 
by previous fi ndings demonstrati ng corti cal thinning13;14, similar subcorti cal atrophy6 and 
reduced integrity in selected white matt er regions15-17. We found evidence that several 
disease processes, such as altered metabolism, excessive iron accumulati on and cell loss, 
play a role in the observed changes. We conclude that changes occur throughout the brain 
from the earliest disease phase onwards. Hence, both premanifest and manifest HD should 
not be regarded as a disorder of the basal ganglia, but as a disease aff ecti ng the whole 
brain.
Identi fying promising biomarkers
 
By reviewing the existi ng literature on cogniti ve functi oning in HD we concluded that the 
most promising cogniti ve biomarkers are measures from the domains of working memory, 
psychomotor speed, recogniti on of negati ve emoti ons, and att enti on or visuospati al 
executi ve functi ons (chapter 2). We showed that a measure of visuospati al working 
memory has good cross-secti onal sensiti vity for disti nguishing premanifest gene carries 
and early HD groups from controls. When assessing the value of visuospati al working 
memory as a biomarker over a 12 month follow-up period, the measure was sensiti ve to 
deteriorati on in pati ents in stage two of the disease (chapter 3). For potenti al therapeuti c 
trials aiming to improve cogniti ve capaciti es, such a measure may be useful from stage two 
HD onwards.
Iron levels were examined for their potenti al as a biomarker. We conclude that iron is not 
suitable as an early biomarker but has good potenti al as a marker of disease state (chapter 
7). Metabolic changes in HD are also apparent from the manifestati on of the disease 
onwards (chapter 5). For this reason reducti ons in creati ne and N-acetylaspartate may also 
be good markers of disease state in HD.
We have shown that several measures reﬂ ect early changes in the brain, prior to the 
appearance of overt clinical signs. We demonstrated that the process of early cell loss in 
the brain encompasses numerous subcorti cal structures (chapter 4). Therefore, in additi on 
to the caudate nucleus and putamen, volume loss observed in the accumbens nucleus 
and pallidum are potenti ally sensiti ve as biomarkers from ten years prior to disease onset 
onwards (chapter 4). In the premanifest phase of the disease, other markers also reﬂ ect 
early changes in the way brain regions interact. Reducti on in integrity of a white matt er 
pathway (chapter 6) and reduced intrinsic functi onal connecti vity of similar regions 
(chapter 8) was demonstrated. These changes in integrity and functi onal connecti vity 
were found to encompass more brain regions in manifest HD (chapters 6 and 8), thereby 
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reﬂ ecti ng the progressive nature of the disease. 
In summary, candidate biomarkers that have the potenti al to objecti vely reﬂ ect the early 
changes and the progressive nature of the disease are measures of subcorti cal atrophy, 
integrity of white matt er pathways and of intrinsic functi onal brain connecti vity. Iron, 
creati ne, and N- acetylaspartate concentrati ons in the caudate nucleus and putamen may 
prove to be most useful as markers of disease state for objecti fying transiti onal disease 
processes from premanifest to manifest HD. Visuospati al working memory could be 
applied as a state marker for stage two HD. 
Future perspecti ves
HD is a disease that aff ects the whole brain. Therefore, to further understanding of HD, 
future research should take a comprehensive approach. Furthermore, this may provide 
more insight into the relati onship between structural changes and functi onal disturbances.
The therapeuti c interventi ons that are currently being developed aim to reverse 
the destructi ve processes of HD. However, it has not been established whether the 
brain changes observed in premanifest gene carriers result from the slow onset of 
pathofysiological processes, or whether the brains of HD gene carriers develop diff erently. 
If brain changes are developmentally determined, reversal is futi le. Prior to disease onset, 
gene carriers experience a healthy life, however, litt le is known about the impact of mutant 
hunti ngti n during the development of their brains. We do not know whether the structural 
and especially functi onal diff erences are already present in very young gene carriers. 
Due to the ethical limitati ons posed by geneti cally testi ng at-risk children, developmental 
research is challenging. However, if a soluti on overcame these challenges, observati onal 
developmental research should be performed. In the absence of such a soluti on, larger 
groups of premanifest gene carriers must be observed in varying stages of proximity to 
disease onset. The premanifest gene carriers examined in these studies were all within 
approximately two decades of disease manifestati on. Future research could include the 
youngest premanifest gene carriers available; those furthest from esti mated disease onset. 
Such groups must be observed over ti me as they transiti on through phases of premanifest 
HD to manifest HD to establish the most sensiti ve measure for early disease detecti on. This 
also requires longitudinal observati on.
Measures of disease change need to be sensiti ve in both premanifest and manifest HD. 
Hence, although focus on premanifest gene carriers is important, observati onal research 
should always include the fullest range of gene carriers possible, also including manifest 
HD pati ents. 
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Summary
The aims of this thesis were to gain further insight into specific disease processes in 
HD and to identify promising biomarkers. To achieve these aims, cognitive functioning, 
structural brain characteristics and intrinstic functional brain connectivity of premanifest 
and early HD subjects were examined.
  
In chapter 2, from a review of the existing literature, we concluded that cognitive deficits 
show a differential progression. During late disease stages all cognitive domains show 
moderate or severe disturbances. The global profile of cognitive functioning in premanifest 
HD is characterised by subtle deficits of psychomotor speed, negative emotion recognition 
and executive functions. In manifest HD these deficits progressively worsen and are 
eventually accompanied by memory dysfunction. Global cognitive abilities and language 
capacities are the last to show deterioration. Eventually, these cognitive deficits in HD 
result in a generalised dementia.
In chapter 3, we demonstrated that visuospatial working memory is not only deficient in 
early manifest patients but also in premanifest gene carriers. Contrary to our expectations 
we found a ‘worse-worse’ phenomenon with worsened accuracy and performance speed 
in early HD patients. Over a period of twelve months, patients with stage two HD showed 
deterioration in visuospatial working memory.
In chapter 4, we discussed that atrophy of subcortical nuclei shows a differential 
deterioration profile. In premanifest gene carriers we found atrophy of the hippocampus, 
accumbens nucleus, globus pallidus, thalamus, brainstem, caudate nucleus and putamen. 
In manifest HD, further atrophy of these structures was observed, with marked loss of 
hippocampal volume. 
In chapter 5 magnetic resonance spectroscopy was applied demonstrating that the 
caudate nucleus and putamen show reduced creatine in early manifest HD suggestive of 
reduced energy metabolism. Furthermore, N- acetylaspartate reductions in the caudate 
nucleus and putamen suggests that the integrity and vitality of neurons is negatively 
affected in early manifest HD. 
In premanifest gene carriers reduced integrity of the white matter pathway of the 
sensorimotor cortex, as measured with DTI, was demonstrated in chapter 6. In manifest 
HD, a more widespread pattern of reduced integrity of white matter pathways was 
observed.
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In chapter 7 we demonstrated that iron accumulati on is present in the early stages of HD 
and that iron accumulati on and atrophy seem to reﬂ ect independent disease processes. 
Increased magneti c fi eld inhomogeneiti es suggesti ve of elevated iron accumulati on were 
found in the putamen and caudate nucleus of early HD pati ents. In premanifest gene 
carriers elevated iron accumulati on was not found in any of the subcorti cal structures 
examined. 
In chapter 8 we found evidence for reduced intrinsic functi onal connecti vity of left  middle 
frontal and pre-central gyrus, and right post central gyrus with the medial visual network 
in premanifest gene carriers. In manifest HD, a similar but more widespread patt ern of 
reduced intrinsic functi onal connecti vity was observed. 
When all structural and functi onal brain changes are considered together, a broad 
picture of multi -level defi cits begins to emerge. Corti cal, subcorti cal and the intermediate 
white matt er brain ti ssue shows evidence of structural and functi onal decline. We 
found evidence that several disease processes, such as altered metabolism, excessive 
iron accumulati on and cell loss, play a role in the observed changes. We conclude that 
changes occur throughout the brain from the earliest disease phase onwards. Hence, both 
premanifest and manifest HD should not be regarded as a disorder of the basal ganglia, 
but as a disease aff ecti ng the whole brain.
  
Candidate biomarkers that have the potenti al to objecti vely reﬂ ect the early changes and 
the progressive nature of the disease are measures of subcorti cal atrophy, integrity of 
white matt er pathways and of intrinsic functi onal brain connecti vity. Iron, creati ne, and 
N- acetylaspartate concentrati ons in the caudate nucleus and putamen may prove to be 
most useful as markers of disease state for objecti fying transiti onal disease processes from 
premanifest to manifest HD. Visuospati al working memory could be applied as a state 
marker for stage two HD. 
As clinical trials for treatment of HD become more frequent, the need for objecti ve 
and sensiti ve biomarkers becomes more signifi cant. Longitudinal establishment of 
promising biomarkers is needed. To further understanding of the complexiti es of HD a 
comprehensive approach is important for future research. Observati onal research of young 
premanifest gene carriers is important for understanding the impact hunti ngti n has on the 
developing brain. Nonetheless, observati onal research should always include the fullest 
range of gene carriers possible. 
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Samenvatting
De doelstellingen van het onderzoek beschreven in dit proefschrift waren om meer 
inzicht te krijgen in de ziekte processen van de ziekte van Huntington (HD) en kandidaat 
biomarkers te identificeren. Om deze doelstellingen te behalen zijn zowel de cognitieve 
functies als structurele en functionele aspecten van de hersenen onderzocht van 
premanifeste gendragers en patiënten in een vroeg stadium van de ziekte. 
Een overzicht van bestaande literatuur (hoofdstuk 2) toonde aan dat de deficiënties in 
de verschillende cognitieve domeinen een gedifferentieerd beloop laten zien. In de latere 
stadia van de ziekte laten alle cognitieve domeinen in meer of mindere mate afwijkingen 
zien. Het cognitieve profiel van premanifeste gendragers laat subtiele deficiënties zien 
in de psycho-motore snelheid, negatieve emotie herkenning en executieve functies. 
In de manifeste stadia van de ziekte verergeren deze afwijkingen en worden er tevens 
stoornissen van het geheugen waargenomen. Globale cognitieve en taalvaardigheden 
zijn de laatste domeinen die een achteruitgang tonen. Uiteindelijk leiden deze cognitieve 
deficiënties bij HD tot een gegeneraliseerde dementie. 
Het visueel-spatieel werkgeheugen toonde niet alleen afwijkingen aan bij HD patiënten in 
een vroeg stadium maar ook bij premanifeste gendragers (hoofdstuk 3). In tegenstelling 
tot onze verwachtingen vonden wij bij patiënten in een vroeg stadium van de ziekte een 
‘worse-worse’ fenomeen met een verminderde accuratesse en een verminderde snelheid. 
Over een periode van twaalf maanden laten stadium twee HD patiënten een aantoonbare 
achteruitgang zien in visueel-spatieel werkgeheugen. 
 
Door gebruik te maken van geautomatiseerde MRI analyses demonstreerden wij dat 
atrofie van de subcorticale grijze stof een gedifferentieerd profiel laat zien (hoofdstuk 
4). Hierbij vonden wij dat er bij premanifeste gendragers sprake is van atrofie van de 
hippocampus, nucleus accumbens, globus pallidus, thalamus, hersenstam, putamen en 
nucleus caudatus. In de vroeg manifeste stadia van de ziekte vonden wij meer atrofie 
van deze hersenstructuren, waarbij de sterk toegenomen atrofie van de hippocampus 
opvallend was. 
Met behulp van ‘magnetic resonance spectroscopy’ toonden wij aan dat zowel de nucleus 
caudatus als het putamen een reductie laten zien in de hoeveelheid aanwezige creatine 
(hoofdstuk 5). Dit suggereert dat er sprake zou kunnen zijn van verminderd energetisch 
metabolisme. Ook suggereert de afname van N-acetylaspartaat in deze kernen dat de 
integriteit en vitaliteit van neuronen in vroeg manifeste HD is aangedaan.
 
Een afname in de integriteit van de witte stof banen van de sensorimotor cortex in 
premanifeste gendragers werd aangetoond met behulp van ‘diffusion tensor imaging’ 
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(hoofdstuk 6). In vroege manifeste HD observeerden wij een uitgebreider patroon van 
integriteitafname in meerdere witt e stof banen.
Toegenomen inhomogeniteiten van het magneti sche veld, duidend op toegenomen 
ijzer, werden aangetoond in het putamen en de nucleus caudatus in vroeg manifest 
HD (hoofdstuk 7). Deze verhoogde ijzerconcentrati e lijkt een onafh ankelijk proces te 
reﬂ ecteren van atrofi e van deze kernen. In premanifeste gendragers werd er in geen van 
de onderzochte subcorti cale hersenstructuren een verhoogde ijzerconcentrati e gevonden. 
Door gebruik te maken van ‘resti ng state fMRI’ toonden wij een afname aan in intrinsieke 
functi onele connecti viteit van; het mediale visuele netwerk met de linker mediale 
frontale en precentrale gyri, en de rechter postcentrale gyrus in premanifeste gendragers 
(hoofdstuk 8). In vroeg manifeste HD werd een vergelijkbaar maar uitgebreider patroon 
van afgenomen intrinsieke functi onele connecti viteit gevonden. 
Wanneer al deze structurele en functi onele veranderingen samen worden genomen, vormt 
zich er een breder zicht op de defi ciënti es op meerdere niveaus. Corti caal, subcorti caal 
en de tussenliggende witt e stof laten aanwijzingen zien voor functi onele en structurele 
achteruitgang. Wij vonden dat meerdere ziekteprocessen, zoals veranderd metabolisme, 
toegenomen ijzer en verlies van cellen, een rol spelen in de waargenomen veranderingen. 
Wij concluderen dat veranderingen in de hersenen voorkomen vanaf het vroegste moment 
in het ziekteproces. Daarom zou premanifeste en manifeste HD niet moeten worden 
beschouwd als een ziekte van de basale kernen alleen, maar als een ziekte die de gehele 
hersenen aangaat. 
Kandidaat biomarkers die het vermogen hebben om op een objecti eve manier de vroege 
veranderingen en de progressieve aard van de ziekte te weerspiegelen zijn maten 
van subcorti cale atrofi e, integriteitsmaten van de witt e stof banen en van intrinsieke 
functi onele connecti viteit. IJzer, creati ne, en N-acetylaspartaat concentrati es zouden 
toepasbaar kunnen blijken voor het objecti veren van de transiti e van premanifeste naar 
manifeste HD. Visueel-spati eel werkgeheugen zou kunnen worden toegepast als een maat 
voor stadium twee HD. 
Er zullen waarschijnlijk meer klinische interventi e studies voor HD komen en daarom wordt 
de behoeft e aan objecti eve en sensiti eve biomarkers steeds relevanter. Om beter begrip 
te krijgen in de complexe ziekteprocessen van HD is het van belang om in toekomsti g 
onderzoek een alomvatt ende aanpak toe te passen. Observati oneel onderzoek van jonge 
premanifeste gendragers is belangrijk om de gevolgen van het mutante hunti ngti n-eiwit 
op de ontwikkelende hersenen beter te begrijpen. Daarom is het van belang om bij 
observati oneel onderzoek het breedste scala aan gendragers te includeren. 
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